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My liposomal journey 
I heard in a lecture about some tiny balls. 
Consisting of lipids and fatty walls. 
Professor said, “Liposomes are future”, I recall. 
So I started my master in liposomes next fall. 
Dissolve lipid in methanol and evaporate “all”. 
Hydrate film to create vesicle walls.  
“Add curcumin, they have potentials”, someone called.  
“Liposomes are super, they can entrap them all!” 
Sonication and extrusion to make them small. 
Most cases sadly on benches, clothes, and walls. 
Experiments seemed to go downfall.  
Wait – master defended. PhD from next fall? 
Osmotically active liposomes, my next call. 
Redesigning LUVs formulations with cholesterol. 
Franz cell experiments – an immense haul. 
Success or not, under tonicity befall. 
Even though my journey has come to a stall. 
Further dreams for these vesicles are post-nasal. 
Start penetrating the brain’s impermeable wall. 
Maybe brain diseases can be cured after all. 
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Central nervous system (CNS) disorders are accounted as the leading cause of disability and 
the second leading cause of death globally. Despite intense research efforts, CNS therapeutics 
covering a wide range of CNS disorders are still limited, possibly because of the complex 
pathophysiology of the CNS disorders and difficulties accessing the brain. One of the major 
barriers preventing drugs to reach the brain is the blood-brain-barrier (BBB). The BBB is 
responsible for preventing over 98% of drug molecules from the systemic circulation to reach 
the brain. Therefore, instead of utilizing the traditional drug administration routes, time and 
investment have been shifted towards new strategies to overcome the BBB. 
 
One of the innovative and promising strategies is the nose-to-brain delivery approach. Nasally 
administered drugs have shown to provide therapeutic effect locally, systemically and within 
the CNS. Despite promising results from in vivo studies, the main limitations using the nose as 
the administration site are related to drug’s potency in small volumes applicable to the nose, 
and the drug’s stability and permeability through the nasal mucus. Liposomes as drug carrier 
system exhibit the ability to entrap a wide range of poorly soluble drugs protecting them from 
early degradation and clearance. However, the nasal mucus tonicity fluctuates greatly due to 
its direct exposure to the peripheral milieu, thus influencing liposomes behaviour and their 
sensitivity to osmotic stress. Our hypothesis was that co-operation between osmotic stress 
and liposomal behaviour might be utilized to achieve controlled drug delivery systems. 
 
In the present study, we selected two markers and six drugs covering a wide range of relevant 
physiochemical properties to be entrapped into large unilamellar vesicles (LUVs). The various 
LUVs were verified to be osmotically active. Both linear and non-linear approximations were 
used to interpret the in vitro diffusion data and showed that release from LUVs was associated 
with their exposure to osmotic stress. These findings were consistent using the standard 
regenerated cellulose and biomimetic Permeapad® as the diffusion barriers. To achieve better 
in vitro/in vivo correlations, mucin was introduced into the in vitro diffusion study to mimic the 
nasal environment. Surprisingly, mucin did not affect the osmotic activity of the LUVs, nor had 
an impact on the drug release from LUVs. LUVs formulated with an increased amount of 
cholesterol incorporated into the bilayer (up to 25% w/w) showed decreased sensitivity to 
osmotic stress. However, the liposomes comprising 11% w/w cholesterol were the most stable 
formulations. Also, these formulations retained relatively good osmotic activity. 
 
The obtained data provide important information on the osmotic activity of liposomes and build 








AD  Alzheimer’s disease 
bFGF  Basic fibroblast growth factor 
BBB  Blood-brain barrier 
BCS  Biopharmaceutics classification system 
CHOL  Cholesterol 
CNS  Central nervous system 
CPP  Cell-penetrating peptide 
DALY  Disability-adjusted life year 
DMPC  Dimyristoylphosphatidylcholine 
DMPG  Dimyristoylphosphatidylglycerol 
DOPC  Dioleoylphosphatidylcholine 
DSPC  Distearoylphosphocholine 
DSPE  Distearoylphosphatidylethanolamine 
EE  Entrapment efficiency 
EPC  Egg-phosphatidylcholine 
GDNF  Glial cell line-derived neurotrophic factor 
GI  Gastrointestinal 
GUVs  Giant unilamellar vesicles 
HSPC  Hydrogenated soy-phosphatidylcholine 
IN  Intranasal administration 
IV  Intravenous administration 
LUVs  Large unilamellar vesicles 
MPEG  Methoxypoly(ethylene glycol) 
MW  Molecular weight 
ND  Not detected 
ODA  Octadecylamine 
PBS  Phosphate buffer saline 
PBS300 Phosphate buffer saline with tonicity of 300 mOsm/kg 
PBS65  Phosphate buffer saline with tonicity of 65 mOsm/kg 
PCL  Poly(ε-caprolactone) 
PEG  Poly(ethylene glycol) 
PI  Polydispersity index 
PLA  Poly(lactic acid) 
PLGA  Poly(lactic-co-glycolic acid) 
PO  Peroral administration 
RGD  Integrin-binding peptide 
SA  Stearylamine 
SD  Standard deviation 
SL  Soy-lecithin 
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1 Introduction 
Central nervous system CNS) disorders are a broad category of conditions, which according 
to the International Neuromodulation Society, are defined as; 
“…conditions in which the brain does not function as it should, limiting health and the ability to 
function. The condition may be an inherited metabolic disorder; the result of damage from an 
infection, a degenerative condition, stroke, a brain tumour or other problem; or arise from 
unknown or multiple factors” (INS, 2013). 
 
Due to the broad category of conditions which CNS disorders represent, they collectively 
account as the leading cause of disability and are the second leading cause of death globally 
(Feigin et al., 2019). In a global burden of disease study published in 2019, the prevalence, 
incidence, and mortality of 15 most relevant CNS disorders were estimated in 195 countries in 
the years 1990-2016. It was reported that in 2016, the three major contributors to CNS 
disability-adjusted life year (DALY) were stroke (42%), migraine (16%), and Alzheimer’s and 
other dementias (10%), as it can be seen in Figure 1.1. 
 
 
Figure 1.1: Ranking of age-standardized DALYs for CNS disorders by demographic region in 2016. 
Reproduced from Feigin et al., 2019, with permission from Elsevier. 
 
In terms of the absolute number of deaths and DALYs, both values have been increasing with 
39 and 15%, respectively, since 1990. On the contrary, age-standardized deaths and DALY 
values have generally been decreasing for all CNS disorders, suggested to be due to socio-
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economic development globally. However, Alzheimer’s and other dementias, and Parkinson’s 
disease do not seem to follow this trend and are suggested to continue to develop 
independently from socio-economic development. The prevalence of Alzheimer’s and other 
dementias are up to 9 times higher than Parkinson’s disease and is causing more deaths and 
DALYs in women compared to men (Feigin et al., 2019). Similar findings were reported in a 
Norwegian burden of disease study from 2018 (Tollanes et al., 2018). Alzheimer’s and other 
dementias were the second leading cause of deaths ranked after the cardiovascular diseases 
in 2016. With this alarming percentage, Alzheimer’s and other dementias are considered to be 
one of the most fatal diseases in Norway (Tollanes et al., 2018). 
 
 
1.1 The global burden of Alzheimer’s and other dementias 
Due to increasing life expectancy globally, the number of people affected by Alzheimer’s and 
other dementias is estimated to almost double by 2030 (82 million) and triple within the year 
2050 (152 million) (ADI, 2018, Alzheimer’s Association, 2018, FHI, 2019, WHO, 2019).  
 
Dementia is a syndrome which covers a broad classification of progressive neurodegenerative 
disorders describing memory impairment and thinking and behavioural disturbances that affect 
the daily life of patients (WHO, 2019). The most common form of dementia is Alzheimer’s 
disease (AD), representing up to 70% of the cases. According to the World Alzheimer report 
in 2018, new cases of AD are developed almost every minute in the United States alone 
(Alzheimer’s Association, 2018). Globally, the incidence rates of AD and other dementias are 
even more alarming, with newly diagnosed patients every three seconds (ADI, 2018). The 
highest incidence rates are anticipated to be 50% in Asia, 25% in Europe and 20% in America, 
respectively (ADI, 2018). 
 
In 2017, over 184 billion unpaid hours were spent by family members and caregivers to provide 
care to people with AD and other dementias in the United States. These hours were estimated 
to value more than 232 billion USD, emphasizing the great socio-economic burden dementias 
cause the society (Alzheimer’s Association, 2018). The annual estimated global cost of 
dementia in 2018 was 1 trillion USD and is predicted to be doubled by the year 2030 (ADI, 
2018). To decrease the global cost, it is of high necessity to develop more effective CNS 
diagnostics, therapeutics and prevention measures across the globe (Feigin et al., 2019). 
 
Despite intense research efforts for better CNS therapeutics, it is estimated that approx. 90% 
of molecules developed by the pharmaceutical industry for the treatment of CNS disorders, 
 Introduction  
3 
never reach the market (Vlieghe and Khrestchatisky, 2013). Since 1998, 100 drugs have been 
tested for the treatment of dementia, whereas only four have been authorized for clinical use 
(ADI, 2018). The low success is presumably because of the complex pathophysiology of AD 
and other dementias, but most importantly the difficulties potential drugs experience in 
accessing the brain (Khan et al., 2017, Patel and Patel, 2017). 
 
Therefore, rather than focusing on the discovery of new drugs, the development of new 
strategies to increase the drug transport to the brain might have a greater impact on the therapy 
(Li et al., 2017, Wong et al., 2012). Five different barriers in the CNS have been attributed to 
limit drug access into the brain. They are namely the blood–brain barrier (BBB), the blood–
cerebrospinal fluid barrier, the arachnoid barrier, the blood– spinal cord barrier, and the blood–
retina barrier (Gorlé et al., 2016). Among all these barriers, the BBB represents the strongest 
resistance to drug permeation and is the largest interface for blood-to-neuronal extracellular 
fluid exchange (Abbott et al., 2010). For this reason, in the next section, the BBB’s anatomy 




1.2 The blood-brain barrier (BBB) 
The BBB is a term commonly used to describe the properties of the blood capillaries found in 
the CNS. The capillaries in the BBB differ from other peripheral capillaries because they are 
generally thinner (approx. 500 nm in diameter) and more complex (see Figure 1.2). 
 
 
Figure 1.2: Schematic representation of the capillaries generally found in the body and brain. Based on 
Abbott et al., 2010, Khan et al., 2017. 
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The main cell types in the BBB are the tightly packed endothelial cells that create the walls of 
the capillaries. Other types of cells include the mural cells (smooth muscle cells and pericytes), 
immune cells (macrophage, astrocytes), and neuronal cells (Abbott et al., 2010, Daneman and 
Prat, 2015). Secrete from astrocytes, endothelial cells, and pericytes create the basal lamina; 
the microenvironment supporting the efficient signalling between the capillary and the neuronal 
cells (Daneman and Prat, 2015). The synergistic interplay between the basal lamina and the 
various cell types contributes to the BBB properties. The BBB is an obstacle for drug transport 
into the brain, and to understand this, the transport mechanisms across BBB (summarized in 
Figure 1.3) will be first briefly described in chronological order. 
 
 
Figure 1.3: Routes of transport across the BBB. Based on Abbott et al., 2010, Patel and Patel, 2017. 
 
The passive diffusion process (Figure 1.3a) allows molecules to move across a cellular 
membrane through their electrochemical gradient (i.e. concentration gradient) without the 
requirement of metabolic energy. It has been observed that small (<500 Da) and lipid soluble 
compounds (logP 1.5-2.7) favour the passive diffusion through the BBB, whereas larger and 
polar compounds (polar surface area >80 Å2) are not suited for this type of transport (Abbott 
et al., 2010, Patel and Patel, 2017). 
 
Transporter-mediated transports (Figure 1.3b-c) are important for the control of influx and 
efflux of poorly permeable solutes that are regarded as either important or not important for 
the optimal synaptic function of the BBB. Influx of nutrients often follows the facilitated diffusion 
requiring no energy, whereas the efflux often happens through efflux pumps that consume 
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ATP. For efficient transport into the brain, transporters expressed on the luminal and/or 
abluminal wall of the BBB can be utilized (Abbott et al., 2010, Patel and Patel, 2017). 
 
Absorption- and receptor-mediated transports (Figure 1.3d-e) are transports related to the 
surface interaction between the neuronal endothelial cell and the potential drug. The 
absorption mediated transport involves electrostatic binding between a cationic compound 
(e.g. IgG, albumin) and the negatively charged endothelial cell membrane. It represents a 
relatively weak interaction in comparison to receptor-mediated transport, where a specific unit 
(e.g. ligand, peptide) binds covalently to specific receptors expressed on the BBB surface (e.g. 
transferrin, albumin, insulin). In both absorption- and receptor-mediated transport, the surface 
interaction triggers endocytosis/transcytosis, engulfing the compound, and leading to 
increased transport across the BBB into the brain (Abbott et al., 2010, Patel and Patel, 2017). 
 
Cell-mediated transports utilize the body’s own cells, such as macrophages, monocytes, and 
neutrophils who are recruited during inflammation (Figure 1.3f). These cells have good ability 
to travel in the systemic circulation and can pass through the BBB using 
endocytosis/transcytosis mechanisms to reach the site of inflammation (Abbott et al., 2010, 
Patel and Patel, 2017). 
 
The transport mechanisms across the BBB are highly selective and strictly controlling the 
transport of essential ions, nutrients and peptides to maintain brain homeostasis and optimal 
neuronal function (Abbott et al., 2010, Daneman and Prat, 2015, Patel and Patel, 2017). 
However, when there is a shift to an imbalance in the BBB, a different situation may occur. 
 
Alterations of the BBB integrity can cause brain damages and have been suggested to be the 
cause of CNS disorders (Abbott et al., 2010, Daneman and Prat, 2015). Several alterations of 
the BBB have been proposed. One theory includes the decrease in resistance in tight junctions 
between the endothelial cells, which allows an increase in paracellular transport of substances 
that is otherwise hindered. Another theory is that alterations in the transporter systems can 
directly affect the transport of essential molecules (i.e. glucose) which are vital to maintaining 
brain homeostasis. Alterations in the enzymes expressed in the cytoplasm of neuronal 
endothelial cells can also be important, as this will hamper the BBB from discarding harmful 
substances (i.e. neurotoxins). Moreover, inflammation has also been suggested to play an 
essential role in CNS disorders as inflammation might cause structural abnormalities and 
damage of the BBB, possibly causing a secondary immune response that can reduce the 
resistances of tight junctions (Abbott et al., 2010, Daneman and Prat, 2015). 
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Therefore, to develop efficient therapeutics for CNS disorders, the drug transport strategies 
across BBB must be applicable at disordered state as well as in a healthy state. Moreover, the 
choice of administration route is important as drug administration following traditional routes 
(i.e. systemic administration) often results in binding of the drug to plasma proteins. 
Consequently, systemic administration reduces the compounds ability to reach therapeutic 
concentrations in the brain without reaching intolerable systemic side effects (Patel and Patel, 
2017). 
 
In the past, strategies such as direct injection of potential drugs into the brain tissues, 
cerebrospinal fluid, or spinal cord have been attempted (Abbott et al., 2010). Furthermore, 
disrupting the BBB using hyperosmotic solution, ultrasound or electromagnetic radiation have 
also been examined (Patel and Patel, 2017). These invasive ways of drug administration are 
limited by the requirement for qualified personnel, as well as with the high risk of infection, 
tissue damage, little patient comfort, and high costs due to hospitalization (Alam et al., 2010, 
Patel and Patel, 2017). 
 
In the urge for finding new ways to circumvent the BBB, the nasal administration of drugs for 
the direct delivery to the brain (namely the nose-to-brain drug delivery) seems to be both 
innovative and promising approach. The nasal route represents a non-invasive administration 
route and offers therapeutic efficacy locally, systemically, and reaching the CNS (Erdő et al., 
2018, Khan et al., 2017, Patel and Patel, 2017). 
 
Before discussing the olfactory and trigeminal nerves` involvement in drug transport from the 
nasal cavity into the brain, a brief introduction of the nasal anatomy and physiology will be 
presented. 
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1.3 Nasal anatomy and physiology 
The nose consists of two nasal cavities with a septum of bone and cartilage between them 
(Crowe et al., 2018, Sahin-Yilmaz and Naclerio, 2011). Each cavity can be further divided into 
the anterior and posterior part as shown in Figure 1.4.  
 
 
Figure 1.4: Lateral section of the human nose and brain, showing the key regions and nerves relevant 
for nose-to-brain drug delivery. Based on Djupesland et al., 2014. 
 
The anterior part (0.4% of total nose area) is the area closest to the peripheral environment 
and creates an opening to the nasal cavity. The posterior part of the nose can be divided into 
the respiratory and olfactory region and represents approx. 90 and 10% of the total nose area, 
respectively. The main functions of the nose are to regulate for humidity and temperature of 
the inhaled air to be transported into the lungs. Along the process, inhaled particles pass 
through the posterior part of the nose and will be either eliminated or absorbed (Crowe et al., 
2018, Illum, 2003, Mistry et al., 2009, Sahin-Yilmaz and Naclerio, 2011). 
 
1.3.1 The respiratory region 
The respiratory epithelium consists of four types of cells. The surface is covered by non-ciliated 
and ciliated cells, the area closest to the epithelium consists of basal cells, and the goblet cells 
are lined among epithelium cells (see Figure 1.5b).  
  




Figure 1.5: Simplified representation of secreted mucin forming the mucus that covers the nasal 
respiratory epithelium. Based on Lock et al., 2018, Murgia et al., 2018. 
 
The respiratory region is highly vascular, and the cells presented here provide for the transport 
of water and ions between nasal mucus, cells, and control the cilia movements. Moreover, the 
goblet cells secrete mucin which is one of the most important components in the nasal mucus 
(Bansil and Turner, 2018, Crowe et al., 2018). 
 
The nasal mucus is a complexed hydrogel consisting mainly of water (95%) and mucins (2%) 
(Bansil and Turner, 2018, Quraishi et al., 1998). The primary structure of mucins is the protein 
backbone consisting of glycosylated and non-glycosylated regions (see Figure 1.5a). The 
glycosylated regions are covalently bound to oligosaccharide side chains and account for up 
to 80% of the molecular weight of mucins. For the non-glycosylated regions, cysteine-rich parts 
serve to form strong bindings with other cysteine-rich regions creating the mesh-like structure 
of the mucus (Bansil and Turner, 2018, Murgia et al., 2018, Quraishi et al., 1998). Due to 
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mucin’s hydrophilic (glycosylated regions) and hydrophobic nature (protein backbone), various 
inhaled particles can be entrapped in the mucus, and be prevented from absorption through 
the nasal epithelium (Bansil and Turner, 2018, Gänger and Schindowski, 2018, Murgia et al., 
2018, Quraishi et al., 1998, Taherali et al., 2018). 
 
1.3.2 The olfactory region 
The olfactory region is located in the upper part of the human nasal cavities (Figure 1.4, yellow 
region). Presented in this region are the olfactory nerves, trigeminal (ophthalmic branch) 
nerves, supporting and basal cells (Crowe et al., 2018). The olfactory epithelium is reported to 
be the only CNS tissue in direct contact with the peripheral environment (Djupesland et al., 
2014). Inhaled particles that come in contact with this nasal region are suggested to give the 
sensation of smell and associations to taste. Drugs that come in contact with the olfactory 
region is suggested to be transported directly into the brain (Crowe et al., 2018, Illum, 2003, 
Mistry et al., 2009). 
 
 
1.4 Nose-to-brain drug delivery 
The most discussed topic considering nose-to-brain drug delivery is the involvement of the 
olfactory and trigeminal nerves (Crowe et al., 2018, Erdő et al., 2018). These nerves expand 
themselves, leaving one end in the nasal cavity and the other end in the brain (Crowe et al., 
2018). The trigeminal nerves are the largest of the cranial nerves and originates from the brain 
stem and branch into the ophthalmic, maxillary, and mandibular nerves. It has to be mentioned 
that the trigeminal (ophthalmic and maxillary branch) nerves are also to be found in the nasal 
respiratory region (Figure 1.4). Drugs that come in contact with these nerves can be potentially 
transported into the brain as well (Crowe et al., 2018, Gänger and Schindowski, 2018). 
 
The transport mechanisms behind the involvement of olfactory and trigeminal nerves in nose-
to-brain drug delivery are not fully understood, but one theory includes both the extracellular 
(paracellular) and intracellular (endocytosis, transcytosis) transport mechanisms (Crowe et al., 
2018, Erdő et al., 2018, Gänger and Schindowski, 2018). Pre-clinical studies suggest that the 
rapid onset of action in CNS after intranasal administration (minutes) is due to paracellular 
transport through the nasal epithelium, leading to direct accumulation in cerebrospinal fluid, 
and thereby distribution into brain tissues. This transport mechanism is suggested to be more 
applicable for hydrophilic molecules below 500 Da. The slow onset of action (hours to days) 
due to neuronal endocytosis and transcytosis transport mechanisms is often reserved for 
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lipophilic molecules (Crowe et al., 2018, Djupesland et al., 2014, Erdő et al., 2018, Gänger and 
Schindowski, 2018). 
 
Utilizing nasal drug administration for brain delivery purposes have shown promising outcomes 
in clinical studies. Nasally administered benzodiazepines (e.g. diazepam and midazolam) for 
the treatment of epileptic seizures have shown to offer more convenience, more rapid onset of 
drug action and better bioavailability in comparison to intravenous or rectal administration 
forms (Henney et al., 2014, Kälviäinen, 2015). Clinical studies have also been carried out on 
nasally administered insulin for the treatment of AD and mild cognitive impairments (Claxton 
et al., 2013, Craft et al., 2017). Insulin administered daily over a study period up to 16 weeks 
showed cognitive and memory improvements suggesting direct nose-to-brain delivery (Claxton 
et al., 2013, Craft et al., 2017). Other clinical studies utilizing the nose-to-brain pathway with 
positive outcomes are summarized in a review by Erdö and colleagues published in 2018. The 
positive therapeutic effects have been suggested to be due to a combination of avoidance of 
first-pass metabolism and renal clearance leading to enhanced drug transport across the BBB 
(Erdő et al., 2018). 
 
Despite that the nose-to-brain drug delivery offers promising results, the long-term effects and 
safety of this administration route are still uncertain (Erdő et al., 2018, Schmid et al., 2018). 
This reflects the limited number of available marketed products. 
 
1.4.1 Nose-to-brain marketed products 
In the Norwegian market (Felleskatalogen, 2019), nasally administered drugs with effect site 
in the brain/CNS are for the chronic pain (fentanyl/Instanyl® from Takeda Pharma AS, Japan) 
and migraine (sumatriptan/Imigran® from GlaxoSmithKline AS, UK and zolmitriptan/Zomig®, 
from Grünenthal GmbH, Germany). Only one marketed local anaesthetic is available for 
intranasal administration (lidocaine/Xylocain®, Aspen Nordic, Denmark). As it can be noticed, 
the marketed drugs are used for symptomatic treatment rather than therapeutic treatment of 
CNS disorders, and these nasal formulations are reserved for short treatment periods. This 
might be due to the many factors that can affect the drug absorption when utilizing nasal route 
of administration. Moreover, long-term use of some intranasal drugs have shown the 
occurrence of local side effects such as congestion, nasal irritation, nose bleed and rhinitis 
(Erdő et al., 2018, Schmid et al., 2018). 
 
Despite the many advantages with nasal administration, the benefit vs safety has to be 
carefully evaluated before developing the nose-to-brain drug delivery system. For this reason, 
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in the next section, some of the considerations when developing nasal formulations are 
discussed. 
 
1.4.2 Considerations for nose-to-brain drug delivery 
The field of nose-to-brain drug delivery is relatively young, where the first patent involving this 
administration route was reported only 33 years ago (Crowe et al., 2018). Despite evidence 
supporting that there might be a direct pathway from the nose to the brain, the transport 
mechanisms are still not clarified (Crowe et al., 2018). Moreover, different factors might affect 
the absorption of drugs through nasal epithelium regarding anatomical, physiological, and 
environmental aspects. In Table 1.1, drug- and formulation-related properties that can affect 
drug absorption through the nasal epithelium are addressed (Khan et al., 2017). 
 
Table 1.1: List of drug- and formulation-related properties that can affect drug absorption through the 
nasal epithelium. 
 Properties For optimal absorption through nasal epithelium 
Drug-related 
Molecular size1 
<300 Da: little influenced by nasal mucus 
<500 Da: cross nasal mucus and epithelium 
>1000 Da: should be formulated with absorption enhancer 
pKa1 Unionized (salt or ester form) preferred 
Solubility1 
Extracellularly: hydrophilic preferred 





Surfactants (e.g. phospholipids), cationic polymers (e.g. 
chitosan), enzyme inhibitors, nanotechnology (e.g. liposomes), 
tight junction modulators, cell-penetrating peptides 
Absorption time1 Within 20 min 
Dosage volume1 Maximum 200 µL per nostril 
Dosage form1,3 Semi-solid > liquid 
pH4,5 
pH 4.6-6.5: favoured 
pH 3-10: minimal cellular and ciliary damage in situ in rats 
Tonicity5,6 
Isotonic and hypertonic (300-600 mOsm/kg): minimal cell and 
ciliary abnormalities 
Information summarized from 1Khan et al., 2017, 2Ghadiri et al., 2019, 3Gänger and Schindowski, 2018, 
4Ohwaki et al., 1987, 5Pujara et al., 1995, 6Homer et al., 2000. 
 
As indicated in Table 1.1, not all drugs are chemically suited for nasal administration, as the 
transport across the nasal epithelium is highly restricted to drugs with certain molecular sizes 
and solubility profiles (Khan et al., 2017). The main barrier regarding drug absorption through 
the nasal epithelium is the nasal mucus (Murgia et al., 2018, Taherali et al., 2018). The ciliary 
action beats 1000 strokes per minute moving the mucus from the anterior to the posterior part 
of the nasal cavity and clears the nose from particles (Gänger and Schindowski, 2018, Illum, 
2003, Murgia et al., 2018, Taherali et al., 2018). The fraction of drug absorbed through the 
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nasal epithelium is thus highly dependent on the compound’s solubility and metabolic stability 
in the mucus, and the drug should be absorbed through the epithelium within 20 min to avoid 
for elimination due to ciliary movements (Ghadiri et al., 2019). 
 
Nasal formulations with the ability to slow down the ciliary action, and protect the drug from 
early degradation and elimination would be attractive when it comes to designing intranasal 
formulations. This can be achieved by the use of absorption enhancers in the drug formulation 
(Ghadiri et al., 2019, Gänger and Schindowski, 2018, Sonvico et al., 2018). Some of the 
promising absorption enhancers include surfactants and cationic polymers (Ghadiri et al., 
2019, Illum, 2003). Surfactants (i.e. fatty acids, phospholipids, and non-ionic surfactants) have 
shown to be promising in improving the paracellular drug transport across nasal epithelium 
with minimal nasal epithelium and mucosa damage in vitro and in vivo (Ghadiri et al., 2019). 
Among the cationic polymers, the chitosan-based ones have shown good mucoadhesive 
properties, increasing residence time on the nasal mucosa, and thereby allowing more drug 
transport through the nasal epithelium. Additionally, chitosan has shown good biocompatibility, 
biodegradability, and low toxicity profiles, making it currently attractive for use in nasal 
formulations (Ghadiri et al., 2019). 
 
In recent years, it has also been proposed that to optimize the brain drug delivery, combining 
nasal administration with nanotechnology-based drug formulation might be an advantage 
(Bourganis et al., 2018, Gänger and Schindowski, 2018, Khan et al., 2017, Patel and Patel, 
2017, Sonvico et al., 2018). 
 
 
1.5 Nanotechnology for nose-to-brain drug delivery 
Nano size is 10-9 of a meter. Applying nanotechnology for biomedical and pharmaceutical 
purposes is a field that is currently rapidly evolving. The first nanoparticulate drug delivery 
system was approved by the FDA in 1996 and since then, a total of 50 nanopharmaceuticals 
are available for use in the clinical practice (Kapoor et al., 2017, Ventola, 2017). The interest 
in using nanotechnology-based delivery systems (called nanocarriers) to deliver drugs to the 
CNS has gained momentum in the recent years (Bourganis et al., 2018, Khan et al., 2017, Li 
et al., 2017). Various animal studies have shown that drugs formulated within nanocarriers can 
enhance drug distribution into the brain, improve drug efficacy, and reduce drug-related side 
effects (Bourganis et al., 2018, Khan et al., 2017, Li et al., 2017, Patel and Patel, 2017). 
 
 Introduction  
13 
Nanocarriers are attractive for their ability to enhance the solubility and potency of potential 
drugs, which are often required for the dosage volumes that are applicable for nasal 
administration (Erdő et al., 2018). Depending on the preparation method, the potential drug 
can be adsorbed to, covalently attached to, or entrapped within the carrier (Li et al., 2017). 
Drug formulated with a nanocarrier can, therefore, be protected from early degradation, thus 
increasing the drug retention time in the nose (Li et al., 2017). In addition, an increase in the 
absorption of compounds through the nasal olfactory or trigeminal nerves might be expected 
(Khan et al., 2017, Patel and Patel, 2017). 
 
The nanocarriers are promising drug delivery systems that can be re-engineered and tailored 
to express certain physiochemical properties with minimal alterations of the potential drug 
(Bourganis et al., 2018, Li et al., 2017). Yet, maximal therapeutic benefits are only achieved if 
the nanocarrier design can ensure optimal available dose at the target site at the right time 
(Bourganis et al., 2018). An overview of the advantages and disadvantages of some of the 
major nanocarrier systems considering nose-to-brain targeting purposes are shown in 
Table 1.2. 
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Table 1.2: Some advantages and disadvantages of lipid- and polymer-based nanocarriers for nose-to-
brain drug delivery. 
Nanosystems Nanocarriers Advantages Disadvantages 
Lipid-based 
Exosomes1 
Good stability, minimal immune 
responses, natural and non-toxic 
Limited knowledge of 




Biocompatible, biodegradable, increase 
BBB transport, low toxic, drug 
protective, provide controlled release, 








Biocompatible, increase BBB transport, 
suitable for surface modifications, 
promote the delivery of small 
molecules, suitable for various 
molecules 
Thermodynamically 






Low toxicity, high drug loading and 
stability, provide controlled release, 
enhance biodistribution 





Biocompatible, biodegradable, increase 
stability and BBB transport, non-toxic, 
provide controlled release, suitable for 





related problems and 





Increase BBB transport, suitable for 
surface modifications and tailorable 




Good stability, increase BBB transport 
and suitable for various molecules 
Limited knowledge of 
biocompatibility 
Microcarriers2 
Compatible with other drug delivery 
systems and mucoadhesive 




Compatible with other drug delivery 
systems, enhance deposition in the 
nasal cavity, increase BBB transport, 
provide controlled release and suitable 
for various molecules 





Increase mucus permeation, nasal 
residence time and BBB transport. 
Suitable for surface modifications and 
tailorable. Natural polymers are cost-
effective, low toxicity and biodegradable 
Limited knowledge of 
catabolites and 
immunologic responses. 
Issues regarding nasal 
irritation and toxicity 
Polymersomes1 
Good stability, suitable for surface 
modifications and various molecules 
Limited knowledge 
Information summarized from 1Li et al., 2017, 2Khan et al., 2017, 3Selvaraj et al., 2018, 4Wong et al., 2012, 
5Bourganis et al., 2018.  
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As shown in Table 1.2, both the lipid- and polymer-based nanocarrier systems offer 
advantages related to increased BBB transport (Li et al., 2017, Patel and Patel, 2017). On the 
other hand, limited knowledge on the biocompatibility, immunogenicity, and toxicity are 
disadvantages seen for several polymer-based nanosystems. 
 
Natural polymers (e.g. alginate, chitosan) are currently preferred in nasal dosage forms due to 
their relatively low cost, low toxicity and good biodegradability compared to the synthetic 
polymers (Bourganis et al., 2018, Ghadiri et al., 2019, Sonvico et al., 2018). However, due to 
their natural origin, batch-to-batch variation may occur. Several synthetic biodegradable 
polymers are approved by the FDA for human use, and they include poly(lactic-co-glycolic 
acid) (PLGA), poly(lactic acid) (PLA), poly(ethylene glycol) (PEG), and poly(ε-caprolactone) 
(PCL) (Marin et al., 2013). To our knowledge, the most studied polymer-based nanosystems 
for nose-to-brain delivery purposes appears to be dominated by the above mentioned synthetic 
polymers (Bourganis et al., 2018, Gänger and Schindowski, 2018, Li et al., 2017, Sonvico et 
al., 2018). Although polymer-based nanocarriers show promising properties, no more focus 
will be given to this topic in this thesis as we have chosen to focus on the liposomes. Liposomes 
provide advantages over many other nanoparticulate drug delivery systems because of their 
low batch-to-batch variation, simple manufacturing, scalable manufacturing possibilities and 
good biocompatibility (Daraee et al., 2016, Sharma et al., 2018). 
 
1.5.1 General introduction to liposomes 
Liposomes are lipid-based vesicles in the nanometric range, consisting of unilamellar or 
multilamellar phospholipid bilayers surrounding an aqueous core. They were first described in 
the 1960s (Bangham and Horne, 1964) and originally, liposomes were used as simple models 
to study biological membranes. For these reasons, the first liposomal formulations were 
extremely simple, consisting of only phospholipids, before eventually adding cholesterol and 
drugs, as demonstrated in Figure 1.6 (de Gier et al., 1968, Immordino et al., 2006). 
  




Figure 1.6: Schematic representation of one unilamellar vesicle comprising drugs and cholesterol. 
 
The first liposome-based drug reached the market in 1996, and liposomes have since then 
been extensively studied for drug delivery purposes. In fact, liposomes are currently 
representing 60% of all the nanosystems in clinical use, and are the most investigated 
nanocarrier for drug delivery purposes (Ventola, 2017). The current focus of liposomes 
development is towards design and creation of sophisticated liposomes for active drug delivery 
purposes (Nisini et al., 2018, Noble et al., 2014, Riaz et al., 2018, Ross et al., 2018). In the 
last decade, liposomes have been expanding into the field of nose-to-brain drug delivery due 
to their promising carrier properties involving good biocompatibility, and tailorable possibilities 
(Bourganis et al., 2018, Li et al., 2017). 
 
1.5.2 Liposomes for nose-to-brain drug delivery 
Liposomes for nose-to-brain drug delivery is a relatively new field, where the first experiments 
carried out in vivo appeared in 2007 (Wattanathorn et al., 2007). Since then, several pre-
clinical studies have shown that drug-loaded liposomal formulations administered via the nose 
increase drug transport into the brain, reduce drug-related systemic side effects and improved 
the drug’s therapeutic efficacy in vivo (Bourganis et al., 2018, Erdő et al., 2018, Vieira and 
Gamarra, 2016). A summary of some nasally administered liposomal drug formulations for 
brain delivery (focused on in vivo rat studies) is represented in Table 1.3. 
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Size: 102 nm 
ZP: -28 mV 
EE: 85% 
Unilamellarity: yes 
Liposomes protected drug from early degradation, safe to 
nasal epithelium, reduced systemic and GI side effects. IN 
increased CNS distribution in comparison to PO. 












Liposomes provided good stability (up to 3 months) and 
prolonged drug release. IN increased drug concentration in 
plasma and CNS in comparison to PO. 
Arumugam 







Size: 112 nm 
ZP: -49 mV 
EE: 84% 
Unilamellarity: no 
Liposomes improved therapeutic efficacy, did not exhibit 
cytotoxic profiles and reduced systemic and GI side 
effects. IN and liposomes increased BBB transport in 
comparison to PO and drug solution. 












IN of liposomes with drug showed neuroprotective and 
neurotropic effects. Liposomes enhanced the antioxidant 
properties of drug when entrapped within liposomes. 
Phachonpai 












Size: 166 nm 
ZP: -10.5 mV 
EE: 33% 
Unilamellarity: ND  
 
Size: 179 nm 
ZP: -9 mV 
EE: 31% 
Unilamellarity: ND 
Surface-modified liposomes increased BBB transport. 
Liposomes provided good stability (up to 4 weeks), 
prolonged drug release and no alterations in ciliary 
movement/nasal epithelium. Surface modified liposomes 
might be cleared out faster than conventional liposomes. 










Size: 112 nm 
ZP: -3 mV 
EE: 71% 
Unilamellarity: yes 
Liposomes protected the peptide from early degradation 
and provided prolonged peptide release. IN compared to 
IV increased peptide concentration in CNS and therapeutic 
efficacy. 
Zheng et al., 
2015 
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IN of liposomes with drug showed decreased anxiolytic-
like activity and enhanced cognitive effects in comparison 
to liposomes without drug. 
Wattanathorn 










Size: 40 nm 
ZP: -48 mV 
EE: 97% 
Unilamellarity: yes 
Liposomes increased iron concentration in CNS. 
Liposomes did not alter nasal epithelium, brain cell, and 
lung epithelial cell morphology. 










Size: 128 nm 
ZP: -15 mV 
EE: 84% 
Unilamellarity: yes 
Liposomes increased therapeutic efficacy. Growth factor 
was transported to CNS with similar efficacy as from 
liposomal formulation and solution, whereas IN had higher 
CNS distribution in comparison to IV. 










Size: 96 nm 
ZP: assumed 
negative at pH 7 
EE: 80% 
Unilamellarity: ND 
Surface modified liposomes expressed higher binding to 
nasal epithelial cells. Liposomes provided prolonged drug 
release and improved therapeutic efficacy. IN decreased 
drug concentration in plasma (assuming drug 











Size: 149 nm 
ZP: 30 mV 
EE: 95% 
Unilamellarity: ND 
IN of liposomes increased CNS distribution, improved 
therapeutic efficacy and decreased side effects. However, 
the liposomal formulation was therapeutically not better in 














Liposomes increased the amount of growth factor into 
CNS in comparison to the solution. Liposomes increased 
therapeutic efficacy. Liposomes did not alter cell viability. 
Yang et al., 
2016 
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Major findings Reference 
Schizophrenia 2 days 
SPC:CHOL 















Size: 91-106 nm 




Size: 99-209 nm 




Size: 99-116 nm 
ZP: -29 to -37 mV 
EE: 54-59% 
Unilamellarity: yes 
Liposomes increased biodistribution of the drug into the 
CNS in comparison to the solution. Amount of drug that 
reached the brain was highest for surface-modified 
liposomes, middle for cationic liposomes and lowest for 
conventional liposomes. IN provided sustained release 
profile in comparison to IV. 
Narayan et 
al., 2016 
bFGF, basic fibroblast growth factor; CHOL, cholesterol; CPP, cell-penetrating peptide; DMPC, dimyristoylphosphatidylcholine; DMPG, dimyristoylphosphatidylglycerol; 
DOPC, dioleoylphosphatidylcholine; DSPC, distearoylphosphocholine; DSPE, distearoylphosphatidylethanolamine; EPC, egg-phosphatidylcholine; GDNF, glial cell line-
derived neurotrophic factor; GI, gastrointestinal; HSPC, hydrogenated soy-phosphatidylcholine; IN, intranasal administration; IV, intravenous administration; MPEG, 
methoxypoly(ethylene glycol); ND, not detected; ODA, octadecylamine; PEG, poly(ethylene glycol); PO, peroral administration; RGD, integrin binding peptide; SA, 
stearylamine; SL, soy-lecithin; SPC, soy-phosphatidylcholine. 
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The human nose consists of approx. 60 µm thick mucus layer, respiratory epithelium and 
olfactory epithelium covering the surface area of 160 and 10 cm2, respectively (Bourganis et 
al., 2018, Crowe et al., 2018, Erdő et al., 2018). The animal models commonly used for 
intranasal drug administration have been dogs, pigs, mice, monkeys, rabbits, rats, and sheep 
(Erdő et al., 2018). The rat’s nasal anatomy is the most different from humans in terms of 
shorter nasal length (2 vs 8 cm), and smaller nasal epithelium surface area (14 vs 160 cm2) 
(Erdő et al., 2018). However, the rat’s olfactory epithelium surface area is approx. 7 cm2, 
relatively comparable to the humans of 10 cm2 (Bourganis et al., 2018). Perhaps that is why 
most pre-clinical in vivo studies on liposomal nose-to-brain drug delivery have been performed 
on rats. 
 
As pointed out in Table 1.3, liposomal sizes in the range from 40 nm (Guo et al., 2017) up to 
10 000 nm (Arumugam et al., 2008) have been studied for nose-to-brain drug delivery, but a 
significant portion was restricted to sizes between 100-200 nm. The most common lipid used 
in the listed liposomal formulations appeared to be the uncharged phosphatidylcholine, often 
in combination with the stabilizing agent, cholesterol. Almost half of the listed studies were of 
more “sophisticated” liposomes, where the surfaces of the nanocarriers were modified (Al 
Asmari et al., 2016, Hoekman et al. 2014, Narayan et al., 2016, Yang et al., 2013, Zheng et 
al., 2015). Surprisingly, these complex liposomes did not necessarily show extraordinary 
improvement in brain transport, side effect profiles or neurological functions in comparison to 
the conventional liposomes or drug solution (Migliore et al., 2014, Yang et al., 2013). One 
reason might be the slow drug release kinetics from these liposomal carriers for both 
hydrophilic and lipophilic compounds (Arumugam et al., 2008, Hoekman et al., 2014, Narayan 
et al., 2016, Yang et al., 2013, Zheng et al., 2015). Another important variable might be the 
physiological aspects using the nose as the administration site. 
 
1.5.3 Challenges for nose-to-brain drug delivery 
The mucociliary clearance rate influences the contact time between the drug formulation and 
the nasal epithelium, which have a direct influence on the distribution into the brain. Many of 
the studies reported in Table 1.3 were conducted under general anaesthesia and/or drug 
administered in a determined position (Arumugam et al., 2008, Guo et al., 2017, Hoekman et 
al., 2014, Li et al., 2012, Phachonpai et al. 2010, Yang et al., 2013, Yang et al., 2016, Zhao et 
al., 2016). It has been emphasized that both of these variables might influence the mucociliary 
function, making it hard to draw comparisons between the therapeutic effects between studies 
(Djupesland et al., 2014, Wu et al., 2008). Moreover, since the mucociliary clearance rate is 
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up to four times faster in rats, the rat animal model might underestimate the efficiency of the 
nose-to-brain pathway (Djupesland et al., 2014, Wu et al., 2008). 
 
Importantly, liposomes administered via the nasal route will be directly exposed to the nasal 
mucus. Under normal physiological conditions, the human nasal mucus tonicity is approx. 
300 mOsm/kg (Pedersen et al., 2007). This value can change considerably as the nasal mucus 
is rather sensitive to the surrounding environment (e.g. air humidity, temperature) (Quraishi et 
al., 1998). It has been reported that hyperventilation in dry air can increase the nasal tonicity 
up to 450 mOsm/kg (Pedersen et al., 2007). These changes are highly relevant for liposomal 
drug formulations as they are colloidal systems. Changes in the dispersing media can cause 
changes at the liposome level, and therefore their release properties. We have focused on 
utilizing the changes in tonicity as a mean to control the drug delivery from nasally administered 
liposomes. To fully understand the consequences of the changes in tonicity on drug release 




1.6 Colligative properties 
Physical phenomena that are mainly influenced by the number of solute molecules in a solution 
are called colligative properties (Sinko and Singh, 2011). The most important colligative 
properties are vapour pressure depression, boiling point elevation, freezing point depression, 
and osmotic pressure (Sinko and Singh, 2011). 
 
The term colligative comes from the Latin word “colligatus” that means connected. In fact, the 
characterization of one of these parameters allows the immediate determination of all the 
others. For instance, the normal freezing, or melting point of a pure compound is the 
temperature at which the solid and liquid phases are in equilibrium under a pressure of 1 atm. 
In this equilibrium, the tendency for a solid to pass into the liquid state, or vice versa, is the 
same. If a solute is added into the liquid at normal freezing point, the temperature lowering 
(namely, freezing point depression) is required to re-establish the equilibrium between solid 
and liquid. In other words, the freezing point depression (or melting point elevation) is colligatus 
with the solute concentration in solution (Sinko and Singh, 2011). The new freezing point (∆Tf) 
can be calculated using Equation 1.1; 
∆𝑇𝑓 = 𝑚𝐾𝑓 
 
Equation 1.1 
where m describes the molality of solute, and Kf the cryoscopic constant. 
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It is known that the liposomal membranes are semi-permeable, and allow neutral, poorly 
polarized, and small molecules to passively diffuse through, whereas ions, highly polarized 
small molecules, and large molecules will not, as shown in Figure 1.7 (Bangham et al., 1967, 
Paula et al., 1996). 
 
 
Figure 1.7: Simplified representation of the semi-permeable nature of the liposomal membrane. 
 
As illustrated in Figure 1.7, the passive migration of solvent molecules through the semi-
permeable membrane is generally called osmosis, and it is initiated by the different chemical 
potential between the two sides of the membrane (Sinko and Singh, 2011). Specifically, solvent 
molecules will diffuse from the side with higher chemical potential (i.e. low solute 
concentration) to the regions with lower chemical potential (i.e. high solute concentration) until 
equilibrium is reached (Sinko and Singh, 2011). Due to osmosis, a pressure (namely, osmotic 
pressure) is created on the liposomal membrane (Sinko and Singh, 2011). 
 
1.6.1 Osmotic pressure 
The osmotic pressure (π) describes the excess pressure applied to a solution to prevent the 
solvents from passing through the membrane (Sinko and Singh, 2011). The first equation 
describing osmotic pressure was proposed by Jacobus van’t Hoff (Equation 1.2). In this 
equation, the osmotic pressure is related to the ideal gas constant (R0), the absolute 







As it can be seen from Equation 1.2, changes in the solute concentration can proportionally 
change the π.  
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It was later found out by Morse and others that if the solute concentration was expressed in 
molality (m) rather than molarity, the calculated theoretical osmotic pressure fitted better to 
experimental findings (Equation 1.3, (Sinko and Singh, 2011)); 
𝜋 = 𝑚𝑅0𝑇 
 
Equation 1.3 
When solutes dissolving in a determined solvent are the electrolytes, the Morse equation 
becomes; 
𝜋 = 𝑖𝑚𝑅0𝑇 
 
Equation 1.4 
In Equation 1.4, i represents the number of dissociating ions (namely, the van’t Hoff factor). 
For non-electrolytes, such as glucose, i remains to be 1, whereas sodium chloride which can 
dissociate into sodium and chloride ions in solution has i=2. It has to be kept in mind that i is a 
value for ideal conditions that do not take into account some not totally dissociating 
compounds, and possibly ion pairings in solution. The measured i, and i for ideal conditions 
might for these reasons deviate for some compounds. However, for strong electrolytes such 
as sodium chloride, i can be considered to be equal to 2 (Sinko and Singh, 2011). 
 
The osmotic pressure created on the liposomal membrane is relevant when it comes to the 
development of liposomal drug delivery systems since the osmotic pressure can cause the 
liposomes to shrink, or swell due to their close vesicle structures (see Figure 1.8) (Alam Shibly 
et al., 2016, Fujiwara and Yanagisawa, 2014, Mui et al., 1993, Ohno et al., 2009). 
 
 
Figure 1.8: Simplified representation of the solvent diffusion process across the liposomal membrane 
under the influence of different environment. 
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As schematically presented in Figure 1.8, due to the migration of the solvent, the liposomes 
swell in a hypotonic environment and shrink in a hypertonic environment. Because of the 
liposomal size changes, and consequently the changes in the liposomal membrane rigidity, 
the drug release kinetics from the liposomes might be affected (Ahumada et al., 2015, 
Chabanon et al., 2017).  
 
In order to achieve controlled drug diffusion across any barrier, it is necessary to understand 
the release mechanism from liposomes. To study the release from liposomes, drug diffusion 
studies can be applied (Solomon et al., 2017). 
 
 
1.7 Drug diffusion study 
Passive diffusion is the movement of molecules due to chemical potential (i.e. concentration) 
gradient. Let us consider the movement of drug molecules dissolved in water that are all 
located on one side of a compartment divided by the physical permeable barrier (Figure 1.9). 
Solute molecules will move from the compartment from areas with high drug concentration 
(with higher chemical potential, donor compartment) to low drug concentration (namely, 
acceptor compartment) (Sinko and Singh, 2011). In this situation, the drug diffusion can be 
assumed to be in just one direction, and the degree of drug diffusion across the barrier can be 
affected by the barrier properties (e.g. barrier structure, interaction) (Brandl et al., 2007, Brodin 
et al., 2010). 
 
 
Figure 1.9: Simplified representation of the one-directional movement of molecules across a physical 
permeable barrier. 
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One common way to describe drug diffusion across a barrier is by using the concept of flux. 
Mass flux (j) is defined as the mass variation over time (dm/dt) across a defined surface area 
(A) as shown in Equation 1.5; 
𝑗 =  
𝑑𝑚
𝑑𝑡






The net drug diffusion across a barrier can be categorized into the steady, and non-steady 
state conditions. The steady state condition, in which the flux is considered to be constant over 
the experimental time interval, is preferential. In this case, the simplified version of Fick’s first 
law (Equation 1.6) is considered acceptable (Brodin et al., 2010); 







In this equation, D represents the diffusion coefficient, (C0d-Ca) the drug concentration 
difference between the two sides of a barrier with thickness = x. From Equation 1.6, the flux is 
proportional to the concentration gradient. If (C0d-Ca)/x = constant, a zero order diffusion kinetic 
is established, and the experimental data can be therefore fitted by the linear regression 
models (see Figure 1.10) (Brodin et al., 2010, Nothnagel and Wacker, 2018). 
 
 
Figure 1.10: Example of a drug diffusion profile representing steady state and non-steady state 
conditions. 
 
Apparent permeability coefficient (Papp) is commonly used to quantify the ability of molecules 
in crossing barriers (Brodin et al., 2010). The constant flux in in vitro diffusion studies can be 
achieved by creating a large enough and constant concentration gradient between the donor 
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and acceptor compartment. This is usually achieved by working under sink conditions, 
therefore by constant removal of accumulated material in the acceptor compartment. It is 
generally considered sink condition when the concentration in the acceptor compartment is 
kept <10% of the donor drug concentration under the whole study period (Brodin et al., 2010). 
Under these premises, the amount of drug applied in donor compartment is assumed to be 
constant over the whole experiment, and the concentration difference (C0d-Ca) can be assumed 
to be equal to the initial drug concentration of the formulation (C0d) (Brodin et al., 2010). 













It is sometimes convenient to highlight the barrier’s resistance (R) to drug permeation. R is the 
inverse of the permeability, as shown in Equation 1.8; 






For studying the release from nanocarriers, the standard way to treat diffusion data is based 
on semi-empirical approaches, where experimental data (e.g. obtained from in vitro drug 
diffusion study) are fitted to mathematical models (Jain and Jain, 2016). By quantifying the 
amount of drug that permeates the diffusion barrier, the diffusion data can be fitted to linear, 
and non-linear regression models to predict drug release from the nanocarrier (Jain and Jain, 
2016, Nothnagel and Wacker, 2018). 
 
1.7.1 Drug release from liposomes 
In the case of drug-loaded liposomal dispersions, drug molecules need to cross two physical 
barriers (first the liposomal bilayer, and thereafter the diffusion barrier) in order to accumulate 
into the acceptor compartment. In this case, the net drug transport across the diffusion barrier 
is considered to be dependent on two diffusion mechanisms (see Figure 1.11, (Wacker, 
2017)). 
  




Figure 1.11: Simplified representation of the currently used semi-empirical approach where drug 
permeation across a diffusion barrier is used to predict the drug release mechanism from the liposome. 
 
Three possible outcomes can be expected when discussing drug release from liposomes (Jain 
and Jain, 2016); 
i) Release rate ≈ flux: constant concentration gradient across the diffusion barrier 
giving a (close to) perfect zero order diffusional curve. In this situation, linear 
regression models could be used. 
ii) Release rate < flux: reduced concentration gradient across the diffusion barrier 
giving a first, or pseudo order diffusional curve. The nanocarrier is contributing to a 
sustained drug release. In this situation, non-linear regression models should be 
used. 
iii) Release rate > flux: increased concentration gradient across the diffusion barrier 
giving a positive deviation from the linear diffusional curve. The nanocarrier is 
enhancing the net transport of the drug across the diffusion barrier. In this situation, 
non-linear regression models should be used. 
 
1.7.1.1 Linear approximation 
Based on the assumption that the total resistance to drug transport of drug-loaded liposomes 
is caused by the sum of single resistances (caused by each of the physical barriers involved), 
the liposomal bilayer’s contribution to drug transport can be calculated using Equation 1.9; 
𝑅𝐿 =  𝑅𝑇 − 𝑅𝐵 
 
Equation 1.9 
where the total resistance to drug transport (RT, calculated from 1/Papp of drug-loaded 
liposomes), and the resistance to drug transport through permeable barrier (RB, measured 
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from 1/Papp of drug reference solutions) can be predetermined to calculate the resistance to 
drug transport through liposomal bilayer (RL). 
 
This linear approximation of the drug diffusion data might lead to wrong interpretations as the 
concentration gradient across the diffusion barrier might not be constant under the whole study 
period when the drug is formulated with liposomes (non-steady state). This can be due to the 
presence of the unentrapped drug in the liposomal formulation, reversible drug binding to the 
carrier, and interaction between drug and the barrier (Modi and Anderson, 2013, Nothnagel 
and Wacker, 2018). The presence of unentrapped drug can be solved by the removal of freely 
unentrapped drug from a liposomal drug formulation so the drug diffusion across the diffusion 
barrier represents the direct release from the nanocarrier. However, it should also be taken 
into consideration that the most common methods to remove freely unentrapped drug are 
based on passive diffusion principles. The removal of the freely unentrapped drug might 
introduce the system to a new shift in drug concentration equilibrium across the liposomal 
barrier which can complicate the interpretation of the drug release from the nanocarrier 
(Nothnagel and Wacker, 2018). For these reasons, it has become more common to fit the in 
vitro diffusion data to non-linear regression models (Jain and Jain, 2016). 
 
1.7.1.2 Non-linear approximation 
Some of the most common non-linear mathematical models to describe drug release 
phenomena from semi-solid dosage forms are the Higuchi and the Korsmeyer-Peppas model 
(Costa and Sousa Lobo, 2001, Jain and Jain, 2016). Experimental data are fitted to any of the 
above-mentioned models taking into account different variables such as the surface area of 
dosage form, or the solubility of the drug (Higuchi) (Costa and Sousa Lobo, 2001, Jain and 
Jain, 2016). 
 
The Korsmeyer-Peppas model is commonly used to analyse the release mechanism from 
nanocarriers which is unknown, or when more than one type of release phenomena might be 
involved (e.g. drug release affected by geometry, swelling, or shrinkage of the nanocarrier) 
(Costa and Sousa Lobo, 2001). The in vitro diffusion data are plotted as the fractional 
permeated drug (Mt/M∞ up to 60%) over time (t) and fitted to the Korsmeyer-Peppas equation 
(Equation 1.10, (Korsmeyer et al., 1983)); 
𝑀𝑡
𝑀∞
= 𝐾 ∙ 𝑡𝑛 
 
Equation 1.10 
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From the fitted curve to Korsmeyer-Peppas equation, the transport constant (K), and transport 
exponent (n) provide information related to the drug formulation such as drug properties, 
structural characteristics of the nanocarriers, and drug release mechanism. The most 
interesting variable is the exponent value, n, that can be used to indicate how far the migration 
process is from Fickian diffusion (Korsmeyer et al., 1983). 
 
When the exponent n=1, it is evident from Equation 1.10 that the drug release rate is directly 
dependent on time. In this situation, the release kinetics correspond to zero order, and the 
diffusion is non-Fickian (see also Figure 1.12). 
 
  
Figure 1.12: Simplified representation of the diffusion curves that can be expected when discussing 
drug release from liposomes. 
 
On the contrary, if the exponent n=0.5, the drug release rate is dependent on the square root 
of the time. In this situation, the release kinetics correspond more to the first order, and the 
diffusion is approximated to exhibit Fickian behaviour (Ritger and Peppas, 1987). The 
interpretation of the exponent n is a bit more complicated when it falls in between 0.5 and 1. 
When 0.5<n<1, the release kinetics correspond to pseudo-first order and can describe both 
phenomena of Fickian- and non-Fickian-controlled drug release. 
 
We have selected markers and drugs to cover a wide range of relevant physiochemical 
properties to challenge the liposomes suitability to be used as osmotically active liposomes for 
nose-to-brain drug delivery. This to prove that controlled release from liposomes can be 
achieved by controlling the environment surrounding the liposomes. 
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1.8 Fluorescent markers and drugs used in this study 
1.8.1 Fluorescent markers 
In the development of a drug formulation, it is common to start formulation development 
applying markers to verify a concept before using drugs. The fluorescent markers (Figure 1.13) 
were chosen because of their physiochemical properties and known applicability when 
studying lipid membrane properties (Ahumada et al., 2015, Chabanon et al., 2017, Maherani 
et al., 2013, Oglecka et al., 2014). Both calcein and rhodamine are reported to be successfully 
entrapped into liposomes and give bright fluorescent signals (Chabanon et al., 2017, Maherani 
et al., 2013). 
 
 
Figure 1.13: Molecular structures and general physiochemical properties of the fluorescent markers 
used in this thesis. Information summarized from aMaherani et al., 2013, bFlaten et al. 2006, cToropainen 
et al., 2001, dPittman et al., 2001. 
 
Calcein is a hydrophilic marker, which upon entrapment, is localized in the liposomal aqueous 
core (Flaten et al., 2006, Maherani et al., 2013). The other fluorescent marker of choice was 
rhodamine, a lipophilic marker which can be incorporated in the phospholipid bilayer of 
liposomes (Pittman et al., 2001, Toropainen et al., 2001). As a result of the different osmotic 
gradient across a liposomal membrane, an increase or decrease of the fluorescence intensity 
can be promoted by the changes in the liposomal inner volume due to osmosis (Ahumada et 
al., 2015, Chabanon et al., 2017, Maherani et al., 2013). This provides important information 
on the mechanism of release from liposomes and is the first step that needs to be validated 
before proceeding with the development of drug-loaded liposomal formulations. 
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1.8.2 Drugs 
As a recap to the previous section (Section 1.2), the controlled microenvironment is essential 
to maintain optimal neuronal functions in the brain. Alterations of the BBB structure and/or 
duration of an imbalance in the microenvironment might contribute to the development of CNS 
disorders (Abbott et al., 2010, Daneman and Prat, 2015). It has been proposed that BBB 
alterations might be due to elevated oxidative stress levels, or inflammation in the brain (Patel, 
2016, Stephenson et al., 2018). Epidemiological observation indicates that long-term 
administration of anti-inflammatory drugs (>1 year) showed delayed or lower risk of CNS 
disorder development such as Alzheimer’s disease, Parkinson’s disease, and multiple 
sclerosis (Aisen, 2002, Onatibia-Astibia et al., 2017). Therefore, anti-inflammatory drugs have 
been proposed to be potential candidates to prevent and/or treat several CNS disorders 
(McCaulley and Grush, 2015, Onatibia-Astibia et al., 2017). 
 
Despite promising pre-clinical results, the statistical evidence that anti-inflammatory drugs can 
prevent and/or treat any CNS disorders are still clinically unproven (McCaulley and Grush, 
2015, Onatibia-Astibia et al., 2017). It has been suggested that these failures might be related 
to patient selection, drug selection, drug dosage, therapy duration, but more importantly the 
low drug delivery across the BBB when utilizing the conventional administration routes (Lehrer, 
2014, McCaulley and Grush, 2015, Onatibia-Astibia et al., 2017). 
 
The therapeutic effect of anti-inflammatory drugs might be enhanced by utilizing liposomes 
and the nasal administration route. Even though it was beyond the scope of this thesis to 
investigate the therapeutic effects associated with nose-to-brain drug delivery, it was important 
to select the relevant drugs to be formulated into liposomes that might have great potential for 
the treatment and/or prevention of a wide range of CNS disorders. For this reason, six already 
marketed drugs with anti-inflammatory properties were chosen (see Figure 1.14) (McCaulley 
and Grush, 2015, Onatibia-Astibia et al., 2017). 
  




Figure 1.14: Molecular structures and general physiochemical properties of the drugs used in this 
thesis. Information summarized from aZhu et al., 2002, bPubChem, 2019a, cPubChem, 2019d, dStein et 
al., 2011, ePubChem, 2019c, fPubChem, 2019b. 
 
As presented in Figure 1.14, the different drugs selected for this study expressed different 
physiochemical properties such as partition coefficient (logD7.4) and ionization constant (pKa). 
Two of the parameters that can be used to predict the bioavailability of a drug are the 
permeability (can be expressed as logD7.4) and solubility (can be expressed as pKa) (Ashford, 
2013). 
 
The partition coefficient describes the concentration ratio of a chemical entity between two 
immiscible solvents at equilibrium. The most common solvent system is octan-1-ol/water. The 
octan-1-ol phase mimics the short hydrocarbon chains that make up in many biological 
barriers, whereas the water phase mimics the aqueous environment. Therefore, the partition 
coefficient of a drug can be used to estimate the permeability of a drug (Gaisford, 2013). 
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The degree of the partitioning of partially ionizable solutes is better described by logD which 
take into account the pH of the aqueous phase (Gaisford, 2013). Since we aimed to perform 
all the experiments in this study at physiological pH, the logD at pH 7.4 (logD7.4) of each of the 
selected drugs are represented in Figure 1.14. 
 
The logD7.4 is not only providing information related to the permeability across biological 
barriers, but it can also be used to predict the drugs’ localization inside liposomes. A logD7.4 
above 1 indicates that more drug is favourably distributed in the octan-1-ol in comparison to 
the aqueous phase, and these drugs will most likely incorporate in the liposomal bilayer (Nii 
and Ishii, 2005). On the contrary, logD7.4 below 1 indicates that more drug is distributed in the 
aqueous phase, and will most likely be entrapped in the inner core of liposomes (Xu et al., 
2012). 
 
The ionization constant (pKa) describes the number of dissociated (i.e. ions) and undissociated 
molecules in a solution, a collective term used for both weakly acidic and basic drugs. Whether 
a drug molecule is dissociated or not in a solution is highly dependent on the pH of the solution. 
The relationship between pH and pKa can be described using the Henderson-Hasselbach 
equations. The equation for a weak acid is shown in Equation 1.11; 






From Equation 1.11, the experimental pH and the pKa of a drug molecule can be used to find 
the ratio between the weak acid (HA) and the conjugate base (A-). When pH is greater than 
pKa of a drug molecule (pH>pKa), the drug will be dissociated, yielding the charged conjugate 
base. On the other hand, when pH is less than pKa (pH<pKa), most of the drug will be in the 
uncharged weak acid form in a solution. The Henderson-Hasselbach equation for a weak base 
is shown in Equation 1.12; 






From Equation 1.12, pH>pKa yields the uncharged weak base (B) form in solution, and 
pH<pKa yields the charged conjugate acid (BH+). The relationship between dissociated and 
undissociated molecules in a solution is relevant as it is directly linked to the drug’s aqueous 
solubility (Aulton, 2013). 
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The relationship between bioavailability, permeability, and solubility can be explained by the 
biopharmaceutics classification system (BCS) (Wu and Benet, 2005). For the oral route of drug 
administration, the drug has to be dissolved in order to be absorbed. For this reason, the BCS 
classifies drugs according to their aqueous solubility at gastric pH range, and permeability 
across the gut wall (Ashford, 2013). 
 
The four BCS classes are; 
1) high solubility and high permeability 
2) low solubility and high permeability 
3) high solubility and low permeability 
4) low solubility and low permeability. 
 
The main purpose of the BCS was to replace in vivo bioavailability study with in vitro data. 
Even though the BCS original purpose was focused on oral dosage forms, BCS is currently 
used by regulatory authorities as a guide to approve generics and is used by scientists as a 
guide to design drug delivery systems for any route of administration (Ashford, 2013). 
 
Generally, BCS class 1 drugs are the most preferable. In this category, the drugs have high 
solubility and high permeability. Unless the drugs form insoluble complexes with biological 
fluids or undergo rapid clearance in vivo, these drugs will be rapidly absorbed and show good 
bioavailability. The BCS class 1 drugs selected for this study were the caffeine, theophylline, 
hydrocortisone and methylprednisolone (Ashford, 2013, Benet et al., 2011). The second most 
preferable is BCS class 2 drugs. In this category, the drugs have low solubility but high 
permeability. These drugs are strictly limited by the drug’s dissolution rate and will likely not 
show good bioavailability unless assisted by the right formulation that enhance the drugs’ 
solubility profile (Ashford, 2013). The BCS class 2 drugs selected for this study were the 
ketoprofen and ibuprofen (Benet et al., 2011). BCS class 3 and 4 drugs have limitation 
regarding low permeability and can be problematic to achieve good bioavailability (Ashford, 
2013, Benet et al., 2011). None of the selected drugs for this study were in these two classes. 
 
To summarize, all the drugs included in this study were mainly chosen due to their reported 
anti-inflammatory properties and potentials in the prevention and/or treatment of CNS 
disorders. All have not been, up to now, proven clinically relevant which might be contributed 
to non-ideal study design, or sub-optimal administration route. It was also important to choose 
the drugs with different physiochemical properties to be entrapped within liposomes. The 
selected six different drugs exhibited logD7.4 ranging from ~0 to 2, and pKa ranging from 4.5 
to 10.4, considered to be relevant for this study. 
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2 Aims of the study 
The general aim of this project was to develop osmotically active liposomes suitable for nose-
to-brain drug delivery. 
 
For these reasons, the specific aims during the project have been to; 
i) Investigate if large unilamellar vesicles (LUVs) made from soy-phosphatidylcholine are 
osmotically active in terms of size and release when formulated with; 
o Fluorescent markers (calcein and rhodamine) 
o Drugs (caffeine, theophylline, ketoprofen, ibuprofen, hydrocortisone, and 
methylprednisolone) 
ii) Evaluate the drug release from LUVs using; 
o Low retention diffusion barrier (regenerated cellulose) 
o High retention diffusion barrier (biomimetic Permeapad®) 
iii) Analyse the in vitro diffusion data using; 
o Linear regression (zero order model) 
o Non-linear regression (Korsmeyer-Peppas model) 
iv) Evaluate the effect of cholesterol incorporation in the liposomal bilayer on the drug 
release from LUVs  
v) Evaluate the effect of mucin on the drug release from LUVs 
vi) Evaluate the stability of the liposomal formulations upon storage. 
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3 Summary of papers 
3.1 Paper I 
The aim of Paper I was to investigate the underlying mechanisms on how changes in the 
environmental tonicity could influence the liposomal size and release. The graphical abstract 
of this paper is represented in Figure 3.1. 
 
 
Figure 3.1: Graphical abstract for Paper I. Reproduced from Wu et al., 2017, with permission from 
Elsevier. 
 
In Paper I, liposomes were prepared in phosphate buffer saline (PBS, pH 7.4) with an 
osmolality of 65 and 300 mOsm/kg, respectively. Giant unilamellar vesicles (GUVs) were 
prepared using a swelling method modified from Mocho et al. (1996) followed with extrusion 
to obtain large unilamellar vesicles (LUVs) within acceptable sizes for nasal administration 
(around 400 nm). To ensure the lamellarity of the LUVs, phase contrast microscopy was 
employed and confirmed the liposomal integrity (unpublished results). Entrapped within the 
LUVs were two fluorescent markers of different physiochemical properties, namely calcein 
(hydrophilic) and rhodamine (lipophilic). 
 
The LUVs were exposed to PBS of different tonicity to generate a different gradient of salt 
concentration within the internal and external environment of the liposomes. This was based 
on the assumption that the measured osmolality of the PBS used to prepare the LUVs would 
represent the inner core tonicity, whereas the osmolality of the PBS that LUVs were exposed 
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to would represent the external environment tonicity. The relative osmotic pressure (πrel), 
generated on the liposomal surfaces was expressed as negative or positive πrel to describe 
the water influx or efflux into/from liposomes, respectively. 
 
Liposomal sizes were monitored after LUVs were exposed to different environment. The LUVs 
seemed to be more susceptible to osmotic swelling than shrinking, and size changes were 
more evident for empty and calcein-LUVs in comparison to rhodamine-LUVs. These findings 
were in agreement with the marker’s different physiochemical characteristics; the lipophilic 
compound (rhodamine) contributes to more rigid liposomal bilayer and reduces liposomes 
sensitivity to osmotic stress. On the other hand, calcein (hydrophilic) have no such effect as it 
is localized in the aqueous core. 
 
The flux of marker through the regenerated cellulose barrier (using Franz diffusion cell set-up) 
was monitored to describe the release from the liposomes. The marker flux across the diffusion 
barrier seemed to correlate with changes in the πrel. Decreased amount of calcein diffused 
through the diffusion barrier when LUVs were exposed to hypotonic environment, whereas the 
enhanced amount of calcein diffused in a hypertonic environment (when compared to isotonic 
condition). These results indicated that the release from LUVs was dependent on the interplay 
between the water flux and marker release direction (probably due to the hydrophilic nature of 
calcein). Rhodamine-LUVs, on the other hand, were generally less affected by the changes in 
πrel. 
 
The LUVs seemed to be suitable to entrap various compounds and showed promising carrier 
properties in terms of their osmotic activity. It would be, therefore, interesting to explore this 
phenomenon further by entrapping the LUVs with various drugs and investigate more 
thoroughly how the different degrees of environmental tonicity perturbations change the drug 
release from liposomes. 
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3.2 Paper II 
The aim of Paper II was to focus on detailed hypotonic exposures of LUVs entrapping six drugs 
of different physiochemical properties (caffeine, hydrocortisone, ibuprofen, ketoprofen, 




Figure 3.2: Graphical abstract for Paper II. Reproduced from Wu et al., 2019b, with permission from 
Elsevier. 
 
The nasal mucus is in direct contact with the surrounding environment and the tonicity of the 
nasal mucus is relatively inconsistent and highly alterable. For these reasons, the physiological 
condition of the nose such as tonicity is an important parameter to consider if liposomal drug 
formulations are intended for nasal administration. 
 
A similar methodology was applied for the investigation of drug release as described in Wu et 
al. (2017) by using the Franz diffusion cell set-up. Unlike the previous paper, the tonicity of the 
prepared LUVs formulations were measured instead of being calculated. To our surprise, 
liposomes itself acted as strong tonicity enhancers increasing the total tonicity of the whole 
formulation with 350-400 mOsm/kg. From these observations, the measured osmolality of the 
whole LUVs dispersion was assumed to represent the tonicity of the inner core of the 
liposomes. 
 
The PBS used to create different external environment was adjusted according to the 
measured osmolality of LUVs, and in total, seven different degrees of hypotonic environment 
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ranging from 0 up to 650 mOsm/kg in differences between the LUVs and the external 
environment were created (∆mOsm/kg). After the exposure of LUVs to hypotonic environment, 
the size distribution was monitored and vesicle populations of bigger sizes could be detected 
for the most hypotonic environment, indicating swelling of the LUVs. 
 
Similarly to findings in Paper I, the changes in drug diffusion across the regenerated cellulose 
barrier were most apparent for the hydrophilic drugs in comparison to the 
lipophilic/hydrophobic drugs. More importantly, all drug-loaded LUVs exposed to hypotonic 
environment (∆mOsm/kg approx. 300) exhibited a significant increase in the apparent 
permeability (Papp) across the diffusion barrier, indicating that the tonicity perturbations played 
an essential role in the drug release from liposomes. To better describe the changes in the 
drug release, the Papp was expressed as the resistance to drug transport through liposomal 
bilayer (RL) to better highlight the contribution given by the liposomal carrier. 
 
The further research scope was to optimize the liposomal formulation and investigate if similar 
behaviour could be found when a more biomimetic diffusion barrier was used. We also wanted 
to investigate the LUVs’ response to both hypotonic and hypertonic environment. 
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3.3 Paper III 
The aim of Paper III was to clarify the dynamics behind the influence of tonicity perturbations 
on the changes in drug release from liposomes. The graphical abstract of this paper is 
represented in Figure 3.3. 
 
 
Figure 3.3: Graphical abstract for Paper III. Reproduced from Wu et al., 2019a, with permission from 
Elsevier. 
 
For this study, LUVs were prepared to entrap individually either caffeine or hydrocortisone, 
and with various amounts of cholesterol incorporated in the lipid bilayer (11 and 25% w/w). 
The in vitro diffusion study was carried out utilizing both the standard regenerated cellulose 
and the innovative biomimetic Permeapad® barrier to achieve better in vitro/in vivo correlation 
for the nasal environment. The LUVs were exposed to 300 mOsm/kg differences between 
initial LUVs and external environment (the optimal tonicity difference according to Paper II). 
Both linear regression (zero order) and non-linear regression (Korsmeyer-Peppas) models 
were used to treat the experimentally determined diffusion data to predict the release from 
liposomes. 
 
Similar to Papers I and II, the amount of diffused drug through the diffusion barrier changed 
according to the tonicity perturbations of the external environment surrounding the LUVs. For 
instance, an increased amount of drug diffused through the diffusion barriers when LUVs were 
exposed to a hypotonic environment. On the other hand, decreased drug diffusion was 
detected in the hypertonic environment. 
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The drug diffusion rate through the regenerated cellulose barrier was higher when compared 
to Permeapad® barrier, which can be explained by the different structures of the diffusion 
barriers. The regenerated cellulose exhibits low retention to drug diffusion (controlled by drug 
concentration gradient). On the other hand, Permeapad® barrier is a thicker barrier containing 
lipids that exhibit higher retention to drug diffusion. 
 
The structural changes of the liposomes (incorporation of cholesterol) and its direct effect on 
the drug diffusion rate across the diffusion barrier were strongly correlated. The incorporation 
of cholesterol in liposomal bilayer seemed to limit the LUVs’ sensitivity to osmotic stress. 
 
The in vitro diffusion data interpreted using the zero order and Korsmeyer-Peppas model were 
in good agreement. Both models provided important information related to the release from 
liposomes. Korsmeyer-Peppas model offered additional advantages as being less time-
consuming due to avoidance of the need for reference experiments including drug solutions, 
which the zero order model required. 
 
This paper confirmed the necessity to use both linear and non-linear regression models during 
the assessment of drug release phenomena from liposomes. The Korsmeyer-Peppas model 
was found to be suitable for this study to improve the interpretation of drug release from LUVs 
under osmotic stress. In terms of stability upon storage, LUVs with 11% w/w cholesterol were 
found to be superior in comparison to 0 and 25% w/w, respectively. These findings can be 
utilized in the development of liposomal formulations intended for nose-to-brain drug delivery. 
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4 Experimental section 
Materials and Methods employed in this thesis are described in Papers I-III. The first part of 
this section describes the calculation used to determine the relative osmotic pressure (πrel) 
generated on the liposomal membrane, used in Paper I. The latter part of this section provides 
information on the preliminary experiments with mucin that are not included in the Papers I-III. 
 
 
4.1 Osmotic pressure calculations 
As previously described in Section 1.6, the osmotic pressure can be calculated using the van’t 
Hoff and the Morse equation. The equations propose that the difference in salt concentration 
on both sides of a semi-permeable membrane will generate an osmotic pressure on the 
membrane. As the internal and external environment of liposomes can have different salt 
concentrations, this assumption may apply to liposomal membranes as well. 
 
In this study, the measured salt concentration of the PBS used to prepare the liposomes, and 
the PBS used to expose the liposomes were represented as the internal and external 
osmolality of LUVs. Based on this assumption, an adaptation of the van’t Hoff and Morse 
equation could be expressed as followed (Equation 4.1); 
𝜋𝑟𝑒𝑙 = (𝑂𝑠𝑚(𝑜𝑢𝑡) − 𝑂𝑠𝑚(𝑖𝑛))𝑅0𝑇 
 
Equation 4.1 
In Equation 4.1, the R0 represents the ideal gas constant, T the absolute temperature, and 
Osm(out)-Osm(in) represents the osmolality difference between the external and internal 
environment of LUVs. A positive πrel indicates that the LUVs are exposed to a hypertonic 
environment, causing solvent molecules to migrate from the inner core to the external 
environment of the liposome. On the contrary, a negative πrel indicates that the LUVs are 
exposed to a hypotonic environment, causing solvent molecules to migrate from an external 
environment to the internal core of liposomes. 
 
 
4.2 Experiments involving mucin 
When performing in vitro diffusion study, it is important to tailor the experimental conditions as 
close as possible to the real biological conditions to obtain good in vitro/in vivo correlation. We 
have already described in Paper III the use of the Permeapad® barrier for the purpose to mimic 
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the nasal epithelium. Furthermore, we also wanted to include mucin in our experiments to 
mimic nasal mucus. 
 
One of the main constituents of nasal mucus is mucin (Bansil and Turner, 2018, Quraishi et 
al., 1998). The purified porcine stomach mucin type III is commonly used for in vitro studies 
due to the resemblance to human mucins in terms of structure and molecular weight (Groo 
and Lagarce, 2014, Lock et al., 2018). Within the range of mucin concentration used in this 
study, the purified mucins were considered suitable for the determination of drug diffusion 
hindrances caused by the electrostatic and hydrophobic interactions (Lock et al., 2018, Murgia 
et al., 2018). 
 
4.2.1 Preparation of mucin dispersions 
Mucin from porcine stomach type III (bound sialic acid 0.5-1.5%, partially purified, Sigma-
Aldrich Chemie GmbH, Steinheim, Nordrhein-Westfalen, Germany) was dispersed in PBS at 
a concentration of 1 mg/mL, following previous reports (Chen et al., 2013, Qiang et al., 2012). 
At this mucin concentration, the mucin was homogeneously dispersed in the PBS. The 
osmolality and pH of PBS before and after the addition of mucin were measured using a Semi-
Micro Osmometer Model 4602 (Knauer, Berlin, Germany) and SensION™ +PH31 pH meter 
(Hach Company, Barcelona, Spain), respectively. To avoid mucin degradation when dispersed 
in PBS, mucin dispersions were stored at 4°C and protected from direct sunlight and used 
within 7 days after preparation. 
 
4.2.2 In vitro diffusion study in the presence of mucin 
The diffusion study was performed as previously described by Wu et al. (2019a). For the in 
vitro diffusion studies involving mucin, mucin dispersion (0.3 mL, concentration of 1 mg/mL) 
was added on top of the different diffusion barriers (regenerated cellulose or Permeapad® 
barrier) instead of PBS before LUVs dispersion was added (0.5 mL). The total concentration 
of mucin was approx. 0.4 mg/mL in the donor compartment at the start of the experiment (t=0) 
in agreement with previously reported conditions (Khatri et al., 2008). The diffusion study was 
conducted under the same conditions as in the experiments where mucin was not included. 
 
 Results and discussions  
45 
5 Results and discussions 
This thesis aimed to develop osmotically active liposomes for nose-to-brain drug delivery. The 
rationale for using liposomes as a drug delivery system is already described in Section 1.5. 
 
As previously discussed, a sufficient amount of drug needs to be efficiently absorbed through 
the nasal epithelium to obtain therapeutic levels of a drug in the brain (Bourganis et al., 2018, 
Khan et al., 2017). To achieve controllable permeation across any biological barriers, it is of 
great importance to first understand the drug release from the nanocarrier when drug is 
delivered via nanocarrier. One of the major challenges considering the development of nasally 
administered liposomal drug formulations is the nasal mucus. Nasal mucus tonicity is known 
to fluctuate greatly due to its sensitivity to the environmental and physiological factors (Quraishi 
et al., 1998). The liposomal membrane has a semi-permeable nature (Bangham et al., 1967, 
Paula et al., 1996), and liposomes that come in direct contact with mucus might undergo 
unpredictable behaviour due to the tonicity differences that can take place. 
 
Therefore, the work was carried out by firstly validating the liposomes’ susceptibility to osmotic 
stress. Once validated, a wider range of liposomal formulations and the tonicity differences 
between the formulation and external tonicity were screened, which assisted us to choose the 
relevant drugs and tonicity differences to investigate. We then tried to optimize the 
experimental condition to better mimic the nasal environment by using the newly developed 
Permeapad® barrier and mucin. Simultaneously, more advanced liposomal formulations were 
prepared by incorporating various amounts of cholesterol, and their drug release and stability 
upon storage were evaluated. All these variables were considered important for the 
development of osmotically active liposomes for nose-to-brain drug delivery. 
 
On those grounds, in the first part of Results and discussions, the focus is put on the general 
characteristics of all LUVs dispersions prepared throughout this project. 
 
 
5.1 Characterization of liposomes (Papers I-III) 
Among the different nanoparticulate drug delivery systems proposed for nose-to-brain drug 
delivery, liposomes exhibit low toxicity to the nasal mucosa and epithelium (Li et al., 2017, 
Patel and Patel, 2017). Liposomes are promising drug carriers for brain targeting as they can 
be tailored in composition (e.g. type of lipid, dispersing medium and stabilizing agent) to 
achieve preferable characteristics (Daraee et al., 2016). The LUVs characteristics are 
important in-process controls considering the development of liposomal formulations and 
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should be determined before the formulation testing stage. In this section, LUVs characteristics 
such as the formulation tonicity, size, lamellarity, surface charge, and drug entrapment are 
discussed in the respective order. 
 
Liposomes were prepared in PBS of different tonicity (0, 65 and 300 mOsm/kg, respectively) 
to obtain LUVs with different inner core tonicity. In Paper I, we assumed that the inner core 
tonicity of LUVs would be equivalent to the tonicity of the hydrating medium used to prepare 
the LUVs. This is an iterative assumption found in the literature (Ahumada et al., 2015, Boroske 
et al., 1981, Fujiwara and Yanagisawa, 2014, Mui et al., 1993, Ohno et al., 2009, Sabin et al., 
2006). Two of the most common tonicity enhancing agents are sucrose and salt (e.g. KCl, 
NaCl). Sucrose and NaCl are suggested to slowly permeate through liposomal membranes, 
and can, therefore, create a tonicity imbalance across the liposomal bilayer (Paula et al., 1996). 
Exposing liposomes to different environmental tonicity after reconstruction generates a relative 
osmotic pressure (πrel) on the liposomal membrane. We decided to calculate the πrel following 
Equation 4.1, in agreement with a similar approach suggested by Jackman et al. (2013). As 
described by Jackman and colleagues, the sign of the osmotic pressure can be arbitrary 
(Jackman et al., 2013). In Paper I, we decided to present πrel as either positive or negative if 
the salt concentration outside the liposomes was higher or lower than the inner core salt 
concentration, respectively. 
 
To our later knowledge and rather surprisingly, liposomes acted as strong tonicity agents. The 
presence of liposomes in the formulation increased the formulation tonicity up to 400 mOsm/kg 
in comparison to the plain PBS. For instance, empty liposomes prepared in PBS65 expressed 
tonicity of approx. 410 mOsm/kg, whereas liposomes prepared with PBS300 expressed 
formulation tonicity around 700 mOsm/kg. The present findings emphasize that the buffer 
tonicity used to prepare the liposomes is not necessarily equivalent to the inner core tonicity 
of the vesicles, which should be taken into consideration when comparing studies. The 
implications of these findings concerning size and release will be later addressed in 
Sections 5.2 and 5.4. 
 
Early work in liposomes field has reported that liposomes are susceptible to osmosis 
(Bangham et al., 1965, Bangham et al., 1967) and that for liposomes smaller than 1000 nm, 
vesicles keep their spherical shape upon swelling and shrinkage (Boroske et al., 1981). To 
study the direct influence the tonicity perturbations have on the liposomal bilayer, unilamellar 
vesicles have been suggested as more suitable due to their simple membrane construction in 
comparison to multilamellar vesicles (Mui et al., 1993, Sun et al., 1986). For these reasons, 
this thesis aimed to utilize large unilamellar vesicles; therefore a modified swelling method for 
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the rapid preparation of giant unilamellar vesicles was used (Moscho et al., 1996). To confirm 
the vesicles spheroid structure, phase contrast microscopy was employed. 
 
 
Figure 5.1: Phase contrast image of empty GUVs before extrusion. The bar shows 100 µm 
(unpublished results). 
 
In Figure 5.1, the phase contrast image of empty giant unilamellar vesicles right after 
reconstruction is shown. Images of the higher resolution were unachievable with the available 
microscope in the laboratory. However, the image illustrates that the liposomes were spherical. 
 
The extrusion method was chosen to optimize the distribution and size of liposomes. The 
extrusion method was found to be a convenient and well-suited method to achieve desired 
vesicle sizes and acceptably narrow PI (<0.5) for our purposes. Photon correlation 
spectroscopy (PCS) is a commonly used technique to quantify liposomal sizes and PI in a 
dispersion. The general rule of thumb is that the PI value below 0.7 is considered acceptable, 
and PI of 0.3 for a liposomal dispersion suggests rather homogeneous size distribution (Danaei 
et al., 2018). 
 
Some of the liposomal formulations exhibited large size variations and PI, especially for the 
marker-loaded LUVs (Paper I). This illuminates some of the PCS technique’s limitations, 
including its shortage to provide information regarding the morphology and shape of the 
particles (e.g. elongated, spherical, etc.). Moreover, the aggregation of particles during the 
measurement tends to be measured as one single particle. Upon realizing that LUVs acted as 
tonicity enhancing agents, diluting the LUVs to the correct intensity before size measurements 
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might have induced small scale of liposomal swelling which might influence the size 
measurements. 
 
The determination of ζ-potential (ZP) of nanocarriers has become a standard measurement of 
liposomal characteristics. Small changes in temperature, pH, ionic strength and solvent might 
all contribute to a dramatic change in ZP (Smith et al., 2017), and therefore the same medium 
used to prepare the LUVs was used to dilute the sample before measurement. The most 
negative ZP values were observed for LUVs prepared in distilled water, and a linear 
relationship between the osmolality of the different PBS used and measured ZP could be 
observed (Papers I-II). The presence of cholesterol in the LUVs dispersions had minimal 
effects on the ZP as expected since all formulations retained neutral ZP values (Paper III). 
These results are the result of the zero net charge of phosphatidylcholine, and cholesterol 
being uncharged (Aniket et al., 2014, Li et al., 2015). 
 
The entrapment efficiency (EE) is a very important parameter during the development of 
liposomal drug delivery systems, as it can influence the available dose at the administration 
site (Bourganis et al., 2018, Khan et al., 2017). It was beyond the scope of this thesis to 
optimize the EE of the loaded liposomes, but for better comparisons, different drugs with 
different physiochemical properties were chosen to be entrapped individually into LUVs. This 
resulted in drug-loaded LUVs with a range of EE but a constant total marker/drug concentration 
of 2 mM. As expected, the EE of the LUVs dispersions were the lowest for the hydrophilic 
(caffeine and theophylline), middle for lipophilic (ibuprofen and ketoprofen) and highest for 
hydrophobic drugs (hydrocortisone and methylprednisolone) (Akbarzadeh et al., 2013, Nii and 
Ishii, 2005, Xu et al., 2012). 
 
We prepared LUVs with cholesterol to investigate its effects on drug release and stability upon 
storage. Cholesterol can be used as a stabilizing agent in liposomal formulations due to its 
steroid structure forming hydrophobic interactions with the hydrocarbon chains of the 
phospholipids (McIntosh, 1978, Milon et al., 1986). As a result, cholesterol contributes to a 
more densely packed liposomal membrane which can influence the liposomes as a carrier 
(Briuglia et al., 2015, de Gier et al., 1968). Lipophilic compounds might compete with 
cholesterol to be embedded within the lipid membrane. In this situation, the compound with 
the strongest affinity to the liposomal membrane will remain highly incorporated, thus 
influencing the EE (Ali et al., 2010). In terms of developing osmotically active liposomes, 
cholesterol might hinder the free solvent movement across the liposomal membrane (Allen 
and Cleland, 1980). Consequently, cholesterol can alter the sensitivity of liposomes to osmotic 
stress. 
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Based on these results, we managed to successfully prepare different LUVs formulations for 
different purposes throughout this study. Liposomes were prepared to exhibit various 
formulation tonicity (i.e. 410 or 700 mOsm/kg) to generate different salt concentration 
gradients with the external environment of LUVs. We prepared different LUVs comprising 
various markers, drugs, and cholesterol for a thorough screening, and comparison. In the 
following section, the results obtained to prove the LUVs osmotic activity are discussed. 
 
 
5.2 Effect of tonicity perturbations on liposomal size (Papers I-II) 
The first papers mentioning osmotic properties of liposomes were published in the 1960s by 
Bangham and colleagues, where they proved that liposomes prepared of egg-
phosphatidylcholine could retain different concentrations of univalent (e.g. K-, Na-, Cl-, I-, F-, 
NO3-) and divalent (e.g. SO2-, HPO42-) ions. They also described the relationship between the 
rate of ion diffusion across liposomal bilayer as a function of the ion size and charge (Bangham 
et al., 1965, Bangham et al., 1967). Due to the slower ion diffusion rate across the liposomal 
bilayer in comparison to water molecules, water could influx or efflux the liposomes and cause 
the liposomes to shrink or swell (Bangham et al., 1967). 
 
Since then, a considerable amount of research has been carried out to investigate the 
influencing factors related to the swelling or shrinking of liposomes. Findings support that 
osmotic stress influences larger unilamellar vesicles (>100 nm) to a greater extent than smaller 
unilamellar vesicles (<100 nm) (Hallett et al., 1993, Mui et al., 1993). It has been suggested 
that unilamellar vesicles remain spherical shapes upon swelling or shrinking (Boroske et al., 
1981, Reeves and Dowben, 1970). 
 
As the liposomal composition, shape and original size can all influence the liposome sensitivity 
to tonicity perturbations, the first set of experiments focused on verifying the osmotic activity 
of the LUVs. If size changes could be detected, it would indicate the liposome susceptibility to 
solvent permeation, therefore liposomes being osmotically active. In the following section, the 
first sets of results indicating that marker-loaded LUVs are osmotically active are discussed 
(Figure 5.2). As a continuation of Paper I, the results obtained for the drug-loaded LUVs are 
presented (Figure 5.3). 
 
Exposure of unilamellar vesicles to the hypotonic environment has been reported to induce 
liposomal swelling (Mui et al., 1993, Oglecka et al., 2014), whereas exposure to hypertonic 
environment induces liposomal shrinkage (Boroske et al., 1981, Ohno et al., 2009). The 
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apparent size changes are directly dependent on the exposure time, and unilamellar vesicles 
exposed to small concentration differences (∆mOsm/kg up to 400) have shown size change 
saturation after approx. 1 hour (Fujiwara and Yanagisawa, 2014, Sun et al., 1986). For these 
reasons, we decided to monitor the LUVs for at least 70 min and the average sizes of the LUVs 
at different environment were plotted as a function of time as shown in Figure 5.2. 
 
 
Figure 5.2: Average liposomal sizes before and after exposure to the hypotonic and hypertonic 
environment. LUVs prepared in a) PBS300 and b) PBS65 were exposed to PBS65 and PBS300, 
respectively. Results represent mean ± SD (n=2). Adapted from Wu et al., 2017, with permission from 
Elsevier. 
 
In Figure 5.2, larger liposomal sizes could be detected when LUVs were exposed to a 
hypotonic environment in comparison to the isotonic environment, and the size enlargement 
became more apparent with time, reaching a plateau after 45 min. These results were in a 
good agreement with the literature (Mui et al., 1993, Oglecka et al., 2014). On the contrary to 
our presumption and literature (Boroske et al., 1981, Ohno et al., 2009), the shrinking 
behaviour of marker-LUVs after their exposure to the hypertonic environment could not be 
observed, and calcein-LUVs showed even larger sizes. 
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Deviations between our results and the literature can arise from several factors. Sabin et al. 
(2006) proposed that liposomal aggregation often affects liposomes exhibiting neutral surface. 
Furthermore, the LUVs were exposed to PBS of different osmolality, thus different amounts of 
ions that can neutralize the liposomal surfaces. The shrinking behaviour of liposomes might 
be masked by aggregated liposomes, disturbing the size detection measurements when the 
PCS technique was used. We could notice that the PI of each size measurement increased 
with time, especially for those LUVs exposed to the hypotonic environment, and, in some 
cases, the PI rose from 0.3 up to 1. This indicated that presenting the distributional results 
rather than the mean size might provide a better interpretation of the vesicle size, which was 
later implemented in Paper II. 
 
For Paper I, we calculated the πrel based on the assumption that the liposomal inner core 
tonicity was equivalent to the tonicity of the PBS used to prepare the liposomes. However, we 
later realized that the LUVs acted as the tonicity agent when in a dispersion. To the best of our 
knowledge, this phenomenon has never been reported in the literature before. If the tonicity of 
the formulation is representing the liposomal inner core tonicity, Figure 5.2 can be 
reinterpreted. What was earlier assumed to be a hypertonic environment in Figure 5.2b will, in 
fact, be a low-hypotonic environment (∆mOsm/kg assumed to be approx. 100). This better 
explains the size enlargements observed for calcein-LUVs and the lack of size decrements of 
empty- and rhodamine-LUVs. Rhodamine is a lipophilic marker (logD7.4 of 2.3 (Toropainen et 
al., 2001)) that incorporates itself in the liposomal bilayer, contributing to the stabilization of 
the vesicle membrane. Consequently, rhodamine-LUVs might be less sensitive to osmotic 
stress. Calcein is a hydrophilic marker (logD7.4 of -3.3 (Maherani et al., 2013)) which is localized 
in the aqueous inner core. As seen in Table 3 (Paper I), the calcein-LUVs expressed a more 
neutral ZP (-2.8 mV) than empty-LUVs (-12 mV) indicating that calcein can be adsorbed onto 
the vesicle surfaces. As this might contribute to a relatively neutral liposomal membrane, this 
might enhance the liposomal osmotic sensitivity. Water permeation across liposomal 
membranes has been reported to be the highest for the positively charged membranes, middle 
for the uncharged, and the lowest for the negatively charged (Allen and Cleland, 1980, 
Bangham et al., 1967, Biondi et al., 1991). 
 
To provide deeper insight into the findings in Paper I, we decided to proceed with a more 
detailed screening of six drug-loaded LUVs formulations. Instead of using the πrel as in Paper I, 
we used the ∆mOsm/kg. The ∆mOsm/kg was determined as the difference between the 
measured osmolality of LUVs formulation and the exposing PBS. In Figure 5.3, the size 
distributions of all drug-loaded LUVs taken at different time points and environment are 
represented. 




Figure 5.3: Size distributions of drug-loaded LUVs in a) isotonic, b) low-hypotonic, and c) hypotonic 
environment (∆mOsm/kg of 3±2, 419±19, and 648±19, respectively). Each line represents the mean 
size distribution (n=2) measured at five different time points within 90 min. Adapted from Wu et al., 
2019b, with permission from Elsevier. 
 
In agreement with the findings in Paper I, the drug-loaded LUVs exhibited size enlargement 
when exposed to hypotonic environment. Based on the distributional curves, no lysis of LUVs 
could be observed, even up to the maximum osmolality difference between the LUVs 
formulation and external tonicity (∆mOsm/kg around 650). Earlier reports have indicated that 
the maximum difference in the concentration LUVs can withstand before lysis strongly depends 
on the phospholipid used to prepare the liposomes. For instance, LUVs of egg-
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phosphatidylcholine and cholesterol (approx. 50% mol/mol) rupture at ∆mOsm/kg greater than 
650 (Mui et al., 1993) while LUVs of dioleoylphosphatidylcholine rupture at ∆mOsm/kg of 2000 
(Alam Shibly et al., 2016). The obtained data verified that the increment in liposomal size 
correlated with the degree of difference between the inner and external environment of LUVs. 
It was, therefore, interesting to see if tonicity perturbations could alter the release kinetics from 
the liposomes. 
 
Before discussing the drug release from liposomes, it is important to point out that currently 
there is no standard method to determine the release from liposomes (Nothnagel and Wacker, 
2018, Wacker, 2017). The common methods utilize techniques such as filtration, 
ultracentrifugation, or solid phase extraction to separate the free unentrapped drug from 
liposomal drug (Nothnagel and Wacker, 2018). The common limitation associated with these 
techniques is the risk of disrupting the nanocarrier due to exposure to mechanical forces during 
the separation procedure (Solomon et al., 2017). 
 
In the present study, we used the Franz diffusion cell set-up to study release from the 
liposomes. This method relies on the drug’s ability to diffuse across a barrier that separates 
the donor and acceptor compartment. Due to lower risk of exposure to mechanical forces, this 
method is considered to be more gentle and is currently one of the preferred methods to study 
drug release from liposomes (Solomon et al., 2017). The downside of the method is that drug 
needs to diffuse through several physical barriers before reaching the acceptor compartment. 
One way to adjust for this is to compare the release profile of a liposomal formulation with a 
reference diffusion of free drug solution (Nothnagel and Wacker, 2018, Wacker, 2017). For 
this reason, before going deeper into the release from liposomes, a short discussion on the 
experimentally collected diffusion data for marker and drug solutions is presented. 
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5.3 Diffusion study with solutions (Papers I-III) 
The markers and drugs were prepared individually in a buffer solution of 65 or 300 mOsm/kg 
tonicity (PBS65 or PBS300, respectively) as represented in Table 5.1. 
 
Table 5.1. Apparent permeability coefficient (Papp) and total permeated marker/drug from free solution 
through regenerated cellulose barrier. Results represent mean ± SD (n≥3). Adapted from Wu et al. 
2017, Wu et al. 2019a and Wu et al. 2019b, with permission from Elsevier. 
Reproduced from Marker/drug PBS 
Papp 
(10-5 cm/sec) 
Total permeated after 
4 hours (%) 
Paper I 
Calcein 
65 0.68 ± 0.06 37.10 ± 7.80 
300 0.90 ± 0.07 46.97 ± 4.17 
Rhodamine 
65 1.55 ± 0.06 83.06 ± 2.61 
300 1.61 ± 0.11 86.22 ± 3.68 
Paper II 
Caffeine 
65 6.18 ± 0.13 63.08 ± 0.94 
300 6.10 ± 0.20 63.90 ± 1.58 
Theophylline 
65 6.34 ± 0.19 65.96 ± 2.59 
300 6.25 ± 0.27 64.66 ± 1.39 
Ketoprofen 
65 4.43 ± 0.16 46.75 ± 1.30 
300 4.82 ± 0.27 51.37 ± 2.68 
Ibuprofen 
65 4.69 ± 0.29 49.25 ± 3.33 
300 4.60 ± 0.34 48.56 ± 3.50 
Hydrocortisone 
65 5.25 ± 0.59 59.24 ± 4.28 
300 4.53 ± 0.33 51.79 ± 3.93 
Methylprednisolone 
65 4.96 ± 0.41 62.39 ± 7.19 
300 4.48 ± 0.67 54.15 ± 7.39 
Paper IIIa 
Caffeine 65 2.79 ± 0.14 32.09 ± 1.61 
Hydrocortisone 65 1.12 ± 0.09 15.23 ± 2.18 
aPermeapad® barrier. 
 
As highlighted in Table 5.1, we used the regenerated cellulose barrier in the first two papers 
(Papers I-II), whereas in Paper III we additionally used the innovative biomimetic Permeapad® 
barrier as a diffusion barrier. If we first look at the findings reported in Paper I, we can see that 
the Papp values for marker solutions were greater in PBS300 in comparison to PBS65, whereas 
opposite trends were found for the drug solutions in Paper II. This might be related to the Franz 
diffusion cell set-up where marker or drug in the donor compartment diffuse one-sidedly across 
a diffusion barrier before being collected in the acceptor compartment. Diffusion data obtained 
using this experimental set-up are sensitive to barrier-related influences (Brandl et al., 2007, 
Brodin et al., 2010). For instance, ions and charged molecules can interact with the barrier, 
and influence the barrier’s susceptibility to permeation (Benavente, 1984). It has been reported 
that regenerated cellulose exhibits slightly negative surface charge, and allows neutral 
molecules rather than charged molecules to permeate (Benavente, 1984, Coday et al., 2015). 
Both markers used in this study are strongly ionized at pH 7.4 (pKa of 1.8 and 3.1 for calcein 
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and rhodamine, respectively) (Flaten et al., 2006, Pittman et al., 2001), whereas ketoprofen 
and ibuprofen ionize at pH>4.5 and 4.9, respectively (PubChem, 2019c, PubChem, 2019b). 
We believe that the greater fluctuations in Papp values of marker solutions correlate with the 
considerably greater number of dissociated ions at experimental pH, thus influencing the 
permeation through regenerated cellulose barrier in comparison to the drugs. 
 
In Table 5.1 it can be observed that the Permeapad® was a more restrictive barrier allowing 
less drug to diffuse in comparison to the regenerated cellulose barrier. The regenerated 
cellulose barrier is a low retention barrier allowing molecules to diffuse across as long as a 
concentration gradient is retained (Bartels et al., 2005, Benavente, 1984, Nothnagel and 
Wacker, 2018). On the other hand, the biomimetic Permeapad® barrier consists of a lipid layer 
in between two support sheets (di Cagno and Bauer-Brandl, 2014). When the barrier comes 
in contact with an aqueous solution, the lipid layer is assumed to create tightly packed vesicles 
mimicking the structure of biological membranes (di Cagno et al., 2015), thus the Permeapad® 
barrier represents a thicker barrier that can provide higher retention to drug permeation. 
 
These data indicate that the PBS (e.g. pH, tonicity) plays a major role in the diffusion across 
barriers, as well as the type of the diffusion barrier used. It emphasizes the importance of 
selecting the correct conditions as a reference to interpret release from liposomes, as small 
variations in the experimental set-up can have a considerable effect on the Papp. For this 
reason, we ensured that the reference experiment was performed in the respective PBS used 
in the formulation. In the following section, a relationship between the tonicity perturbation and 
changes in release kinetics from liposomes are discussed in more details (Papers I-II). 
 
 
5.4 Tonicity perturbation and liposomal release (Papers I-III) 
As shown and discussed in the previous section (Section 5.2), we verified that the LUVs were 
osmotically active, and we suspected that tonicity perturbations might as well influence the 
drug release from liposomes (Ahumada et al., 2015, Ohno et al., 2009, Wolfram et al., 2014). 
 
In the earliest reports, water or ion permeation changes across the liposomal membrane for 
shrunken or swollen liposomes consisting of synthetic or natural origin phosphatidylcholine 
have been extensively described (Abuin et al., 1995, Bangham et al., 1967, Biondi et al., 1991, 
Paula et al., 1996, Polozov et al., 2001). Attempts in controlling the liposomal leakage under 
their exposure to osmotic stress have also been tried using cholesterol, PEGylation, and 
surfactants (Allen and Cleland, 1980, Cipolla et al., 2014, Leite et al., 2018, Milon et al., 1986, 
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Wolfram et al., 2014). In more recent years, the burst and pulsating leakage from giant 
unilamellar vesicles have been observed when liposomes were exposed to the extreme 
hypotonic environment (∆mOsm/kg >2000) (Alam Shibly et al., 2016, Chabanon et al., 2017, 
Oglecka et al., 2014). In spite of the efforts put in preventing leakage from liposomes upon 
osmotic stress, rather few studies have tried to investigate if osmotic stress can be used to 
control the release from liposomes. An explanation might be that the currently marketed 
liposomal products are developed for parenteral routes (Bulbake et al., 2017, Choi and Han, 
2018). We agree that for parenteral routes, the tonicity perturbations will be rather irrelevant 
due to the body homeostasis. Moreover, immunogenicity, opsonisation and reticuloendothelial 
system are more common challenges the liposomes are facing when administered parenterally 
(Sercombe et al., 2015). 
 
As previously discussed in Section 1.3, the nasal epithelium provides a great platform for drug 
absorption to the brain overcoming the BBB and systemic side effects (Erdő et al., 2018, Khan 
et al., 2017, Patel and Patel, 2017). However, most of the nasal epithelium is covered with 
nasal mucus, which creates a large obstacle to efficient drug absorption. The nasal mucus 
directly captures inhaled drugs, which can challenge the drug’s stability and permeability 
across the mucus layer (Ghadiri et al., 2019). It becomes even more complex when the nasal 
mucus is exposed to constant change due to direct contact with the peripheral environment. 
The changes in either humidity, temperature, lifestyle (e.g. cigarette smoking) and nasal 
condition (e.g. inflammation, rhinitis, sinusitis) are all associated with changed mucociliary 
clearance rate, nasal mucus rheology as well as tonicity exploited in the nasal cavity (Pedersen 
et al., 2007, Quraishi et al., 1998, Taherali et al., 2018). For these reasons, it is necessary to 
take into account the possibility of osmotic influences when developing liposomes for nose-to-
brain drug delivery. It would be even greater if osmotic stress can be utilized to direct the 
release from liposomes. 
 
In this project, the mass transport across the diffusion barrier was monitored over time, and 
the accumulated diffused amount was analysed to predict the release kinetics from liposomes. 
In Paper I, the changes of fluorescent marker release from liposomes were determined by 
monitoring the marker flux across the regenerated cellulose barrier as a function of change in 
πrel (see Figure 3 in Paper I). From the data, it was evident that the release was changing more 
drastically for calcein-LUVs than for rhodamine-LUVs, presumably due to the marker’s 
localization inside the LUVs and its solubility. 
 
To our later knowledge, the presence of LUVs changed the formulation tonicity with an 
increase of approx. 350-400 mOsm/kg. Even though we did not exactly measure the marker-
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loaded LUVs formulations used for the diffusion study, measurement of empty liposome 
formulations in PBS65 and PBS300 suggests that the initial tonicity should have been approx. 
410 or 700 mOsm/kg, respectively. If reanalysing the marker-loaded LUVs release data, 
assuming that the tonicity of the LUVs formulation was representing the liposomal inner core 
tonicity, all the LUVs formulations were probably exposed to different degrees of hypotonicity. 
In Figure 5.4, the flux in a different environment as a function of ∆mOsm/kg is displayed. With 
a new representation of the diffusion data, the conclusions made in Paper I remain the same, 
however, we could postulate more on the findings. 
 
 
Figure 5.4: Flux (j) under the influence of hypotonic environmental changes. Results represent 
mean ± SD (n=3), and a statistically significant difference in j (*p≤0.050, **p≤0.010, ***p≤0.001) between 
the highlighted bars. Adapted from Wu et al., 2017, with permission from Elsevier. 
 
As already mentioned, calcein is a hydrophilic marker (Maherani et al., 2013). It is by now 
generally accepted that solvent influx into the LUVs can cause the liposomes to swell, thus 
stretching the liposomal membrane, and allowing more of the entrapped content to be released 
(Ahumada et al., 2015, Alam Shibly et al., 2016, Allen and Cleland, 1980, Ertel et al., 1993). 
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As it can be seen from Figure 5.4a-b, we repeatedly saw that the flux of calcein is decreasing 
with an increasing degree of hypotonic exposure. These findings might be related to the 
direction of solvent migration. As the marker concentration gradient across the liposomal 
bilayer can be disturbed due to the solvent influx, it seems possible that a decrease in the 
release can occur, especially for hydrophilic compounds. On the contrary, rhodamine is a 
lipophilic drug that is highly incorporated within the liposomal bilayer. The rhodamine-LUVs 
were somehow less sensitive to environmental changes since smaller variations in flux were 
found in comparison to calcein-LUVs. These results correspond well with previous studies, 
where compounds incorporated into the liposomal bilayer increase the membrane rigidity, thus 
decreasing sensitivity to osmotic influences (Ali et al., 2010, Leite et al., 2018). 
 
We also observed that the calcein flux across the diffusion barrier for the LUVs formulation 
prepared in PBS300 was higher than for LUVs prepared in PBS65. Again, the diffusion seemed 
to be highly influenced by the presence of ions, similarly to the data obtained from solutions 
that have already been discussed in Section 5.3. 
 
A more insightful way to report in vitro diffusion data is using the permeability across a barrier 
(namely, Papp), or R (inverse of Papp) instead of the mass flux (j) (Baker et al., 2010). In Paper II, 
the focus was to achieve a more detailed screening of the influences the hypotonic 
environment had on the drug release from liposomes. Since we could see in Paper I that the 
hydrophilic marker was more susceptible to tonicity changes in comparison to lipophilic marker, 
six different drugs with different logD7.4 were chosen to be entrapped individually into LUVs. 
The tonicity difference between the LUVs and external environment was reported as 
∆mOsm/kg instead of the πrel for simplicity. Moreover, the RL calculations were implemented, 
and the obtained results are represented in Figure 5.5. 
  




Figure 5.5: Resistance to drug transport through liposomal bilayer (RL) under the influence of hypotonic 
environmental changes. Results represent mean ± SD (n=4), and a statistically significant difference in 
RL (*p≤0.050, **p≤0.010 and ***p≤0.001) when compared to the isotonic environment. Adapted from Wu 
et al., 2019b, with permission from Elsevier. 
 
As highlighted by Figure 5.5, the RL obtained for the different LUVs formulations in an isotonic 
environment (∆mOsm/kg approx. 0) expressed the lowest values for the hydrophilic drugs 
(caffeine and theophylline) and the highest for the hydrophobic drugs (hydrocortisone and 
methylprednisolone). The higher RL for hydrophobic compounds in comparison to hydrophilic 
compounds is not surprising since the hydrophobic compounds are tightly incorporated within 
the liposomal bilayer and will experience more difficulties to become released. A linear 
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correlation could be found between the RL and the different degrees of hypotonic environment, 
and a significant drop in RL (p<0.05) could be observed for all of the formulations at ∆mOsm/kg 
around 300 mOsm/kg. Decreasing RL values indicate that more drug permeates the liposomal 
bilayer when the vesicles swell. Interestingly, an increase in RL could be observed at 
differences lesser than 300 mOsm/kg for caffeine and theophylline. These results demonstrate 
two things. First, hydrophilic compounds are highly influenced by solvent flux direction probably 
due to their hydrophilic nature. These findings are directly in line with our previous findings 
(Paper I). Second, when large enough difference is created between the LUVs and the external 
environment (∆mOsm/kg around 300), the release from liposomes for both hydrophilic and 
hydrophobic compounds will overrule the effect of solvent influx. 
 
The present findings confirmed that changes in tonicity (within nasal environment) can be used 
to alter the release from LUVs. However, both Papers I and II have been casting more light on 
LUVs exposed to a hypotonic environment, and not addressing hypertonic environmental 
influences as thoroughly. Sun et al. (1986) suggested that tonicity induced liposomal shrinking 
is often more complexed than liposomal swelling. To get a deeper understanding of the release 
from swollen and shrunken liposomes, we decided to test all formulations in both hypotonic 
and hypertonic environment. We also decided to focus on the development at: i) formulation 
level, ii) experimental set-up level, and iii) data interpretation level, which will be more closely 
discussed in the next sections. 
 
 
5.5 The effect of liposomal composition on drug release (Paper III) 
Based on the findings so far, the LUVs seemed to be responsive to osmotic stress when the 
difference between LUVs and external environment showed a ∆mOsm/kg of 300. For 
simplicity, we prepared all LUVs formulations in PBS65 to obtain dispersions with tonicity 
around 400 mOsm/kg to be used in both environment. We chose to focus on one hydrophilic 
(caffeine) and one lipophilic (hydrocortisone) drug to be entrapped into LUVs with various 
amounts of cholesterol incorporated in the liposomal bilayer (up to 25% w/w). 
 
Cholesterol is a component in most of the currently available marketed liposomal products 
(Bulbake et al., 2017), and also within the liposomal formulations designed for nose-to-brain 
drug delivery (see Table 1.3). Early liposomal research showed that the increase of cholesterol 
content within the liposomal bilayer was correlated with a decrease in membrane elastic 
properties, thus influencing the permeability of water and small molecules through the 
liposomal bilayer (Allen and Cleland, 1980, McIntosh, 1978). The incorporation of cholesterol 
 Results and discussions  
61 
into liposomal bilayers has shown to delay the release of both hydrophilic and lipophilic 
compounds from liposomes (Ali et al., 2010, Briuglia et al., 2015, Grit and Crommelin, 1993). 
With the manipulation of the phospholipid and cholesterol content, liposomes can be altered 
to exhibit favourable drug release profiles (Briuglia et al., 2015). It has been estimated that 
liposomes consisting of phosphatidylcholine can incorporate up to 50% w/w cholesterol 
(Sułkowski et al., 2005). Therefore, the release of the liposomal drug (localized either in the 
aqueous core or in liposomal bilayer) was examined by preparing LUVs with various amounts 
of incorporated cholesterol (up to 25% w/w). 
 
All the results for cholesterol-containing liposomes experiments are summarized in 
Figures 5.6-5.8. The in vitro diffusion studies were performed employing different diffusion 
barriers; a synthetic (regenerated cellulose) and a biomimetic (Permeapad®). Synthetic 
barriers (e.g. regenerated cellulose) are convenient and cost-effective and are often preferred 
in the early stage of drug development. However, the synthetic barriers do not include/consider 
the lipid effect which plays a major role in all biological tissues, including the nasal epithelium. 
For this reason, we decided to use the newly developed biomimetic Permeapad® barrier due 
to its higher similarity to the nasal epithelium (di Cagno et al., 2015). Moreover, Permeapad® 
barriers have shown good reproducibility, stability at a wide range of pH, and tolerance to 
different surfactants and co-solvents (Bibi et al., 2015, Bibi et al., 2016). With a relatively long 
shelf life (1 year), the Permeapad® barriers are handy, requiring no hydration or cutting before 
use, which is often required for the synthetic diffusion barriers. 
 
As a continuation of Paper II, we calculated the RL values for the various formulations, diffusion 
barriers, and external environment as it can be seen in Figure 5.6. The RL values were 
calculated by normalizing with the reference experiment involving free drug solution using the 
method established in Paper II. 
  




Figure 5.6: Resistance to drug transport through liposomal bilayer (RL) of LUVs comprising a) caffeine, 
b) hydrocortisone, and various amounts of cholesterol (0-25% w/w). The regenerated cellulose and 
Permeapad® barriers were used as diffusion barriers. LUVs were exposed to isotonic, hypotonic, and 
hypertonic environment (∆mOsm/kg of 0, -300, and 300 between LUVs formulation and external 
environment, respectively). Results represent the mean ± SD (n=3), and a statistically significant 
difference in RL (*p≤0.050, **p≤0.010, ***p≤0.001) between the highlighted bars. Adapted from Wu et 
al., 2019a, with permission from Elsevier. 
 
As illustrated in Figure 5.6, the external environment plays an essential role in RL. The lowest 
RL values were found in a hypotonic and the highest values for the hypertonic environment. 
Lower RL indicates a higher release from the liposomes. Even though the liposomal size 
changes in the different environment were not carried out for these formulations, a clear 
indication of the relation between the release changes and the liposomal swelling and shrinking 
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in the hypotonic or hypertonic environment, respectively, can be seen. These findings are in 
great accordance with our earlier reports (Papers I-II), and important for the understanding of 
the release kinetics from liposomes. Interestingly, the RL trends could be observed 
independently of the amount of incorporated cholesterol and the diffusion barrier used. 
However, the RL with respect to the different environment fluctuated less for the formulations 
with 25% w/w cholesterol, or if the Permeapad® barrier was used. Other reports also confirm 
the negative effect the increasing levels of cholesterol have on the release from liposomes (Ali 
et al., 2010, Allen and Cleland, 1980, Briuglia et al., 2015). The differences between 
regenerated cellulose and Permeapad® barriers might be related to the different ion transport 
rate through the diffusion barriers. Previous observations of filling the acceptor compartment 
to a Franz cell with distilled water, and the donor compartment with PBS300 has shown ion 
diffusing across the regenerated cellulose barrier with almost twice as fast rate as compared 
to the rate across the Permeapad® barrier (43 vs 26 mOsm/kg hour, unpublished results). 
 
We noticed in Paper II that the drug diffusion profiles showed deviation from linearity over time, 
especially for the LUVs exposed to osmotic stress. Ali et al. (2010) have also reported similar 
observations, where the drug release profile of several lipophilic drugs changed from zero 
order to first order profile for cholesterol-containing liposomes. In Paper II, we only used the 
linear part of the curve to calculate the RL (the first 2.5 hours). This is a rather precarious 
assumption as relatively few data points are proving its linearity. Hence, a non-linear 
regression approximation was introduced in Paper III to elaborate on the collected diffusion 
data. The Korsmeyer-Peppas model was chosen as it could fit a larger portion of the collected 
experimental data (Mt/M∞ up to 60%). Moreover, it can provide information related to the 
structural characteristics of the nanocarrier (transport constant, K), and the release mechanism 
from the nanocarrier (transport exponent, n). 
 
The experimentally obtained diffusion data were fitted to the Korsmeyer-Peppas equation 
(Equation 1.10), and the predicted curve showed a good fit with the experimental data (R2 
≥0.96). The slope of the fitted curve represents the K and describes the constant drug diffusion 
across a barrier. The higher K the higher release from liposomes can be assumed. In 
Figure 5.7, all the K obtained for the various LUVs formulations are represented. 
  




Figure 5.7: Transport constant (K) of LUVs comprising a) caffeine, b) hydrocortisone, and various 
amounts of cholesterol (0-25% w/w). The regenerated cellulose and Permeapad® barriers were used as 
diffusion barriers. LUVs were exposed to isotonic, hypotonic, and hypertonic environment (∆mOsm/kg 
of 0, -300, and 300 between LUVs formulation and external environment, respectively). Results 
represent the mean ± SD (n=3), and a statistically significant difference in K (*p≤0.050, **p≤0.010, 
***p≤0.001) between the highlighted bars. Adapted from Wu et al., 2019a, with permission from Elsevier. 
 
As seen in Figure 5.7, a trend starting from the highest K for hypotonic, middle for isotonic, 
and lowest for hypertonic environment could be observed. As higher K indicates a higher 
release, the trend of K should exhibit the opposite trend of RL (Figure 5.6) if zero order data 
treatment was the optimal approach. As implied, differences were observed especially for the 
LUVs formulations containing cholesterol and when using Permeapad® as a diffusion barrier. 
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This indicates that the cumulative released drug was elapsing with time, and confirms the 
necessity of a non-linear regression model. Further, changes in K were generally smaller for 
Permeapad® in comparison to regenerated cellulose as a diffusion barrier. Regenerated 
cellulose barrier (due to its low retention to drug diffusion) might therewith be excellent in 
detecting formulation-related diffusional changes. On the other hand, it might not provide the 
best in vitro/in vivo correlations as the diffusion trends obtained using the regenerated cellulose 
barrier were rather different from results obtained using a more biomimetic barrier. 
 
In regards to transport exponent n, the order of the curve describes the release mechanism 
from the liposomes. As a recap to the previous section (Section 1.7), if the drug release is only 
controlled by Fickian diffusion, a graph of cumulative percentage of released drug vs square 
root of time will originate a straight line (n≤0.5). On the other hand, no linear relationship gives 
n>0.5 and indicates a non-Fickian-controlled diffusion mechanism (Costa and Sousa Lobo, 
2001, Jain and Jain, 2016). In Figure 5.8, all the obtained n are represented. Generally, lower 
n values could be observed for the caffeine experiments (Figure 5.8a) in comparison to the 
hydrocortisone experiments (Figure 5.8b). This indicates that the release of caffeine was more 
indicating a Fickian-controlled diffusion mechanism in comparison to hydrocortisone, which 
might be explainable by different lipophilicity and solubility. 
  




Figure 5.8: Transport exponent (n) of LUVs comprising a) caffeine, b) hydrocortisone, and various 
amounts of cholesterol (0-25% w/w). The regenerated cellulose and Permeapad® barriers were used as 
diffusion barriers. LUVs were exposed to isotonic, hypotonic, and hypertonic environment (∆mOsm/kg 
of 0, -300, and 300 between LUVs formulation and external environment, respectively). Results 
represent the mean ± SD (n=3), and a statistically significant difference in n (*p≤0.050, **p≤0.010, 
***p≤0.001) between the highlighted bars. Adapted from Wu et al., 2019a, with permission from Elsevier. 
 
For the experiments carried out utilizing regenerated cellulose barrier, most of the obtained n 
was between 0.5 and 1, which describes both Fickian- and non-Fickian-controlled diffusion 
mechanisms (Figure 5.8). This was expected as the liposomal barrier (a boundary layer) may 
influence the passive diffusion across a diffusion barrier. The caffeine experiments involving 
liposomes incorporating various amounts of cholesterol showed the lowest n in hypotonic and 
higher n in isotonic/hypertonic environment. Lower n indicates a more Fickian-controlled drug 
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release. In other words, the boundary layer which the liposomal carrier originally represented 
was affecting less the liposomal release when liposomes became more stretched in a 
hypotonic environment. The n values for hydrocortisone-LUVs were generally higher than for 
the caffeine-LUVs, and the n varied less according to environmental changes. These results 
are in agreement with the drug’s lipophilicity, and the findings in Papers I and II, as previously 
discussed. Another important finding was that n was the closest to 1 for the experiments 
carried out using Permeapad® barrier. Hydrocortisone-LUVs with 11 and 25% w/w cholesterol 
showed n greater than 1, indicating that the liposomes enhanced the drug transport across the 
diffusion barrier. The possible explanations could be the liposomes affinity for the Permeapad® 
barrier or the presence of cholesterol (Leite et al., 2018). Compared to the LUVs formulations 
without cholesterol, the presence of cholesterol in liposomal bilayer seems to provide superior 
diffusion across the Permeapad® barrier. 
 
In summary, these data demonstrate how the release from liposomes can be manipulated by 
careful tailoring of the lipid and cholesterol content of liposomes. Both linear and non-linear 
regression models should be used to achieve a more accurate interpretation of the diffusion 
data. The Korsmeyer-Peppas model was, in comparison to the zero order approach, more 
timesaving since it did not require reference experiments using drug solutions to normalize the 
data. Diffusion data for LUVs under osmotic stress fitted well with the Korsmeyer-Peppas 
model and gave equal to or better results than the currently accepted for the linear regression 
approximation. Different diffusion profiles could be observed when utilizing the regenerated 
cellulose and Permeapad® barriers. While the low retention diffusion barrier allows monitoring 
of release changes on the formulation level, the Permeapad® barrier recognized the lipid and 
retention effect, which are highly relevant considering the net transport across biological 
barriers. Due to the great differences in drug diffusion between the synthetic and biomimetic 
barrier, we wanted to introduce mucin to our experiments to further mimic the nasal 




5.6 The effect of mucin on drug permeation (preliminary results) 
In the first part of experiments involving mucin, we needed to select the mucin concentration 
to use in our experiments. In the literature, 1 mg/mL mucin dispersions have been used to 
study the binding of liposomes to mucin (porcine stomach type III) intended for nasal 
administration (Chen et al., 2013, Qiang et al., 2012). Using this as a reference, we screened 
mucin dispersions at concentrations ranging from 0.1 to 1.9 mg/mL. We found out that 
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1 mg/mL was the highest mucin concentration achievable without altering the original PBS 
tonicity. A representation of the measured osmolality and pH of PBS before and after the 
addition of mucin are shown in Table 5.2. 
 
Table 5.2: Experimentally determined osmolality and pH of the prepared PBS and mucin dispersions 
used for the in vitro diffusion study with mucin present. Results represent mean ± SD (n≥2). 
 
 



















0 420 ± 11 
Hypo 119 ± 10 7.5 ± 0.1 123 ± 19 7.5 ± 0.0 
Iso 418 ± 10 7.3 ± 0.0 422 ± 24 7.3 ± 0.0 
Hyper 718 ± 12 7.2 ± 0.0 727 ± 19 7.2 ± 0.0 
11 392 ± 12 
Hypo 95 ± 16 7.6 ± 0.0 73 ± 3* 7.6 ± 0.0 
Iso 386 ± 5 7.3 ± 0.0 363 ± 3*** 7.3 ± 0.0 
Hyper 693 ± 23 7.2 ± 0.0 663 ± 6* 7.2 ± 0.0 
25 388 ± 4 
Hypo 88 ± 8 7.5 ± 0.0 90 ± 5 7.5 ± 0.0 
Iso 393 ± 4 7.3 ± 0.0 380 ± 5** 7.3 ± 0.0 
Hyper 692 ± 8 7.2 ± 0.0 650 ± 10*** 7.2 ± 0.0 
Ketoprofen 0 394 ± 7 
Hypo 95 ± 5 7.6 ± 0.0 91 ± 5 7.5 ± 0.0 
Iso 394 ± 7 7.4 ± 0.0 390 ± 13 7.3 ± 0.0 
Hyper 695 ± 5 7.2 ± 0.0 675 ± 14* 7.1 ± 0.0 
Hydro-
cortisone 
0 383 ± 5 
Hypo 85 ± 5 7.6 ± 0.0 83 ± 8 7.6 ±  0.0 
Iso 385 ± 5 7.3 ± 0.0 359 ± 9*** 7.3 ± 0.0 
Hyper 685 ± 5 7.2 ± 0.0 667 ± 17 7.2 ± 0.0 
11 405 ± 5 
Hypo 105 ± 5 7.6 ± 0.0 105 ± 16 7.6 ± 0.0 
Iso 405 ± 5 7.3 ± 0.0 402 ± 13 7.4 ± 0.0 
Hyper 705 ± 5 7.2 ± 0.0 703 ± 15 7.2 ± 0.0 
25 383 ± 19 
Hypo 86 ± 16 7.6 ± 0.0 85 ± 5 7.6 ± 0.0 
Iso 385 ± 16 7.3 ± 0.0 380 ± 11 7.4 ± 0.0 
Hyper 687 ± 15 7.2 ± 0.0 685 ± 5 7.2 ± 0.0 
A statistically significant difference in osmolality (*p≤0.050, **p≤0.010, ***p≤0.001) between PBS before and 
after addition of mucin. 
aAdapted from Wu et al. 2019a, with permission from Elsevier. 
 
As demonstrated in Table 5.2, the osmolality of the PBS after the addition of mucin varied 
more, and, in some cases, caused a significant alteration of the PBS tonicity. These changes 
are rather hard to explain as the same batch of mucin was used during the whole study. The 
changes might be related to the biological origin of mucin, or possibility that mucin influence 
the readings of the osmometer. To limit mucin degradation upon storage, the mucin 
dispersions were always used within 7 days after original preparation. 
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To understand the influence of mucin on drug diffusion across diffusion barriers, reference 
experiments were carried out similarly to those established in Papers II and III. The Papp of 
marker/drug solutions determined without the presence of mucin are already discussed in 
Section 5.3. To investigate mucin’s effect on drug diffusion across the different diffusion 
barriers, we carried the diffusion study of drug solutions in the presence of mucin, and the 
results are summarized in Table 5.3. 
 
Table 5.3: Apparent permeability coefficient of drug solutions in the presence of mucin (Pappm). Results 
represent mean ± SD (n≥2). 











65 a 6.18 ± 0.13c 5.78 ± 0.89 85.70 ± 18.78 -0.4 
65b 2.79 ± 0.14c 3.49 ± 0.11 35.79 ± 0.95 0.7 
Ketoprofen 
65 a 4.82 ± 2.48 4.43 ± 0.33 70.77 ± 17.88 -0.4 
65b 1.18 ± 1.98 1.32 ± 0.02 13.80 ± 0.81 0.1 
Hydrocortisone 
65 a 5.25 ± 0.59c 3.34 ± 0.80 52.03 ± 6.08 -1.9 
65b 1.12 ± 0.09c 1.18 ± 0.36 14.24 ± 3.23 0.1 
aRegenerated cellulose barrier. 
bPermeapad® barrier. 
cPapp replotted from Table 5.1. 
 
As highlighted in Table 5.3, the Papp
m values determined in the presence of mucin were lower 
than the Papp values in the experiments utilizing the regenerated cellulose barrier as a diffusion 
barrier (Papp
m<Papp). The opposite trend was found when the Permeapad® barrier was used 
(Papp
m>Papp). These findings indicate that mucin plays a major role in the drug diffusion across 
barriers, and different diffusion trends can be observed based on the type of the diffusion 
barrier used. These data emphasize the importance of selecting the correct reference 
experiment, as small changes in the experimental set-up can result in large variations in Papp 
or Papp
m, and lead to misleading interpretations of the release from liposomes (Jain and Jain, 
2016, Modi and Anderson, 2013). We decided to use the reciprocal function of Papp
m to 
calculate the RL for experiments performed in the presence of mucin. The obtained RL values 
for caffeine- and hydrocortisone-LUVs are represented in Figure 5.9. 
  




Figure 5.9: Resistance to drug transport through liposomal bilayer (RL) of LUVs comprising a) caffeine, 
b) hydrocortisone, and various amounts of cholesterol (0-25% w/w). A total of 0.12 mg mucin was added 
on top of the regenerated cellulose and Permeapad® barriers. LUVs were exposed to isotonic, 
hypotonic, and hypertonic environment (∆mOsm/kg of 0, -300, and 300 between LUVs formulation and 
external environment, respectively). Results represent the mean ± SD (n=3), and a statistically 
significant difference in RL (*p≤0.050, **p≤0.010, ***p≤0.001) between the highlighted bars. 
 
The RL showed a similar trend to one observed for the experiments without mucin (Figure 5.6), 
indicating that the LUVs remained osmotically active even in the presence of mucin. The LUVs 
formulations without cholesterol showed the greatest differences in RL values between the 
results obtained using regenerated cellulose and Permeapad® barriers, whereas the presence 
of cholesterol in liposomal bilayers reduced these differences. To ensure that the zero order 
approximation is applicable, we also applied the Korsmeyer-Peppas model to fit our 
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Figure 5.10: Transport constant (K) of LUVs comprising a) caffeine, b) hydrocortisone, and various 
amounts of cholesterol (0-25% w/w). A total of 0.12 mg mucin was added on top of the regenerated 
cellulose and Permeapad® barriers. LUVs were exposed to isotonic, hypotonic, and hypertonic 
environment (∆mOsm/kg of 0, -300, and 300 between LUVs formulation and external environment, 
respectively). Results represent the mean ± SD (n=3), and a statistically significant difference in K 
(*p≤0.050, **p≤0.010, ***p≤0.001) between the highlighted bars. 
  




Figure 5.11: Transport exponent (n) of LUVs comprising a) caffeine, b) hydrocortisone, and various 
amounts of cholesterol (0-25% w/w). A total of 0.12 mg mucin was added on top of the regenerated 
cellulose and Permeapad® barriers. LUVs were exposed to isotonic, hypotonic, and hypertonic 
environment (∆mOsm/kg of 0, -300, and 300 between LUVs formulation and external environment, 
respectively). Results represent the mean ± SD (n=3), and a statistically significant difference in n 
(*p≤0.050, **p≤0.010, ***p≤0.001) between the highlighted bars. 
 
Again, the experimental data showed a good fit with the predicted curve (R2 of 0.97-1.00). The 
K and n values obtained in the caffeine experiments were close to identical to the experiments 
carried out without the mucin (Figures 5.7-5.8). Hydrocortisone experiments showed 
decreasing K values starting from the hypotonic to hypertonic environment for experiments 
using the regenerated cellulose as a barrier. This trend was not as apparent for the 
experiments conducted in the absence of mucin. The results suggest that mucin might 
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enhance the LUVs’ osmotic activity even when cholesterol was incorporated within liposomal 
bilayers. Permeapad® experiments indicated a relatively stable K for all environment 
highlighting that even though the release from liposomes alters due to tonicity perturbations, 
the net transport across a biomimetic barrier (and possibly biological barrier) are not much 
different. In retrospect, we should have carried the experiments with Permeapad® for a longer 
time (more than 4 hours) due to the barrier’s inherent nature of expressing high retention to 
drug diffusion. The longer study would probably provide more apparent differences in the 
diffusion across the Permeapad® barrier over time. However, due to the awareness that nasal 
mucus renews every 20 min (Illum, 2003, Taherali et al., 2018), we believed that experiments 
over a total of 4 hours were sufficient at this point in the project. 
 
Considering the mucin concentrations used in this study, the mucin content was sufficient to 
cause drug diffusion hindrances because of electrostatic and hydrophobic interactions (Lock 
et al., 2018, Murgia et al., 2018). Mucin had generally little effect on the n of caffeine which 
seems to be explainable by caffeine’s good permeability across cellulose and lipid barriers (di 
Cagno et al., 2015, Flaten et al., 2006). Due to caffeine’s small molecular size (MW of 
194.2 g/mol), the mucin was not an obstacle to diffusion. On the other hand, due to the larger 
molecular size and more lipophilic nature of hydrocortisone (MW of 362.5 g/mol), it was not 
surprising that the n of hydrocortisone was more affected. An increase in n can be explained 
by increased interaction between drug and mucin resulting in a stronger boundary layer, 
shifting the release mechanism away from a Fickian-controlled diffusion mechanism. 
 
As both investigated drugs are neutral at pH 7.4, we also performed some preliminary study 
with ketoprofen. Ketoprofen is ionized at pH>4.5 (PubChem, 2019c), conferring to a negatively 
charged ketoprofen molecule at high pH. Due to the demanding manual work required to obtain 
these data, we have only been able to screen the ketoprofen-LUVs free of cholesterol. The RL, 
K, and n are all summarized in Figure 1.12. 
  




Figure 5.12: Resistance to drug transport through liposomal bilayer (RL), transport constant (K), and 
transport exponent (n) of ketoprofen-LUVs (0% w/w cholesterol). Experiments were conducted with the 
a) absence and b) presence of mucin (a total of 0.12 mg mucin was added) on top of the regenerated 
cellulose and Permeapad® barriers. LUVs were exposed to isotonic, hypotonic, and hypertonic 
environment (∆mOsm/kg of 0, -300, and 300 between LUVs formulation and external environment, 
respectively). Results represent the mean ± SD (n=3), and a statistically significant difference in n 
(*p≤0.050, **p≤0.010, ***p≤0.001) between the highlighted bars. 
 
Considering Figure 1.12, if we first focus on the results obtained using regenerated cellulose 
as a diffusion barrier and starting from the hypotonic to the hypertonic environment, we can 
see that; 
1) RL increased (liposomal bilayer resists more to drug transport) which correlates with 
2) K decreased (less drug diffuses across diffusion barrier), and  
3) n increased (release mechanism from liposomes shifts towards non-Fickian diffusion). 
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This trend remained independently of the mucin absence (Figure 1.12a) or presence 
(Figure 1.12b) and indicated that both linear and non-linear regression can be used to interpret 
the diffusion data obtained using regenerated cellulose as a diffusion barrier. 
 
On the other hand, the Permeapad® experiments were more complex. First, the highest RL 
values were found in the hypotonic environment, in disagreement with the findings for caffeine- 
and hydrocortisone-LUVs (previously shown the lowest RL values, Paper III). The difference in 
RL between the isotonic and hypotonic environment could be as great as 37000 sec/cm. 
Second, the K showed a trend with increasing values going from the hypotonic to hypertonic 
environment, indicating that upon liposomal shrinkage, the release was enhanced (correlate 
with decreasing trend of n). The large deviations between the caffeine/hydrocortisone and 
ketoprofen results might be due to the drugs’ charge. As previously described, caffeine and 
hydrocortisone are both neutral at experimental pH, whereas ketoprofen is negatively charged. 
Charge-related corruptions of the Brownian movement of drug molecules might play an 
essential role in the net drug transport across the different diffusion barriers (Newby et al., 
2018). To our surprise, the ketoprofen results did not differ regardless of the mucin presence. 
This might be due to the negative charge of both ketoprofen and mucin at experimental pH 
resulting in little mucin influence on the ketoprofen drug diffusion (Newby et al., 2018, Taherali 
et al., 2018). It is too preliminary to draw any conclusions, but it seemed that using the non-
linear regression model to interpret the diffusion data might be a more appropriate model to 
use, whereas the linear regression model provided the worst fit when investigating release 
from swollen or shrunken ketoprofen-LUVs. 
 
To summarize, the presence of mucin in the diffusion study did not change the osmotic activity 
of LUVs, and in some cases, it seemed to even contribute to the higher osmotic activity. In 
agreement with our previous reports (Paper III), the obtained RL and K values showed that the 
drug release was enhanced when LUVs were exposed to a hypotonic environment, and the 
release decreased in the hypertonic environment for LUVs containing uncharged drugs. The 
presence of cholesterol in LUVs hampered their sensitivity to osmotic stress. For the negatively 
charged drug, ketoprofen, diffusion across the regenerated cellulose and Permeapad® barrier 
differed and showed different trends. When the net transport of ketoprofen changed in the 
different environment using the regenerated cellulose barrier, the net transport across 
Permeapad® barrier remained similar. The ketoprofen results might indicate that the 
osmotically active LUVs contribute to rather small diffusional changes across real biological 
barriers and that the drugs’ lipophilicity and charge might be larger contributors to the net 
transport across lipid-containing barriers, especially in the presence of mucin. It would be, 
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therefore, highly relevant to verify the diffusion across Permeapad® barrier with more drugs 
before any conclusions can be made. 
 
Furthermore, liposomal physical stability is a crucial factor that needs to be addressed during 
the liposomal drug formulation development. For this reason, we followed the formulation’s 
stability upon storage. 
 
 
5.7 Stability study (Paper III and preliminary results) 
Liposomes developed to enter the market as pharmaceutical products must be stable during 
the storage period. The stability issue was beyond the scope of Papers I and II, but we started 
to follow the stability for caffeine- and hydrocortisone-LUVs in Paper III. In this section, the 
focus will also be given to our preliminary stability results obtained for the ketoprofen-LUVs 
(0% w/w cholesterol, Table 5.4) which was used in the experiments involving mucin. 
 
Table 5.4: Characterization of LUVs dispersions during storage at 6 and 22°C over 65 days, 






Size (nm) PI ZP (mV) EE (%) 
6°C 3 398 ± 15 291 ± 49 0.26 ± 0.03 -7.2 ± 0.5 33 ± 2 
6°C 
14 395 ± 17 266 ± 41 0.24 ± 0.02 -6.8 ± 0.4* 42 ± 2*** 
35 385 ± 17 267 ± 40 0.23 ± 0.02 -7.0 ± 0.5 36 ± 1 
65 383 ± 21 253 ± 38 0.24 ± 0.02 -8.2 ± 0.7*** 46 ± 3*** 
22°C 
14 400 ± 12 258 ± 38 0.20 ± 0.02* -9.1 ± 0.7*** 39 ± 3** 
35 398 ± 15 288 ± 46 0.25 ± 0.03 -10.5 ± 1.3*** 41 ± 2** 
65 390 ± 18 250 ± 34 0.20 ± 0.02* -26.3 ± 13.4*** 57 ± 9*** 
A statistically significant difference in means (* p≤0.050, **p≤0.010, ***p≤0.001) when compared to day 3 
measurements. 
 
For the development of osmosis-controlled liposomes, it is crucial that the formulations 
maintain constant tonicity upon storage. Caffeine- and hydrocortisone-LUVs prepared in this 
study with various amounts of cholesterol incorporated (0-25% w/w, Paper III, results not 
shown), and ketoprofen-LUVs (0% w/w cholesterol, Table 5.4) all indicated stable osmolality 
upon storage at both conditions up to 65 days. This finding is highly relevant for further 
formulation development. 
 
In terms of size, PI and EE, LUVs stored at 6°C were more stable than those stored at 22°C, 
as expected (Grit and Crommelin, 1993). Upon storage at lower temperatures, the lipid bilayer 
elasticity is suggested to decrease and contribute to more stable colloidal dispersions (Tayebi 
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et al., 2012). The addition of cholesterol within liposomes has also been suggested to reduce 
liposomal leakage due to an increase in the dense packing of the phospholipids (de Gier et al., 
1968). The stabilizing effect of cholesterol on ketoprofen-LUVs has not been confirmed yet, 
but as indicated in Table 5.4, the EE of ketoprofen-LUVs (free of cholesterol) varied 
significantly upon storage (p<0.01). Introducing cholesterol into the ketoprofen-LUVs might be 
beneficial to achieve more stable dispersions as suggested by the literature (Briuglia et al., 
2015, Grit and Crommelin, 1993). 
 
Alterations in ZP values measured for ketoprofen-LUVs upon storage (Table 5.4) matched the 
results obtained for caffeine- and hydrocortisone-LUVs (Paper III). The more negative ZP 
obtained after storage might indicate liposomal membrane degradation which is commonly 
observed for the liposomes composed of phospholipids of natural origin (Li et al., 2015). If the 
liposomal membrane is degraded, the visual perception of the liposomal dispersion might 
change. For this reason, pictures were taken of the different LUVs formulations after 65 days 
of storage. The pictures of caffeine- and hydrocortisone-LUVs are not included in this section 
as they have been extensively discussed in Paper III. Instead, the focus was on the preliminary 
formulations of ketoprofen-LUVs (see Figure 5.13). 
 
 
Figure 5.13: Photographs of ketoprofen-LUVs (0% w/w cholesterol) after 65 days of storage at 6 and 
22°C. Each tube represents one replicate out of a total of two replicates (n=2). 
 
As illustrated in Figure 5.13, all the dispersions appeared bright and white in colour. However, 
for one of the ketoprofen-LUVs stored at 22°C (left tube) were slightly more translucent 
indicating a possible change in liposomal integrity. Better pictures were not achievable with 
the camera available in the laboratory. However, these pictures might be of assistance to 
understand the stability issues regarding liposomal dispersions. It also suggests that with the 
use of better camera and more frequent monitoring might provide more extensive information 
about the liposomal integrity in the dispersion upon storage. 
 
Considering all the variables measured, caffeine- and hydrocortisone-LUVs with 11% w/w 
cholesterol were found to be the most stable formulations in comparison to 0 and 25% w/w 
cholesterol. Even though the stabilizing effect of cholesterol was not investigated for 
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ketoprofen-LUVs, preliminary results suggest that cholesterol might be beneficial to reduce 
leakage from these LUVs. Collectively, the stability results obtained so far might be important 
for the further development of drug-loaded LUVs. More importantly, all the formulations 
exhibited stable tonicity at all storage conditions making them suitable for the development of 
osmotically active LUVs for nose-to-brain targeted drug delivery. 
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6 Conclusions 
We have proven that liposomal release can be manipulated by tonicity environment and can 
be used for the development of nose-to-brain drug delivery systems. In detail, the following 
conclusions can be drawn: 
 
Large unilamellar vesicles (LUVs) consisting of soy-phosphatidylcholine and cholesterol 
swelled and shrank when exposed to the hypotonic and hypertonic environment, respectively, 
proving their osmotic activity. The liposomal release of both hydrophilic and lipophilic 
compounds changed due to tonicity perturbations, particularly at tonicity difference greater 
than 300 mOsm/kg. The presence of cholesterol in the LUVs formulations reduced the LUVs’ 
osmotic sensitivity, however, liposomes with 11% w/w cholesterol maintained a relatively good 
osmotic activity in addition to being the most stable formulations upon storage. 
 
For better mimicking the nasal epithelium, the biomimetic Permeapad® was used as a diffusion 
barrier and compared to the standard regenerated cellulose barrier. The drug diffusion profiles 
were different through the two barrier types. We suggest that regenerated cellulose is sensitive 
to detect small diffusional changes on the liposome level, whereas the Permeapad® is superior 
in detecting the net transport across lipid-containing barriers. To additionally improve the 
experimental set-up, studies involving mucin were carried out to mimic the nasal environment. 
Mucin maintained the LUVs’ osmotic activity and expressed low hindrance to drug diffusion. 
 
Both zero order and Korsmeyer-Peppas models can be used to interpret the in vitro diffusion 
data of LUVs. Korsmeyer-Peppas model offered additional advantages, by being less time-
consuming since reference experiments using drug solutions are omitted, which are 
compulsory for the zero order model. The Korsmeyer-Peppas model was found to be suitable 
to improve the diffusion data interpretation of LUVs experiencing osmotic stress. 
 
In summary, these results provide a fundament and can be utilized for the further development 
of liposomal formulations for nose-to-brain drug delivery. 
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7 Future perspectives 
We have carried out studies to prove that LUVs are osmotically active within tonicity that 
resemble nasal environment. In the future, it would be valuable to determine the liposomal lipid 
content and tailor the liposomal lipid composition. 
 
Furthermore, more drugs with a wider range of physiochemical properties should be tested to 
validate our hypothesis. The use of Permeapad® barrier as a diffusion barrier and mucin to 
simulate the nasal environment are worth investigating in more detail. In particular, substituting 
the porcine mucin type III with more gel-forming mucin (e.g. MUC5B, MUC5AC, MUC2 found 
in the nasal cavity) and the use of different mucin concentrations should be thoroughly 
screened. 
 
In this thesis, the stability of the formulations upon storage were evaluated in PBS at two 
different temperature conditions. The stability of the liposomes in nasal enzymes, plasma, and 
brain homogenate will be of equivalent importance to verify if the liposomes are susceptible 
for nose-to-brain drug administration. 
 
We have only focused on LUVs of sizes between 200-400 nm, but the confirmation of the 
osmotic activity of smaller or larger liposomes might be of value as well. It would be also 
beneficial to investigate different surface modifications to increase the mucoadhesion and 
absorption through the nasal epithelium. 
 
The ideal nasal formulation should not affect mucus secretion or cause morphologic changes 
on the nasal epithelium while serving its purpose of improving the mucoadhesion and 
absorption through the nasal epithelium. Further cell experiments, in vivo and clinical studies, 
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a  b  s t r a  c t
In  this  work,  the  influence  of environmental  tonicity  perturbations  on the  size  and  release kinetics  of
model  markers  from  liposomes  (calcein  and  rhodamine)  was investigated. Large unilamellar  vesicles
(LUVs)  were  prepared  from  a  mixture  composed of organic solvents  containing  dissolved  phosphatidyl-
choline  and phosphate buffered  saline (PBS,  pH 7.4). Organic  phase was removed  by  rotary  evaporation
and the  obtained  liposomal dispersions were  extruded to reduce  the  liposomal  sizes to  approx. 400  nm.
The LUVs  were  exposed  to PBS of different  tonicity  to induce water migration,  and  consequently,  gen-
erate  an osmotic  pressure  on the  vesicle membranes.  The markers  release kinetics  were  studied  by  the
dialysis  method employing  Franz  diffusion  cells. LUVs  appeared  to  be  more susceptible to the  osmotic
swelling  than  the  shrinking  and the  size  changes were  significantly  more  pronounced for  calcein-loaded
LUVs  in comparison to  rhodamine-loaded LUVs. The calcein  release from  LUVs  was  highly affected  by  the
water influx/efflux,  whereas rhodamine  release  was less affected by  the  tonicity perturbations.  Mech-
anistically,  it appeared  that  hydrophilic  molecules  (calcein)  followed  the  water  flux,  whereas lipophilic
molecules (rhodamine) seemed to be  more affected by  the changes  in LUVs  size  and  consequent  alteration
of  the  tightness  of the  phospholipid  bilayer (where the  lipophilic  marker  was  imbedded  in).  These results
demonstrate that  the  different tonicity  (within  the  inner  core  and external  environment of vesicles) can
enhance/hamper  the  diffusion  of a marker from LUVs  and  that  osmotically active liposomes  could  be
used as  a novel  controlled  drug  delivery system.
©  2017  Elsevier B.V.  All  rights  reserved.. Introduction
Since their first description [1], several applications of liposomes
ave been proposed, among which their use as drug carrier remains
he most studied [2,3].  Currently, liposomes account for a signifi-
ant portion of the market share in  nanomedicine [4].
Liposomes are spherical vesicles consisting of single or multi-
le phospholipid bilayers surrounding an aqueous core. Due to the
mphiphilic nature of the phospholipids, liposomes have the abil-
ty to entrap both hydrophilic and lipophilic compounds [5].  The
iposomal membranes are semipermeable, allowing neutral, poorly
olarized and small molecules to  diffuse through it, whereas ions,
ighly polarized small molecules and large molecules will not [6,7].
∗ Corresponding author.
E-mail address: massimiliano.p.cagno@uit.no (M.P. di Cagno).
ttp://dx.doi.org/10.1016/j.colsurfb.2017.05.062
927-7765/© 2017 Elsevier B.V. All  rights reserved.Liposomes are appealing for drug delivery because of their abil-
ity to solubilize poorly water-soluble compounds [8,9]. Chemical
entities confined into liposomes are less subjected to  early degrada-
tion and elimination, and an improved drug distribution compared
to non-entrapped drugs can be achieved [10]. The shape and prop-
erties of liposomes are similar to human cells, which provide good
compatibility and low toxicity [10].
As all systems composed by semipermeable membranes, lipo-
somes shape and size can be subjected to osmosis. Osmotic pressure
() is defined as the force that applies on the surface of a  semiper-
meable membrane when water diffuses through it due to the
different tonicity between the solutions on the two  side of  the
membrane. In these conditions, water diffuses from the side with
lowest solute concentration (higher chemical potential) to the
regions of highest solute concentration (lower chemical potential)
until the equilibrium is  reached [11]. If liposomes are  exposed to
a hypertonic environment, water effluxes through the phospho-
lipid bilayer to the external environment, generating a  positive
66 I.Y. Wu et al. / Colloids and Surfaces B:  Biointerfaces 157 (2017) 65–71








































Measured tonicity, pH (mean ± SD, n =  3)  and calculated concentrations of the dif-
ferent types of PBS used.
PBS type Tonicity (mOsm) pH Concentration (mM)
300 300 ± 4 7.40 ± 0.02 74
190 187 ± 3 7.46 ± 0.02 44Fig. 1. Molecular structure, molecular weight (MW),  partition coeffi
smotic pressure and induces size reduction [12]. On the con-
rary, when liposomes are exposed to a  hypotonic environment,
ater influxes from the external environment, generating a  nega-
ive osmotic pressure and size enlargement [12].
The influence of osmotic stress on lipid bilayers has been inves-
igated on different vesicle models such as multilamellar vesicles
6,13] and large unilamellar vesicles (LUVs) [14–16].  Unilamellar
esicles are reported to be an appropriate model system to study
he permeability properties associated with osmotic swelling or
hrinking [6,13,15]. However, to the best of our  knowledge, the
nfluence that the environmental tonicity perturbations have on the
elease of chemical entities from liposomes has not been clarified
et.
The aim of this study was to verify if, and to which extent, the
nvironmental tonicity perturbations affect the release kinetic of
odel substances from LUVs.
For this reason, two chemically different fluorescent markers
calcein and rhodamine) were used to study their release kinetics
orm LUVs. Fluorescent markers of different solubility were chosen
o  simplify the mechanistic study [17–20]. Calcein is a hydrophilic
arker that can be entrapped in  the inner aqueous core of LUVs
19], whereas rhodamine is  a  lipophilic marker (Log P  of 2 [21])
hat is expected to  be incorporated in the phospholipid bilayer of
UVs.
. Materials and methods
.1. Materials
Calcein and rhodamine B (Fig. 1 reports the chemical
tructure of both markers together with meaningful physicochem-
cal characteristics [19,21–23]), disodium hydrogen phosphate
ihydrate (Na2HPO4·2H2O), sodium chloride (NaCl), sodium
ydroxide (NaOH), sodium dihydrogen phosphate monohydrate
NaH2PO4·H2O), chloroform, ethanol (96%, v/v), methanol and non-
onic surfactant Triton X-100 were purchased from Sigma-Aldrich
hemie GmbH (Steinheim, Germany). Soy  phosphatidylcholine
100 (SPC) was a  gift from Lipoid GmbH (Ludwigshafen, Germany).
.2. Phosphate buffer saline (PBS) preparation
A 74 mM phosphate buffer saline (PBS) solution (buffer 300) was
repared dissolving 22.5 g NaH2PO4·H2O  and 36.8 g Na2HPO4·2H2O
n 5 L distilled water. The pH was adjusted to 7.4 with NaOH,
hereas NaCl was employed to fix tonicity at 300 mOsm (Semi-
icro Osmometer K-7400, Knauer, Berlin, Germany). Buffer 300
as diluted with distilled water in  order to  obtain two  other solu-
ions (buffer 190 and 65 respectively, Table 1)  with lower tonicity.65 65 ± 1 7.56 ± 0.01 15
2.3. Liposomes preparation
LUV dispersions were prepared following a  method pre-
viously described [24,25] with some modifications. In brief,
0.2 mL  methanol was mixed with 1 mL  SPC/chloroform solution
(200 mg/mL) in  a  50 mL  round bottom flask. PBS (10.5 mL)  was  gen-
tly added, and the organic phase was subsequently removed by
rotary evaporation (40 ◦C, 40 rpm and 0.1 bar for 90 min) (Büchi R-
124 rotavapor equipped with Büchi vacuum pump V-500 and Büchi
B-480 water bath, Büchi Labortechnik AG, Flawil, Switzerland).
All liposomal dispersions were prepared employing buffer 300
(74 mM,  Table 1) or, alternatively, buffer 65  (15 mM,  Table 1).
LUV dispersions were spontaneously formed after the removal of
organic phase. In  order to reduce liposomal sizes, the dispersions
were extruded at room temperature (23–25 ◦C) through polycar-
bonate membrane filters (lowest pore-size of 400 nm, Nuclepore
Track-Etched Membranes, Whatman International Ltd., Bucking-
hamshire, UK). To load the fluorescent markers in  liposomes,
calcein was  dissolved in PBS (obtaining a  calcein solution with a
concentration of 2 mM)  prior to  the lipid film reconstitution. Dif-
ferently, for the preparation of rhodamine-LUVs, the marker was
dissolved in chloroform together with lipid (rhodamine-lipid molar
ratio approx. 1:1).
2.4. Size and surface potential analysis
Photon correlation spectroscopy (PCS) (Nicomp Submicron Par-
ticle Sizer 370, PSS Nicomp Particle Sizing Systems, California, USA)
was employed for the determination of LUV size distributions after
the extrusion. Samples were diluted to a count rate of  250–350 kHz
at room temperature (23–25 ◦C), and each sample was measured
in  three parallels. Size changes of LUVs induced by  tonicity pertur-
bations were measured on the Zetasizer Nano Zen 2600 (Malvern,
Worcestershire, UK). Samples were diluted 1/100 (v/v) with PBS
300 (or alternatively PBS 65) previous analysis and LUV dispersions
were filtered to remove eventual impurities. Experiments were
performed over a  period of 70 min  at 25 ◦C in duplicates (n =  2), and
each sample was  measured in three parallels. The -potential (ZP)
of  LUVs was measured on the Zetasizer Nano Zen 2600 (Malvern).
The respective dispersions were diluted 1/20 (v/v) with filtrated




























































Types of PBS inside (inner core) and outside (external environment) LUVs and rela-
tive  osmotic pressures generated. Relative osmotic pressures (rel)  were calculated
employing Eq. (1).
PBS type rel
Inner core LUVs External environment LUVs (bar)
300 300 0
300  190 −3
300  65 −6I.Y. Wu et al. / Colloids and Surfa
eionized water. All analyses were performed at 25 ◦C in duplicates
n = 2), and each of the samples was measured in three parallels.
.5. Entrapment efficiency determination
Entrapment efficiency of liposome dispersions was  estimated
ombining a dialysis method to quantify the unentrapped marker
oncentration (Cfree) with a  sedimentation method for estimating
he volume occupied and unoccupied by  LUVs. For quantification
f the unentrapped marker concentration (Cfree), the method pre-
iously described by di Cagno and Luppi [9] was  employed. In
rief, lower compartment (donor) of a  Franz diffusion cell (dif-
usional area of 0.64 cm2,  jacketed flat ground joint, PermeGear
nk, Hellertown, USA) was filled with liposomal dispersion (5 mL)
hereas the upper compartment (acceptor) was filled with the
orresponding PBS (1 mL). A  cellulose hydrate membrane (Visk-
ng dialysis tubing MWCO  12–14 kDa, Medicell International Ltd.,
ondon, UK) was placed between the donor and acceptor compart-
ent and used as dialysis barrier. The system was  let to  equilibrium
t room temperature (23–25 ◦C) over a  period of 48 h. The con-
entration of the marker in  the acceptor compartment (Cfree)
as quantified by  fluorescence spectroscopy (FLUOstar/POLARstar
alaxy fluorometer, BMG  Technologies, Offenburg, Germany). Exci-
ation and emission wavelengths were 485 nm and 520 nm for
alcein, and 544 nm and 590 nm for rhodamine, respectively.
n order to  evaluate the ratio between liposome-occupied and
iposome-unoccupied volume, non-dialyzed liposomal dispersions
ere centrifuged (30 min, 10 ◦C, 200 000g, Beckman model L8–70 M
ith SW 60 Ti rotor, Beckman Instruments, California, USA) in
rder to precipitate the vesicles. The liposome-unoccupied volume
as used together with the unentrapped marker concentration
Cfree)  to quantify the total amount of unentrapped marker (i.e.
ot entrapped in liposomes, Mfree). In order to  determine the ini-
ial amount of marker in  original dispersions (Mtot), LUVs were
estroyed by adding 5% (v/v) triton/PBS solution for calcein-loaded
iposomes or, alternatively, a  50% (v/v) methanol/PBS solution for
he rhodamine-loaded LUVs, and the total concentration of marker
n the liposomal dispersion (Ctot) was quantified by the fluores-
ence spectroscopy. The entrapment efficiency (EE) was calculated
y using the following equation:
E (%) = Mtot − Mfree
Mtot
∗ 100 (1)
here Mtot represents the total amount of marker in  the original
ispersion and Mfree is  the amount of unentrapped marker. Exper-
ments were performed in duplicates (n = 2) and each sample was
easured in  four parallels.
.6. In vitro release of fluorescent markers from LUVs
Release studies of fluorescent markers were performed by
ranz diffusion cells (Standard 1.77 cm2 diffusional area jack-
ted flat ground joint, PermeGear Ink, Hellertown, USA) equipped
ith cellulose hydrate membrane (Visking dialysis tubing MWCO
2–14 kDa, Medicell) in  between donor and acceptor (12 mL)  com-
artment. Experiments were performed at 35 ◦C (Julabo F12-ED,
ulabo Laboratechnik, Seelback, Germany) in  triplicates (n  =  3) and
ach sample was analysed in two parallels. At time zero (t = 0 h,
tarting of the experiment) dialyzed liposomal dispersion (0.8 mL)
as added to  the donor compartment. As control experiments,
olutions of calcein (2 mM)  or  rhodamine (1 mM) prepared in  both
uffer 300 and 65 were employed. Samplings (0.5 mL)  were carried
ut at intervals of 1 h over a period of 8 h.  Equal volumes of PBS were
eintroduced into the acceptor compartment after withdrawal of
amples in order to maintain sink condition. The concentration of
he markers in the acceptor compartment was detected by fluores-65 65 0
65 190 3
65 300 6
cence spectroscopy (see Section 2.5) and the cumulative amount of
diffused marker over time calculated. The flux of  each of the marker
through the cellulose hydrate membrane (J) was determined by Eq.
(2) [26]:





where dm/dt represents the variation of mass over time and A  is
the diffusional area. For each marker, the apparent permeability
coefficient (Papp)  was calculated using Eq.  (3):
Papp = JC (3)
where C represents the initial marker concentration. Papp was cal-
culated with either the total initial marker concentration in  the
dispersion (Ctot) or, alternatively, the initial concentration of the
unentrapped marker (Cfree, named Pøapp)  [9]. As control, the appar-
ent permeability coefficient of the markers from solutions (P0app)
were measured.
2.7. Osmotic pressure calculation
In this work, the relative osmotic pressure (rel)  was  estimated
by  Eq. (4) as:
rel = R  ∗ T  ∗
(
Osm(out) −  Osm(in)
)
(4)
where R represents the gas constant, T is  the absolute temperature
and Osm(out) − Osm(in) is  the difference between the external and
internal osmolality (units of mOsm)  of LUVs. Based on Eq. (4),  a  posi-
tive relative osmotic pressure (Table 2) is produced when the water
diffuses from the internal core of liposomes to the external environ-
ment (Osm(in) < Osm(out)) and negative relative osmotic pressure
(Table 2) when the water diffuses from the external environment
to the internal core (Osm(in) >  Osm(out))  [12].
2.8. Statistical evaluation
Student’s t-test was performed to evaluate a  significance in the
collected data. A p value ≤ 0.05 was  considered as significantly dif-
ferent.
3. Results
3.1. LUV dispersions characterization
The relevant characteristics of the different LUV dispersions
prepared are summarized in Table 3. Liposomal size distributions
varied between the different types of dispersions prepared. Empty
LUVs show similar size distributions when prepared in  different
PBS, whereas calcein and rhodamine-LUVs expressed differences
in  size distributions. For both calcein- and rhodamine-loaded LUVs,
tonicity of the PBS seemed to have a  significant effect (p <  0.05) on
liposome sizes. Moreover, the PBS composition appeared to have a
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Table 3
Size, polydispersity index (PI), -potential (ZP) and entrapment efficiency (EE) of
LUVs  prepared in different types of PBS. Results are reported as mean ± SD.
Marker Dispersing PBS
type
Size (nm) PI  ZP (mV) EE (%)
0 309 ± 20 0.10 ± 0.01 −20.4 ± 0.8 –
65 327 ± 52 0.32 ± 0.09 – –
300 393 ± 92 0.33 ± 0.04 −12.0 ± 1.6 –
Calcein 65 649 ± 8 0.44 ± 0.04 −2.8 ± 0.4 41 ± 5.3
300 449 ± 20 0.30 ± 0.02 −0.5 ± 0.2 43 ± 0.6
Rhodamine 65  386 ± 8 0.15 ± 0.00 −16.7 ± 0.4 85 ± 0.6
300 762 ± 104 0.42 ± 0.06 −8.6 ± 0.3 89 ± 0.7
Table 4
Apparent permeability coefficients (P0app) through cellulose hydrate membrane of
calcein and rhodamine measured from two different PBS type  solutions. Experi-
ments were conducted at neutral pH  and the results are reported as mean ± SD
(n  = 3).
P0app (10−5 cm/sec)






































300 0.90 ± 0.07 1.61  ± 0.11
65  0.68 ± 0.06 1.55  ± 0.06
reat impact on the repulsive electrokinetic potential (ZP) in all dis-
ersions. Specifically, empty LUVs and rhodamine-LUVs appeared
o preserve the partial negative potentials at tested tonicity (buffer
5 and 300), whereas calcein-LUVs surface potentials remained
lmost neutral. The overall entrapment efficiency were approx.
-fold higher for rhodamine in comparison to calcein (Table 3).
.2. Effect of the dispersing media tonicity on liposomal size
istributions
The changes in size  distributions of LUV dispersions after their
xposure to PBS with varied tonicity are reported in Fig. 2.  As a
ontrol, LUV size distributions in  the isotonic environment are also
eported (white symbols). For empty LUVs prepared in  buffer 300
Fig. 2A, upper line), a significant increase in  size over time was
bserved when LUVs were exposed to  the hypotonic environment
buffer 65) in comparison to  the isotonic environment. In hyper-
onic environment (Fig. 2A, lower line), no significant differences
ere detected. For calcein-loaded LUVs, size enlargement was mea-
ured for both LUV dispersions (buffer 300 and 65 respectively)
fter the exposure to a dispersing medium of different tonicity
buffer 65 and 300 respectively, Fig. 2B). For rhodamine-LUVs (both
uffer 300 and 65), no significant changes in vesicle sizes were
bserved after exposure to the hypertonic or hypotonic environ-
ent (buffer 65 and 300 respectively, Fig. 2C)  in comparison to the
espective isotonic environment (white symbols).
.3. In vitro release study
As it  can be seen in  Table 4,  rhodamine (in solution) exhibited
 higher apparent permeability coefficient in comparison to cal-
ein (in solution). Interestingly, the tonicity of the PBS had a  strong
nfluence on the calcein permeability. In buffer 300, the apparent
ermeability of calcein was approx. 24% higher than in  buffer 65
level of significance). For rhodamine, a  similar trend was observed.
ialysis method is  a common method used to estimate the kinet-
cs of drug release from nanocarriers [27].  This method is  based
n the assumptions that the accumulation of the drug in the sink
eceiver (i.e. acceptor chamber of Franz cell) is directly proportional
o the kinetics of drug release from the carrier. The relationship
etween the flux of markers through cellulose hydrate membrane
nd the calculated relative osmotic pressure is shown in  Fig. 3.
s it can be  seen, calcein flux through cellulose membrane was Biointerfaces 157 (2017) 65–71
highly influenced by the PBS in which the calcein-LUV dispersions
were prepared (same trend as for the calcein in solutions) and by
the relative osmotic pressure that was generated when LUVs were
dispersed in non-isotonic dispersing medium. When calcein-LUVs
were prepared in buffer 300, the flux of calcein through semiper-
meable membrane was  significantly (p <  0.05) higher (approx. 44%)
in comparison to buffer 65 (Fig. 3A). Interestingly, the flux of cal-
cein through the cellulose membrane decreased (Fig. 3A, light-grey
columns) when influx of water molecules increased (i.e. nega-
tive osmotic pressures). On the contrary, when a  positive osmotic
pressure was  applied (i.e. efflux of water molecules from LUVs),
a significant increase in  the calcein flux was observed (Fig. 3A,
dark-grey columns). Interestingly, the flux  of lipophilic marker
(rhodamine) through the cellulose hydrate membrane seemed to
be less affected by the differences in  the PBS tonicity and osmotic
pressures generated on the LUV membranes (Fig. 3B). A signifi-
cant (p < 0.05) decrease in rhodamine flux through cellulose hydrate
membrane was  observed only when a positive osmotic pressure
(i.e. efflux of water molecules) applied. These changes were how-
ever minimal in comparison to the changes found for calcein. The
normalized fluxes over the initial concentration of the markers in
the LUV dispersions (i.e. apparent permeability coefficients) are
reported in  Table 5. For  calcein, both estimated values of  perme-
ability coefficients (Papp and Pøapp)  were quite comparable to the
P0app (calcein in solution, Table 4). For rhodamine, Pøapp (i.e. calcu-
lated using the unentrapped marker concentration) was in  the same
order of magnitude as reference values (P0app, Table 4) whereas,
the Papp values (i.e. calculated using the total initial concentration
of rhodamine) were 5-fold lower in comparison to P0app (Table 4).
4. Discussion
Photon correlation spectroscopy is  a  common method employed
for analysing liposomal size [28,29].  Some of the LUV dispersions
loaded with marker remain unexpectedly large after the extrusion
through 400 nm pore size filter (Table 3). This could be due to the
aggregation that often affects the colloidal dispersions, and even
more when the dispersed particles own neutral surface potentials
[30].  Liposomal aggregation is the result of an interplay between
the van der Waals forces (attractive) and repulsive electrokinetic
potential [16,31,32].  With increasing electrolyte concentration, the
changes in the electrostatic repulsion of liposomes can be estimated
by the direct determination of -potential (ZP) of liposomes [16,33].
In this study, a  decreased ZP seemed to  induce aggregation for
rhodamine-LUVs, whereas calcein-LUVs exhibited a  different trend
(Table 3), probably due to the different physicochemical character-
istics of the markers (Fig. 1).
An  expected lower ZP (Table 3)  was  observed for LUV disper-
sions prepared in  buffer 300 in comparison to  buffer 65, probably
due to  the ion shell formation [16,33]. Rhodamine-loaded and
empty LUVs expressed a negative ZP  at investigated tonicities
(Table 3). Since rhodamine is  lipophilic (Log P of 2) [21] and
zwitterionic at neutral pH [34],  it is reasonable to  think that
this compound is  imbedded into the lipid-bilayer, producing lim-
ited effects on the surface potential of liposomes. Differently, the
ZP of calcein-LUVs was almost neutral at investigated tonicities,
implicating that highly hydrophilic (Log P  of  −4 [19])  and highly
polarized marker (negatively charged at neutral pH,  pKa of 1.8)
[22] might contribute somehow to  strengthening of the ion shell
surrounding LUVs.
The entrapment efficiency (EE)  of the markers into LUVs was
determined by standard centrifugation method and was  13% for
calcein and 79% for rhodamine, respectively. These results were
in accordance with the literature for rhodamine (and lipophilic
compounds in general) [35],  whereas, for calcein they were rather
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Fig. 2. Size distributional changes of LUVs (empty, calcein-loaded and rhodamine-loaded) prepared in buffer 300 (upper line) and buffer 65 (lower line) after exposure to
hypotonic and hypertonic environment (buffer 65 and 300 respectively). Results are reported as mean ± SD (n  =  2).
Table 5
Apparent permeability coefficients of calcein and rhodamine through cellulose hydrate membrane measured under tonicity imbalance condition between internal and
external  environment of LUVs. For the calculations, the total marker concentration in the LUV dispersion (Papp)  and,  alternatively, the unentrapped marker concentration
(i.e.  molecular dissolved marker concentration (Pøapp)) were employed. Results are reported as mean ± SD (n  = 3).
Calcein Rhodamine
Dispersing PBS type rel(bar) Papp(10−5 cm/sec) Pøapp(10−5 cm/sec) Papp(10−5 cm/sec) Pøapp(10−5 cm/sec)
300 0 0.86 ± 0.05 1.34 ± 0.08 0.33 ± 0.02 2.22 ± 0.14
−3  0.76 ± 0.00 1.20 ± 0.00 0.35 ± 0.03 2.29 ± 0.17
−6  0.65 ± 0.06 1.01 ± 0.09 0.31 ± 0.00 2.05 ± 0.02
–
65 0  0.47 ± 0.06 0.75 ± 0.10 0.36 ± 0.02 2.48 ± 0.17






















6  0.70 ± 0.05 
sotonic conditions are reported in bold.
ow in  comparison to previous reports [35].  Applying the dial-
sis/centrifugation method, an entrapment of approx. 40% was
ound for calcein and approx. 85% for rhodamine, respectively.
nterestingly, the different methods gave relatively similar EE of
hodamine, while they differed a  lot for calcein-LUVs. This find-
ng could be explained by the different chemical nature of the
wo markers (Fig. 1). Rhodamine is a quite lipophilic marker (Log
 of 2 [21]) and expected to be incorporated in the lipid bilayer.
n the other hand, calcein is  extremely hydrophilic at neutral pH
Log P of −4  [19])  and is  expected to be entrapped in  the liposo-
al  inner aqueous core. It  is  reasonable that liposomes rupture
ould influence EE of calcein during ultracentrifugation, whereas
hodamine-LUVs could be more resistant to damage.
Swelling and shrinking are standard responses of liposomes to
he environmental tonicity changes. They reflect the ability of phos-
holipid bilayers to  exchange water molecules within internal and
xternal environment, inducing volume changes [6,7,13,15].  In this
tudy, a significant size increase over time was observed when
mpty and calcein-loaded LUVs were exposed to the hypotonic
nvironment (Fig.  2A, B,  upper line) as a  result of water influx into.13 ± 0.08 0.29 ± 0.01 2.00 ± 0.09
the LUVs in comparison to isotonic environment. These findings are
in agreement with reported literature on other unilamellar vesicle
systems composed of either same phospholipid [15,28] or other
phospholipids [36].  The fact that no significant size  decrement
was measurable when liposomes were exposed to the hypertonic
environment might be related to  the physical limitation associ-
ated to shrinking of liposomes (Fig. 2A, B,  lower line) [37].  The
increased size  of calcein-LUVs in  comparison to  their size in  the
isotonic environment might be due to  liposomal aggregation that
occurs due to  neutral surface charge of LUVs and that hampered the
detection of size decrement (Fig. 2B,  lower line). Rhodamine-LUVs
showed no significant size changes before and after the alteration
of the environmental tonicity in comparison to isotonic environ-
ments (Fig. 2C). This could be explained by the lipophilic nature of
rhodamine in comparison to the hydrophilic calcein. Similarly to
cholesterol, rhodamine might also contribute to a more rigid and
impermeable membrane retaining the incorporated marker [38].
Regarding the marker release studies, the control permeabil-
ity of both markers through the cellulose hydrate membrane
(P0app)  was  surprisingly higher in the PBS with the highest tonicity





























ig. 3. Correlation between the relative osmotic pressures (rel) (generated by  the di
uxes  of calcein (A) and rhodamine (B) in LUV dispersions (2 mM total marker conc
Table 4). The same trend was observed when the markers were
oaded into LUVs (Fig. 3,  central bars). This phenomenon could be
elated to the nature of the barrier utilized for the release study.
he cellulose hydrate membranes are reported to express a  slightly
egative charge [39,40]. This could reduce the flux of calcein and
hodamine (to a  minor extent, Table 4) due to  the electrostatic
epulsion; more evident for calcein (negatively charged at this pH).
t is plausible that in  high tonicity (PBS 300), the negative potential
f the barrier is neutralized by  the ion deposition, improving the
ux of the markers [41].
When liposomal dispersions were studied, the flux of cal-
ein through cellulose hydrate membrane was highly affected
y the induced osmotic changes (Fig. 3A). At  positive osmotic
ressures (i.e. efflux of water molecules), the flux of calcein
ncreased, whereas at negative osmotic pressure (i.e. influx of water
olecule) it decreased. This phenomenon could be  explained by the
arker/water flux interplay through the lipid bilayer. When pos-
tive osmotic pressure was  applied, the flux of water and calcein
ere both directed outwards (synergistic effect), in agreement with
eported literature, even though the lipid composition in  the com-
aring studies differed [36,42]. On  the other hand, when negative
smotic pressure applied, the marker still followed the concen-
ration gradient (directed outwards) but the flux of water was
irected inwards (antagonistic effect). While the flux of calcein was
irectly correlated to the osmotic pressure, the rhodamine flux was
elatively stable and only slightly influenced by positive osmotic
ressures (Fig. 3B). This phenomenon could be  due to the fact thatce in tonicity between internal and external environment of LUVs) and the observed
tion). Results are reported as mean ± SD (n =  3,  *p ≤  0.05, **p ≤ 0.01).
rhodamine is  a lipophilic compound that is primarily incorporated
in the phospholipid bilayer of LUVs. When positive osmotic pres-
sure was applied (i.e. efflux water), liposomal membrane could
become tightly packed hampering/reducing the marker release.
Table 5 reports the normalization of all fluxes according to the
initial concentration of the markers in the liposomal dispersions. To
have a  better understanding of the mechanism involved, all fluxes
were normalized according to  the initial concentration of  markers
(total and unentrapped marker concentration) in  the dispersion.
For calcein, the permeability coefficients normalized over the total
(Papp) or unentrapped marker concentration (Pøapp) were similar
and comparable to the reference value (P0app,  Table 4). On  the other
hand, for rhodamine, only Pøapp (Table 5) were in  the same order
of magnitude as the control permeability (P0app,  Table 4). These
results are in agreement with previous finding [9] supporting the
theory that for the lipophilic substances, the freely molecularly
dissolved fraction of the drug is the primary contributor to the
permeability.
5. Conclusion
This study shows that tonicity perturbations affect the release
of hydrophilic and, to a  minor extent, lipophilic markers from LUVs.
The sizes, as well as the release kinetics of the two  different mark-
ers loaded inside LUVs were altered by the tonicity differences.
LUV dispersions seemed to  be more susceptible to  the osmotic














































strength on  salt passage through reverse osmosis membranes, DesalinationI.Y. Wu et al. / Colloids and Surfa
nd calcein-LUVs in comparison to rhodamine-LUVs. The release
f calcein from LUVs was highly influenced by the environmen-
al tonicity changes, whereas the release of rhodamine was  less
ffected. In conclusion, these results demonstrate that different
onicity (within inner core and external environment of LUVs) can
nhance/hamper the release of markers from LUVs and that osmot-
cally active liposomes could be  used as a  new controlled drug
elivery system.
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Systemic administration of drugs is ineffective in the treatment of central nervous system disorders
because of the blood-brain barrier. Nasal administration has been suggested as an alternative adminis-
tration route as drugs absorbed in the olfactory epithelium bypass the blood-brain barrier and reach the
brain within minutes. However, the nasal mucosa properties (e.g., tonicity, pH) are not constant because
of physiological and environmental factors, and this might limit the therapeutic outcome of nanocarrier-
based formulations. To shine light on the impact of environmental ionic strength on nanocarrier-based
formulations, we have studied how liposomal formulations respond to the change of tonicity of the
external environment. Large unilamellar vesicles loaded with 6 different drugs were exposed to different
hypotonic environments, creating an osmotic gradient within the inner core and external environment of
the liposomes up to 650 mOsm/kg. Both size and polydispersity of liposomes were significantly affected
by tonicity changes. Moreover, the release kinetics of hydrophilic and lipophilic drugs were largely
enhanced by hypotonic environments. These results clearly demonstrate that the environmental ionic
strength has an impact on liposomal formulation stability and drug release kinetics and it should be
considered when liposomal formulations for nose-to-brain targeted drug delivery are designed.
© 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.Introduction
Standard therapies for the treatment of the majority of central
nervous system (CNS) disorders (i.e., Alzheimer’s disease, multiple
sclerosis, Parkinson’s disease, etc.) are based on daily systemic
administration of drugs. The most serious limitation of systemic
administration of drugs is that the blood-brain barrier (BBB) pre-
vents drugs from reaching the CNS.1-3 The BBB consists of tightly
packed endothelial cells separating the systemic circulation from
the neuronal cells. It is estimated that the BBB limits the access to; EE, entrapment efficiency;
red saline; PI, polydispersity
nerated cellulose barrier; RL,
r; RT, total resistance to drug
tidylcholine; ZP, z-potential;
and external environment of
lephone: þ47-22856598).
di Cagno).
®. Published by Elsevier Inc. All rithe brain for 98% of small molecules and 100% of large ones.4 To
overcome these limitations, alternative routes of drug administra-
tion to the brain have lately emerged. One of the most promising
routes of administration appears to be the nose-to-brain targeted
drug administration.5,6 The nasal epithelium is divided into the
olfactory and respiratory region.5-7 Drugs that are absorbed
through the olfactory region have the potential to avoid systemic
elimination (i.e., first-pass metabolism, renal clearance etc.), reach
the cerebrospinal fluid, and accumulate in the brain bypassing the
BBB.5-8 This route of drug administration is unfortunately limited
by low absorption through the olfactory epithelium because of the
limited surface area, early enzymatic degradation, and rapid ciliary
clearance.9 However, new research has shown that liposomes can
optimize nose-to-brain targeted drug delivery.10 Liposomes are
spherical vesicles consisting of single or multiple phospholipid bi-
layers surrounding an aqueous core.11,12 Liposomes for nose-to-
brain targeted delivery have shown to protect drugs from early
degradation and elimination because of their ability to entrap both
hydrophilic and lipophilic compounds.13,14 Recent in vivo studies in
rats have shown that liposomal formulations administered via the
nose reduce systemic side effects, improve apparent neurologicalghts reserved.
Table 2
Experimentally Determined Osmolality, pH, and Calculated Phosphate Concentra-
tion for Each of the PBS Solutions Employed
Buffer Solution Osmolality (mOsm/kg) pH Phosphate (mM)
PBS700 707 ± 6 7.21 ± 0.01 74 ± 0
PBS300 298 ± 12 7.39 ± 0.03 74 ± 0
PBS190 183 ± 2 7.49 ± 0.04 44 ± 0
PBS65 64 ± 3 7.60 ± 0.04 15 ± 0
Results represent mean ± SD (n ¼ 5).
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Alzheimer’s and Parkinson’s disease.10,15 Despite the promising
results, liposome-based formulations intended for nose-to-brain
targeted drug delivery seem to show inconsistent improvement
in the therapeutic effects when compared with other nano-
particulate systems.16,17 It has been suggested that one of the rea-
sons might be the slow drug release kinetics (for both hydrophilic
and lipophilic compounds) from the liposomal carrier.18-20 Another
important variable is related to physiological changes at the nasal
mucosal level. In fact, as the mucus is directly open to the external
milieu, environmental factors such as air humidity or temperature
can perturb the mucus properties such as viscosity, pH, and most
importantly, tonicity.21,22 These alterations might also occur during
the inflammation state.23 It is well accepted that liposomal phos-
pholipid bilayer allows small neutralmolecules to pass through it to
equalize the chemical activity gradient.24-26 For instance, when the
ionic strength of the liposomal core is higher than the outside
environment, water molecules will diffuse through the lipid bilayer
from the outside to the inside of the liposomes (following the
chemical activity gradient). As a result of solvent movement, an
osmotic pressure is generated on the liposomal surfaces and lipo-
somes swell (water influx).27-29 We have recently proved that the
release of a medium-sized hydrophilic marker (calcein) and lipo-
philic marker (rhodamine) from large unilamellar vesicles (LUVs) is
influenced by osmotic stress.30 Specifically, we proved that the
release of a hydrophilic marker from LUVs was significantly more
affected by the tonicity perturbations in comparison with a lipo-
philic marker. This suggests that the magnitude of these changes
could be related to the interplay between the changes in liposomal
size and the direction of water flux through the liposomal mem-
brane (water influx or efflux). The aim of this study was therefore to
verify how the changes in environmental ionic strength might in-
fluence liposomal formulations designed for nasal administration.
Specifically, we investigated how the exposure of LUVs to hypotonic
environment affects the drug release kinetics of 6 active pharma-
ceutical ingredients (caffeine, hydrocortisone, ibuprofen, ketopro-
fen, methylprednisolone, and theophylline). The drugs were chosen
to cover a range of relevant physiochemical properties (different
partition coefficients and ionization constants, see Table 1) within
potential candidates in the treatment or prevention of the Alz-
heimer’s disease.37,38 The liposomal dispersions were characterized
in terms of size, z-potential (ZP), and entrapment efficiency (EE),
whereas drug release kinetics in uneven tonicities were studied by
the classic Franz cell diffusion system equipped with regenerated
cellulose barriers.Materials and Methods
Materials
Caffeine, hydrocortisone, ibuprofen, ketoprofen, methylpred-
nisolone, theophylline, disodium hydrogen phosphate dihydrateTable 1
Molecular Weight (MW), Dissociation Constant (pKa), Distribution Coefficient at pH
7.4 (logD7.4) and Wavelength of Maximum Absorbance (lmax) of the Investigated
Drugs
Drug MW (g/mole) pKa logD7.4 lmax (nm)
Caffeine 194.2 10.431 0.032 273
Theophylline 180.2 8.833 0.132 272
Ketoprofen 254.3 4.534 0.235 261
Ibuprofen 206.3 4.936 1.035 222
Hydrocortisone 362.5 Not relevant 1.532 247
Methylprednisolone 374.5 Not relevant 2.132 248(Na2HPO4$2H2O), sodium chloride (NaCl), sodium hydroxide
(NaOH), sodium dihydrogen phosphate monohydrate (NaH2-
PO4$H2O), chloroform, and methanol were purchased from Sigma-
Aldrich Chemie GmbH (Steinheim, Nordrhein-Westfalen, Ger-
many). Lipoid S100 (soy-phosphatidylcholine [SPC] >94%) was
kindly provided by Lipoid GmbH (Ludwigshafen, Rheinland-Pfalz,
Germany).
Preparation of Phosphate Buffered Saline
Phosphate buffered saline (PBS) solutions were prepared
following a method previously described.30 In brief, a 300 mOsm/
kg neutral (pH 7.4) buffer (PBS300) was obtained by dissolving
NaH2PO4$H2O, Na2HPO4$2H2O, NaOH, and NaCl (4.5 g/L, 7.4 g/L, 0.8
g/L, and 4.4 g/L, respectively) in distilled water. PBS300 was diluted
3:5 or 1:5 (v/v) with distilled water to achieve buffer solutions with
reduced ionic strength (approx. 190 and 65 mOsm/kg, see Table 2).
The ionic strength of PBS300 was increased by adding droplets of a
200 g/L NaCl solution (dissolved in PBS300) until a tonicity of 700
mOsm/kg tonicity was reached (PBS700). The measured osmolality
(Semi-Micro Osmometer K-7400; Knauer, Berlin, Germany) and pH
(sensION™ þ PH31 pH meter; Hach, Barcelona, Spain) of the
different PBS solutions used in this study are represented in Table 2.
Preparation of LUVs
LUV dispersions were prepared following a method previously
described.30 A buffer solution (10 mL, PBS300 or PBS65) was gently
added on top of an organic phase containingmethanol (0.2 mL) and
SPC/chloroform solution (200 mg/mL, 1 mL) in a 50-mL round
bottom flask. LUV formulations containing caffeine, ibuprofen,
ketoprofen, or theophylline were prepared by dissolving the drug
(2 mM concentration) in the aqueous phase (PBS300 or PBS65,
respectively), whereas LUVs with hydrocortisone or methylpred-
nisolone were prepared by dissolving the drug in the SPC/chloro-
form solution (drug-lipid ratio approx. 0.035 w/w). Unilamellar
vesicles (containing 20 mg/mL lipid and 2 mM drug) were spon-
taneously formed after the removal of the organic phase by rotary
evaporation (40C, 40 rpm, 0.1 bar, 90 min, Büchi R-124 rotavapor
equipped with Büchi vacuum pump V-700 and Büchi B-480 water
bath; Büchi Labortechnik AG, Flawil, Switzerland). Liposomal dis-
persions were subsequently extruded through polycarbonate
membrane filters (5  800 nm and 10  400 nm, Nuclepore Track-
Etched Membranes; Whatman International Ltd., Maidstone, Kent,
UK) at room temperature (23C-25C) to obtain vesicles of homo-
geneous sizes.
Size Characterization
LUVs' size distribution was measured by photon correlation
spectroscopy (angle of 173, 25C, Zetasizer Nano Zen 2600; Mal-
vern Panalytical, Malvern, Worcestershire, UK). Before analysis,
each LUV dispersion was diluted 1:100 (v/v) with the same buffer
used to prepare LUVs and filtered through polyethersulfone
Figure 1. Schematic representation of the passive diffusion setup. RB represents the
resistance to drug transport through the regenerated cellulose barrier (measured for
drug in solution), whereas RT represents the total resistance to drug transport
(measured for liposome dispersion) and RL represents the resistance to drug transport
through the liposomal bilayer (calculated with Eq. 4).
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PA). Analysis were performed in 4 replicates (n ¼ 4), where each
sample was measured thrice. For the investigation of LUV sizes in
non-isotonic conditions, LUV dispersions (prepared from PBS300
with measured tonicity of approx. 710 mOsm/kg) were diluted
1:100 (v/v) with hypotonic buffers (PBS300 or PBS65, Table 2) and
sizes were detected at intervals (approx. every 15 min) over a
period of 90 min. Each experiment was repeated twice (n ¼ 2), and
each sample was measured 3 times.
z-Potential Characterization
The electrokinetic potential (z-potential [ZP]) of LUVs was
measured by a Zetasizer Nano Zen 2600 (Malvern Panalytical)
following a procedure previously described.30 LUV dispersions
were diluted 1:20 (v/v) with filtrated deionized water (0.2 mm pore
size; VWR International, Radnor, PA) prior measurements, and
analysis were conducted at room temperature (23C-25C). Mea-
surements were performed in 4 replicates (n ¼ 4), where each
sample was measured thrice.
Entrapment Efficiency of Drugs
LUVs were separated from the supernatant (containing freely
unentrapped drug) by ultracentrifugation (200,000 g, 10C,
30 min, Beckman model L8-70M with SW 60 Ti rotor; Beckman
Instruments, Brea, CA). The pellet obtained after ultracentrifugation
was dissolved in 1 mL methanol, and drug concentration was
quantified in the supernatant as well as in the pellet solutions by
UV-visible spectroscopy using a Microtiter plate reader (Spectra
Max 190 Microplate Spectrophotometer; Molecular Devices, Sun-
nyvale, CA) (see Table 1 for the specific detection wavelengths of
each drug). EE was calculated using Equation 1:
EE ð%Þ ¼ MLUVs
MLUVs þMfree
,100 (1)
where MLUVs represents the amount of liposomal entrapped drug
(i.e., recovered in the pellet) and Mfree represents the amount of
freely unentrapped drug (i.e., detected in the supernatant). The
drug recovery was determined from the total amount of drug
(entrapped and unentrapped drug in LUVs) after centrifugation in
comparison to the nominal amount of drug in the LUVs (i.e., initial
total drug content before centrifugation). Analyses were performed
in minimum duplicates (n  2), whereas 3 samples of each batch
were measured 4 times.
In Vitro Drug Transport Study
Drug transport studies were conducted using the Franz diffusion
cell system (0.64 cm2 diffusional area jacketed flat ground joint;
PermeGear, Hellertown, PA) following a method previously used.30
In brief, the acceptor chamber was filled with 5 mL PBS (see
Table 2). Regenerated cellulose barriers (VISKING dialysis tubing
MWCO 12-14 kDa; Medicell Membranes Ltd., London, UK) were
placed between acceptor and donor chambers. The experiment
started by adding 0.8 mL of a liposomal dispersion (containing 20
mg/mL lipid, 2 mM total drug concentration) or, alternatively, drug
solution (a.k.a. reference) to the donor chamber. In the case of
soluble or poorly soluble compounds (caffeine, ibuprofen, keto-
profen, theophylline), 2 mM reference aqueous solution was used,
whereas for very poorly soluble drug (hydrocortisone and meth-
ylprednisolone), saturated suspension (1 mg/mL) was used to
maintain a consistent concentration gradient between donor and
acceptor compartments. The thermodynamic solubility waspredetermined to be 1 mM and 0.3 mM for hydrocortisone and
methylprednisolone in PBS (both PBS65 and PBS300), respectively.
Samplings (0.5 mL) from the acceptor chamber were carried out at
intervals of 30 min over a period of 4 h. After withdrawal of sam-
ples, equal volumes of the respective PBS (with same tonicity) were
reintroduced into the acceptor chamber to maintain sink condition.
At the end of the experiment, drug concentrations in the acceptor
and donor chambers were quantified by UV-visible spectroscopy
(see Entrapment Efficiency of Drugs). The cumulative amount of
diffused drug over time was calculated, and the linear part of the
slope (representing steady state condition) was used to determine
the apparent permeability coefficient (P, cm/s) as shown in








where dm/dt represents the rate of mass transfer of free drug
molecules over time, A is the diffusional area, and cd represents the
initial total drug concentration in the formulation.Resistance to Drug Transport Through Phospholipid Bilayer
Calculation (RL)
The resistance to drug transport of a compound through a bar-





In a permeation process where different layers need to be
crossed, the total resistance to drug transport (RT) can be calculated
from the sum of the single resistances (of each of the barriers
involved) to transport. In the case of LUV dispersion studies, drug
molecules need to first cross the liposomal bilayer, representing the
first resistance to drug transport (RL, Fig. 1). Second, drug molecules
need to cross the regenerated cellulose (dialysis) barrier encoun-
tering a second resistance to drug transport, namely RB (Fig. 1).
Based on this assumption, measuring the total resistance to drug
transport (RT) and RB (measured in the reference experiment with
drug solutions), RL can be calculated by Equation 4:
RL ¼ RT  RB (4)
Table 3
Measured Tonicity, Size, Polydispersity Index (PI), z-potential (ZP), Entrapment Efficiency (EE), and Drug Recovery for All Formulations Investigated
Drug Buffer Solution Tonicity (mOsm/kg) Size (nm) PI ZP (mV) EE (%) Drug Recovery (%)
Caffeine PBS65 430 ± 17 288 ± 53 0.34 ± 0.03 2.99 ± 0.85 22 ± 4 97 ± 3
PBS300 719 ± 18 262 ± 42 0.27 ± 0.03* 0.87 ± 0.95*** 18 ± 3* 99 ± 1
Theophylline PBS65 455 ± 6 341 ± 72 0.37 ± 0.04 1.99 ± 0.93 30 ± 0 100 ± 3
PBS300 719 ± 22 327 ± 62 0.31 ± 0.04 0.08 ± 1.28*** 23 ± 6* 103 ± 3
Ketoprofen PBS65 429 ± 4 368 ± 68 0.34 ± 0.03 5.40 ± 0.98 42 ± 1 97 ± 2
PBS300 718 ± 28 249 ± 36*** 0.22 ± 0.02** 3.97 ± 0.98 41 ± 4 98 ± 1
Ibuprofen PBS65 429 ± 1 252 ± 36 0.22 ± 0.02 8.68 ± 1.05 56 ± 4 99 ± 3
PBS300 686 ± 23 246 ± 33 0.20 ± 0.02* 6.26 ± 1.01** 46 ± 9* 101 ± 1
Hydrocortisone PBS65 437 ± 6 332 ± 60 0.31 ± 0.03 5.86 ± 1.10 77 ± 3 94 ± 5
PBS300 718 ± 14 314 ± 58 0.32 ± 0.03 2.49 ± 0.95* 74 ± 7 97 ± 4
Methylprednisolone PBS65 425 ± 7 285 ± 46 0.29 ± 0.03 3.12 ± 0.91 85 ± 3 97 ± 3
PBS300 701 ± 9 256 ± 35*** 0.20 ± 0.02*** 0.75 ± 0.94*** 84 ± 5 97 ± 3
Results represent mean ± SD (n  2).
Significant difference (*p  0.050, **p  0.010, ***p  0.001) between the LUVs prepared in PBS300 in comparison with PBS65.
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Two-sample Student’s t-test assuming unequal variances was
used to determine the significant differences between the mean of
2 data sets. A value of p below or equal to 0.050 was considered as
statistically significant.Results
LUVs Characterization
The most relevant physical characteristics of the different lipo-
somal dispersions studied are summarized in Table 3.
LUV dispersions prepared in PBS300 exhibited a tonicity of
approximately 710mOsm/kg, whereas in PBS65, the tonicity of LUV
dispersions was found to be between 425 and 455 mOsm/kg. In all
dispersions, the liposome average sizes and polydispersity index
(PI) were higher when prepared in PBS with lower ionic strength
(65 mOsm/kg in respect to 300 mOsm/kg). The size differences
were found significant for ketoprofen- (p ¼ 0.001) and
methylprednisolone-LUVs (p ¼ 0.000). The same trend could be
found for PI in addition to significant difference for caffeine- (p ¼
0.042) and ibuprofen-LUVs (p ¼ 0.020). The ZP of all LUV disper-
sions prepared was close to neutral and significantly more negative
(p  0.026) for the dispersion prepared in PBS65 in comparison
with PBS300. EE was rather low for caffeine and theophylline (18%-
30%) with significant enhanced entrapment for the LUVs prepared
in PBS65 in comparison with PBS300 (p ¼ 0.040 and 0.014,
respectively). We determined medium-high entrapment for keto-
profen and ibuprofen (41%-56%) and considerably higher entrap-
ment for hydrocortisone and methylprednisolone (above 74%).Effect of the Ionic Strength on LUV Sizes
The changes in LUV size distributions after the exposure to
isotonic (a) and hypotonic environments (b and c) are reported in
Figures 2 and 3. As it can be seen, LUVs were quite homogeneous in
isotonic and low-hypotonic conditions (up to approx. 410 mOsm/kg
differences, Figs. 2a and 2b). When exposed to a higher tonicity
gradient (approx. 650 mOsm/kg difference between initial LUV
dispersion and external environment tonicity), the liposomal dis-
persions clearly indicated enlargement of the size. Similarly, the PI
was relatively constant over time for LUVs in the isotonic and low-
hypotonic conditions (Figs. 3a and 3b). When the tonicity gradient
between initial LUV dispersion and external environment of LUVs
increased to approximately 650mOsm/kg (Fig. 3c), an increase in PI(as well as standard deviation) was observed over time for all for-
mulations tested.
In Vitro Transport Study
Drug Solutions
The initial drug concentration, tonicity, and the resistance to
drug transport through the regenerated cellulose barrier (RB) are
presented in Table 4. As shown in Table 4, RB was not significantly
affected by the tonicity of the PBS used to prepare the solutions. The
lowest RB were found for caffeine and theophylline (around 1.6 
104 s/cm), whereas for all other drugs (hydrocortisone, ibuprofen,
ketoprofen, and methylprednisolone), RB was slightly higher and
between 1.9  104 and 2.3  104 s/cm (Table 4).
LUV Dispersions
The phospholipid bilayer's resistance to drug transport (RL) over
the tonicity gradient is reported in Figure 4. As the tonicity gradient
between initial LUV dispersion and external environment of lipo-
somes increases (DmOsm/kg), a decrease in the RL was observed for
all drugs to a different extent (Fig. 4). For caffeine and theophylline,
a drastic shift in resistance was detected at a tonicity gradient of
approximately 400 mOsm/kg, whereas for the other drugs, the
decrement in RL seemed to be more gradual. A significant decrease
in RL (p  0.026) could be found for all the LUV dispersions pre-
pared at tonicity differences around 300 and 400 mOsm/kg with
the exceptions of caffeine andmethylprednisolone. Only in the case
of caffeine, the liposomal bilayer produced significantly higher
resistance (p  0.009) at low-hypotonic conditions (Fig. 4, upper-
left) but not in isotonic conditions. For methylprednisolone, a sig-
nificant decrease in RL (p ¼ 0.026) was already apparent at tonicity
differences around 100mOsm/kg. For all LUV dispersions prepared,
the reduction in RL at the highest concentration gradient (approx.
650 mOsm/kg) was found significantly different (p-value between
0.000 and 0.037) compared with the lowest concentration gradient
(0 mOsm/kg, isotonic condition). The overall reduction in RL was
found to be between 75% and 114% for the hydrophilic drugs
(caffeine and theophylline), between 49% and 65% for the lipophilic
drugs (ibuprofen and ketoprofen), and approximately 27% for the
hydrophobic drugs (methylprednisolone and hydrocortisone).
Discussion
LUVs Characterization
The LUVs were prepared using natural lipid (SPC) and PBS
(adjusted to physiological pH and tonicities) to achieve LUV
Figure 2. Size distributional changes for drug-loaded LUVs in (a) isotonic condition (DmOsm/kg of 3 ± 2 mOsm/kg), (b) low-hypotonic condition (DmOsm/kg of 414 ± 19 mOsm/kg),
and (c) hypotonic condition (DmOsm/kg of 648 ± 19 mOsm/kg). Each line represents the mean size distribution (n ¼ 2) measured at 5 different time points within 90 min.
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liposomal sizes, PI and ZP, the prepared LUV formulations
exhibited suitable profiles when compared with other liposomal
formulations intended for nasal administration.13,14,42,43 In
agreement with our previous findings,30 the ZP was found to be
slightly more negative for the LUVs prepared in PBS65 compared
with PBS300 (Table 3). Although the neutral ZP at higher ionic
strength can be expected because of the formation of a thicker
ion shell surrounding the liposomes,44 the larger sizes of LUVs
prepared in PBS65 in comparison with PBS300 are difficult to
explain. It could be argued that this discrepancy is related to
small changes in elasticity of the phospholipid bilayers in envi-
ronments of different ionic strengths. The prepared LUVs were
also found to be suitable carriers to entrap all the drugs withdifferent magnitude of loading. In accordance with their distri-
bution coefficients at pH 7.4 (logD7.4, Table 1) and the literature,
hydrophobic drugs (hydrocortisone and methylprednisolone)
reached the highest EE into liposomes (between 74% and 85%,
respectively), whereas the entrapment was much lower for hy-
drophilic drugs (close to 25% for caffeine and theophylline).45
The lipophilic drugs (ibuprofen and ketoprofen) showed a
medium-high EE ranging between 41% and 56% (similarly to
what has been reported previously by Nii and Ishii).46 The
entrapment was significantly enhanced for LUVs with hydro-
philic drugs prepared in PBS65 when compared with PBS300
(caffeine p ¼ 0.040, theophylline p ¼ 0.014, respectively). This
might be related to the increased size of liposomal carriers when
prepared in different PBS (Table 3). In our previous study, we
Figure 3. Polydispersity index (PI) changes for drug-loaded LUVs in (a) isotonic condition (DmOsm/kg of 3 ± 2 mOsm/kg), (b) low-hypotonic condition (DmOsm/kg of 414 ± 19
mOsm/kg), and (c) hypotonic condition (DmOsm/kg of 648 ± 19 mOsm/kg). Results represent mean ± SD (n ¼ 2).
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the total tonicity of the liposomal formulation should have been
primarily influenced by the ionic strength of the solution.30 In
the present work, we measured the tonicity of each of the LUV
dispersions (Table 3), and surprisingly, a significant discrepancy
in tonicity for LUV dispersions in comparison to plain buffer
(Table 2) was found for all formulation tested. As the drug alone
did not affect the buffer’s tonicity at the experimental condition
(Table 4), assuming that at the equilibrium, the tonicity of theinner core of liposomes is equal to the measured tonicity of the
LUV dispersion (i.e., external environment), it appears that li-
posomes themselves acted as strong tonicity agents (the influ-
ence on total tonicity accounts for more than 300 mOsm/kg). A
very similar trend was observed for empty liposomes (measured
tonicity of 718 ± 34 mOsm/kg and 448 ± 22 mOsm/kg when
prepared in PBS300 or PBS65, respectively). To the best of our
knowledge, this phenomenon has not been described earlier and
it might be of extreme importance in liposomal drug research.
Table 4
Regenerated Cellulose Barrier's Resistance to Drug Transport (RB) of Drug Solutions in Phosphate Buffered Saline
Drugs Buffer Solution Drug Concentration (mM) Tonicity (mOsm/kg) RB (104 s/cm)
Caffeine PBS65 2.04 ± 0.03 65 ± 1 1.64 ± 0.03
PBS300 2.00 ± 0.00 300 ± 2 1.64 ± 0.05
Theophylline PBS65 1.92 ± 0.03 65 ± 1 1.58 ± 0.05
PBS300 1.99 ± 0.02 297 ± 1 1.60 ± 0.07
Ketoprofen PBS65 2.00 ± 0.04 66 ± 2 2.26 ± 0.08
PBS300 2.00 ± 0.00 298 ± 0 2.08 ± 0.11
Ibuprofen PBS65 2.03 ± 0.00 68 ± 4 2.14 ± 0.14
PBS300 2.01 ± 0.00 308 ± 10 2.18 ± 0.15
Hydrocortisone PBS65 1.02 ± 0.01 66 ± 1 1.92 ± 0.23
PBS300 1.03 ± 0.02 298 ± 0 2.22 ± 0.17
Methylprednisolone PBS65 0.26 ± 0.00 64 ± 0 2.03 ± 0.18
PBS300 0.25 ± 0.00 301 ± 5 2.27 ± 0.34
Results represent mean ± SD (n ¼ 4).
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It has been reported previously that LUV sizes can be affected
by changes in tonicity of the surrounding environment.30,47 If the
environment surrounding liposomes is hypotonic in comparisonFigure 4. Liposomal bilayer resistance (RL) to drug transport under the influence of hypoton
environment of liposomes are shown as DmOsm/kg. Results represent mean ± SD (n ¼ 4)
between the hypotonic compared with isotonic condition.to the liposomal core, liposomes have a tendency to increase in
size as a result of water influx into the liposomes.27-29 Photon
correlation spectroscopy is a powerful technique applied to
quantify liposomal sizes and PI in a dispersion. However, in these
experiments, it was difficult to determine an accurate size of theic environmental changes. The tonicity difference between the inner core and external
, and significant difference (*p  0.050, **p  0.010, ***p  0.001) in RL is determined
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better and clear picture of the effect that hypotonic surrounding
environments had on the formulations, LUV dispersions (approx.
710 mOsm/kg) were exposed to 2 buffers of different ionic
strengths (300 mOsm/kg and 65 mOsm/kg) and sizes of the li-
posomes were measured at approximately 15-min intervals for a
total period of 90min. The size distribution of all formulations was
rather homogenous (Fig. 2). Interestingly, the dispersions were
more homogeneous in the low-hypotonic conditions rather than
isotonic conditions (Figs. 2a and 2b). Because ions are capable of
neutralizing liposomal surface charges due to ion-shell forma-
tion,44,48-51 it is reasonable to assume that liposomal aggregation
is more significant in isotonic conditions than in low-hypotonic
conditions because of the surface charge neutralization of lipo-
somes (see also Table 3). When the surrounding liposomal envi-
ronment was highly hypotonic (DmOsm/kg of 648 ± 19 mOsm/kg,
Fig. 2c), the size distribution became very heterogeneous. The
same trend could be observed for the PI that was significantly
increased over time just at the high tonicity gradient (Fig. 3c). The
combination of these results clearly indicates that LUVs grew in
sizes when exposed to hypotonic environments at the difference
of approximately 648mOsm/kg, whereas smaller differences were
not apparent because of the disturbances on the liposomal sur-
faces, which might have affected the LUVs behavior and the size
measurements.
Resistance to Drug Transport Through Regenerated Cellulose Barrier
(RB)
In this work, the kinetics of transport for the investigated drugs
through barrier(s) were described by calculating the resistance of
each single barrier involved. This was done to better differentiate
the role of each barrier involved in the total net transport of drug
(Eq. 3) and is essential for a correct interpretation of transport
studies that involve liposomes. The RB was determined by
measuring the drug's permeability (Eq. 2) from drug solutions, or in
the case of very poorly soluble drugs (hydrocortisone and meth-
ylprednisolone), employing aqueous drug suspensions (no lipo-
somes present). As can be seen in Table 4, the lowest RB was found
for caffeine and theophylline, whereas the highest was found for
hydrocortisone and methylprednisolone. The reason for the sig-
nificant discrepancy could to be attributed to the different size (i.e.,
molecular weight, Table 1) of the molecules. In fact, Equation 5
(adaptation of Fick's first law) can describe the permeability of a







where D represents the diffusion coefficient and dc/dx is the
gradient of concentration between donor and acceptor compart-
ments. From this equation, it is evident that, normalizing the con-
centration and assuming same thickness of the barrier in all
experiments, the differences in permeability (and therefore in
resistance to transport) within different drugs through cellulose
barriers are solely given by the different diffusion coefficients of
each drug. Indeed, D is higher for small compounds such as caffeine
(measured diffusivity in similar conditions, 9  106 cm2/s52) and
lower for larger compounds such as ketoprofen (measured diffu-
sivity in similar conditions, 6  106 cm2/s52).
Resistance to Passive Transport Through Liposomal Barrier (RL)
The liposomal bilayer of LUVs represents an additive barrier
that drug molecules need to cross to reach the acceptorcompartment (Fig. 1). To calculate the resistance to drug trans-
port through the phospholipid bilayer (RL), the permeability of
drugs through the regenerated cellulose barrier of LUVs loaded
with drug (RT) needed to be measured and subtracted from RB
(Eq. 4). In isotonic conditions (Fig. 4, DmOsm/kg of approx.
0 mOsm/kg), hydrophilic compounds (caffeine and theophylline)
exhibit a RL of approximately 0.4 to 0.7  104 s/cm and this
resistance rises with the lipophilicity of the compounds (Table 1)
up to 14.6  104 s/cm for a very hydrophobic compound, meth-
ylprednisolone. The higher resistance to transport through the
lipid bilayer expressed by hydrophobic compounds in compari-
son with hydrophilic is not surprising and is due to the fact that
the lipophilic compounds are tightly embedded in the lipid bi-
layers and cannot escape (be released) easily. These results are in
agreement with previous findings.18 Interestingly, for the hy-
drophilic compounds (caffeine and theophylline) and to a minor
but substantial extent, lipophilic acidic drugs (ketoprofen and
ibuprofen), a strong reduction in RL was measured with reduced
external ionic strength (increased DmOsm/kg, Fig. 4). This is a
clear evidence that exposure of drug-loaded LUVs to hypotonic
environment is a powerful trigger of drug release. This can be
attributed to the stretching of the phospholipid bilayers induced
by LUV size enlargements that makes the barrier leakier and
drugs can permeate more easily.29,53 This phenomenon is in
agreement with previous findings.54-56 An alternative hypothesis
to explain the increased drug release in hypotonic conditions is
the pore formation during liposomes swelling, which can cause a
pulsating release of entrapped content.47,57-59 For caffeine and
theophylline, the RL becomes practically zero (i.e., no resistance
to drug transport caused by phospholipid bilayers) when the
tonicity differences between the inner core and external envi-
ronment of LUVs reached around 350 mOsm/kg. Interestingly, RL
increases at the lowest tonicity gradient for caffeine (below 300
mOsm/kg, Fig. 4 upper-left). It can be argued that at low tonicity
gradients, the stretching of phospholipid bilayers might be
compensated (if not overdriven in the case of caffeine) by the
water flux directed inward (i.e., against drug flux), causing
therefore an increasing in RL. For ibuprofen and ketoprofen, the
reduction in RL seemed to be more proportional and reaching a
minimum of approximately half of the initial RL at the highest
tonicity gradient (DmOsm/kg above 600mOsm/kg). Interestingly,
the release of hydrophobic compounds (hydrocortisone and
methylprednisolone) was also positively affected by the hypo-
tonic surrounding environment, however, to a minor extent in
comparison with the other compounds tested. At a tonicity
gradient above 600 mOsm/kg, the RL for hydrophobic hydrocor-
tisone and methylprednisolone is reduced by approximately 27%
in comparison with isotonic condition. These results are in
agreement with our previous findings where we demonstrated
that the kinetic of calcein release (hydrophilic marker) from LUVs
was more affected by tonicity perturbation in comparison with
the lipophilic marker (rhodamine).30 It is clear that the effect of
the environmental tonicity on the release of liposomal drugs
needs to be studied to assist in optimization of liposomal for-
mulations destined for nasal administration.
Conclusions
In this work, we have proven that the tonicity of the envi-
ronment surrounding liposomes plays a crucial role in LUVs'
physical characteristics (i.e., size, polydispersity, and surface
charge) and drug release profiles. First, we have showed that li-
posomes themselves significantly affect the total tonicity of the
dispersions. Second, we have demonstrated that LUV size and
polydispersity increase after exposing liposomes to hypotonic
I.Y. Wu et al. / Journal of Pharmaceutical Sciences 108 (2019) 2570-25792578environment proven them osmotically active. Finally, we have
proven that the exposure of drug-loaded LUVs to hypotonic en-
vironments reduces RL and therefore enhances drug release ki-
netics of both hydrophilic and lipophilic/hydrophobic drugs. The
findings have clear implications in the development and opti-
mization of liposomal formulations targeting nasal administra-
tion. Moreover, the observed effects can be utilized to tailor the
release of liposomal drugs within nasal environment.
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A B S T R A C T
The aim of this work was to clarify the dynamics behind the influence of ionic strength on the changes in drug
release from large unilamellar vesicles (LUVs). For this purpose, we have investigated the transport of two
different model drugs (caffeine and hydrocortisone) formulated into liposomes through different types of bar-
riers with different retention properties (regenerated cellulose and the newly introduced biomimetic barrier,
Permeapad®). Drug release from liposomes was studied utilizing the standard Franz diffusion cells. LUV dis-
persions were exposed to the isotonic, hypotonic and hypertonic environment (difference of 300mOsm/kg
between the initial LUVs and the environment) and experimental data treated with both linear and non-linear
(Korsmeyer-Peppas) regression models. To alter the rigidity of the liposomal membranes, cholesterol was in-
troduced in the liposomal barriers (up to 25% w/w). Korsmeyer-Peppas model was proven to be suited to analyse
experimental data throughout the experimental time frame, providing important additive information in com-
parison to standard linear approximation. The obtained results are highly relevant as they improve the inter-
pretation of drug release kinetics from LUVs under osmotic stress. Moreover, the findings can be utilized in the
development of liposomal formulations intended for nose-to-brain targeted drug delivery.
1. Introduction
Liposomes are lipid-based vesicles with a nanometric size range
(Bangham and Horne, 1964; New, 1990). Since liposomes were first
described in the 1960s (Bangham and Horne, 1964), they have been
extensively studied as drug delivery systems for both hydrophilic and
lipophilic drugs (Allen and Cullis, 2013; Li et al., 2019). Nasally ad-
ministered liposomal drug formulations have shown promising poten-
tials for the treatment of some brain diseases such as Alzheimer's and
Parkinson's disease (Lai et al., 2013; Vieira and Gamarra, 2016).
However, to achieve maximal therapeutic benefits, controlled release
from the liposomes in the nasal cavity is required to obtain optimal
available dose at the target site in vivo (Bourganis et al., 2018; Lai et al.,
2013).
One important parameter that is often underestimated in the
development of formulations for nasal drug delivery is the variability of
physiological conditions at the administration site. For example, under
normal physiological conditions, the nasal mucus tonicity is approxi-
mately 300mOsm/kg (Pedersen et al., 2007). However, this value can
change considerably as the nasal mucosa is rather sensitive to the ex-
ternal environment such as air humidity and temperature (Quraishi
et al., 1998). For instance, hyperventilation in dry air can increase the
human nasal tonicity up to 450mOsm/kg (Pedersen et al., 2007).
Variation in the ionic strength at the administration site is highly re-
levant for liposomes since they consist of semi-permeable membrane,
and are therefore, highly sensitive to osmosis (Bangham et al., 1967;
Paula et al., 1996; Pencer et al., 2001). To predict performance of li-
posomes in vivo, good in vitro models that can determine the release
kinetics from liposomes at the early stage of the liposomal drug de-
velopment process are necessary (Solomon et al., 2017; Wacker, 2017).
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Currently, there are no standard methods for studying drug release
from liposomes in vitro (Nothnagel and Wacker, 2018; Solomon et al.,
2017; Wacker, 2017). The proposed methods are based on separating
the dissolved fraction (released drug) from the undissolved fraction
(liposomal drug) (Nothnagel and Wacker, 2018). Some of the most
common methods applied to liposomes are filtration, ultracentrifuga-
tion, solid phase extraction, and dialysis-based methods (Nothnagel and
Wacker, 2018). The dialysis-based methods utilize the drug's diffusion
across barriers to separate liposomal drug from released drug (Solomon
et al., 2017). The liposomal formulation is placed in the donor com-
partment which is separated from the acceptor compartment by a
barrier that can exhibit low retention (e.g. dialysis barrier) or high re-
tention (e.g. biomimetic, biologic barrier) to drug permeation
(Nothnagel and Wacker, 2018). Disadvantages regarding the dialysis-
based methods are related to violation of sink condition (Solomon et al.,
2017), and the fact that drug released from liposomes needs to cross an
additional barrier before being quantified (Fig. 1) (Nothnagel and
Wacker, 2018; Wacker, 2017). On the other hand, dialysis-based
methods are convenient, cost-effective and simple. Consequently, the
dialysis-based devices have been implemented into USP dissolution
apparatuses (e.g. glass basket, dispersion releaser, flow-through), and
used in the development of in situ methods (Nothnagel and Wacker,
2018; Solomon et al., 2017; Tang et al., 2019; Yuan et al., 2017). It has
to be mentioned that the improved dialysis-based methods are still
limited by the barrier properties that separates the liposomal drug from
released drug. Therefore, more processing of the diffusion data is still
required for correct interpretation of the release mechanism from li-
posomes (Jain and Jain, 2016; Wacker, 2017).
The most common way to treat diffusion data is by simple zero
order mass transport kinetic (Brandl et al., 2007; Brodin et al., 2010;
Nothnagel and Wacker, 2018). In both previous studies (Wu et al.,
2017; Wu et al., 2019), we applied a zero order model to interpret the
mass transport data. The release from liposomes was calculated by
using a reference experiment of free drug solution (Wu et al., 2019). We
observed that the release kinetics from liposomes were altered due to
tonicity perturbations in the external environments (i.e. uneven ionic
strength within inner core and external environment of liposomes).
Moreover, we noticed that when the osmotic stress was applied, the
drug transport profiles through regenerated cellulose barrier showed
deviations from linearity, indicating possible modifications of the drug
release kinetics from the liposomes over time. In such situations, the
non-linear regression models for data fitting could have been applied to
analyse the diffusion data (Jain and Jain, 2016).
The non-linear regression models such as Higuchi and Korsmeyer-
Peppas are the two most applied mathematical models to interpret non-
linear diffusion profiles (Costa and Sousa Lobo, 2001; Jain and Jain,
2016). The Korsmeyer-Peppas model has previously been successfully
used to describe the drug release kinetics from liposomes
(Haghiralsadat et al., 2018; Jain and Jain, 2016). In this study, ex-
perimental data from the dynamic dialysis studies are fitted to Eq. (1)





In this equation, Mt/M∞ represents the fractional permeated drug, t
is the time, K is the transport constant (dimension of time−1), and n is
the transport exponent (dimensionless). The release constant K provides
mostly information on the drug formulation such as structural char-
acteristics of the nanocarriers, whereas n is important since it is related
to the drug release mechanism (i.e. Fickian diffusion or non-Fickian
diffusion). In the case of liposomes and assuming sink conditions, the
flux of the drug (j) through a low retention barrier (e.g. regenerated
cellulose) of constant thickness (x) can be described by Eq. (2) (sim-
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In this equation, c0d is the freely dissolved unentrapped drug con-
centration outside liposomes in the donor compartment, ca the acceptor
drug concentration and D is the diffusion coefficient. According to this
model, the net flux of drug through the barrier is the result of two
diffusion mechanisms (Fig. 1). One is the diffusion of drug molecules
from the donor compartment to the acceptor compartment (experi-
mentally measured K, Fig. 1). The second is the diffusion through the
phospholipid bilayer of liposomes that is dependent on the liposomal
release rate (KI, Fig. 1). In the case where K≈KI, the gradient of
concentration (driving force of the diffusion) should be constant, giving
as result of data fitting an n equal (or close) to 1 (zero-order transport
kinetic, non-Fickian diffusion). If n is lower than 1 (n < 1), this in-
dicates a reduced concentration gradient over time (first-order/pseudo
first-order kinetic, Fig. 1). In the last scenario possible, the gradient of
concentration ((c0d-ca)/x) is increasing over time, producing a positive
deviation from linearity of mass transport profiles. This anomalous
behaviour (associated to n > 1) is generally called “super case” (Costa
and Sousa Lobo, 2001; Jain and Jain, 2016).
Under these premises, in this work, caffeine and hydrocortisone
(hydrophilic and a lipophilic drug, respectively) were the chosen drugs
to be formulated into large unilamellar vesicle (LUV) dispersions of
controlled size and tonicity. Drug transport studies were performed
employing two different types of barriers; one with a low retention
(regenerated cellulose) and another with a high retention (Permeapad®
(Di Cagno et al., 2015)). Moreover, LUV compositions were altered by
the addition of different amount of cholesterol (from 0 up to 25% w/w)
to increase liposomal barrier rigidity. To evaluate the influence of os-
motic stress on drug release kinetics from liposomes, liposomal dis-
persions were exposed to environment of different ionic strengths. The
obtained experimental data were analysed by the means of linear and
non-linear (Korsmeyer-Peppas) regression models. The results obtained
from this study might provide a new insight into the drug release me-
chanism from liposomes, and might be relevant for the development of
liposomal drug formulations intended for nose-to-brain drug delivery.
2. Materials and methods
2.1. Materials
Caffeine, hydrocortisone, disodium hydrogen phosphate dihydrate
(Na2HPO4·2H2O), sodium chloride (NaCl), sodium hydroxide (NaOH),
sodium dihydrogen phosphate monohydrate (NaH2PO4·H2O), chloro-
form and methanol were purchased from Sigma-Aldrich Chemie GmbH
(Steinheim, Germany). Lipoid S100 (SPC, soy-phosphatidylcholine>
94%) was kindly provided from Lipoid GmbH (Ludwigshafen,
Germany) and Permeapad® barriers from InnoME GmbH (Espelkamp,
Germany).
2.2. Preparation of phosphate buffered saline (PBS)
PBS of pH 7.4 and 65mOsm/kg (namely PBS65) was prepared ac-
cording to Wu et al. (2017). The measured osmolality (Semi-Micro
Osmometer Model 4602, Knauer, Berlin, Germany) and pH (Sen-
sION™+PH31 pH meter, Hach, Barcelona, Spain) of the different PBS
used in this study are represented in Table 1. To create isotonic PBS
(namely PBSiso that exhibited same tonicity as the LUVs, approx.
400mOsm/kg), 0.05 g of NaCl was dissolved in1 L of PBS65. For the
preparation of hypertonic PBS (PBShyper), 0.10 g of NaCl was dissolved
into 1 L of PBS65 (tonicity of approx. 700mOsm/kg). Droplets of NaCl
dissolved in PBS65 (concentration of 200 g/L) were added to PBS65 in
order to adjust its tonicity to PBShypo's tonicity (approx. 100mOsm/
kg).
2.3. Preparation of LUVs
LUV dispersions were prepared following a method previously de-
scribed (Wu et al., 2017). In the case of cholesterol-LUVs (11 and 25%
w/w), solutions of SPC/cholesterol (ratio of 9:1 w/w or 4:1 w/w) in
chloroform were used as organic phase. LUV formulations containing
caffeine were prepared by dissolving the drug in the PBS65 (2mM),
whereas in the case of hydrocortisone, the drug was dissolved in the
organic phase together with lipids.
2.4. Size, zeta potential and entrapment efficiency characterization
LUV dispersions were diluted with PBS65 (same buffer used to
prepare the LUVs) 1:100 (v/v) and filtered through polyether sulfone
membranes (0.2 μm pore size, VWR International, Radnor, USA) prior
to size measurement. For the determination of the electrokinetic po-
tential (ZP) on liposomes surface, LUV dispersions were diluted 1:20 (v/
v) with freshly filtrated deionized water (0.2 μm pore size filter) and
analysis conducted at room temperature (23–25 °C) using the DTS1070
cell (Malvern, Worcestershire, UK). The liposomal size and ZP were
measured using a Zetasizer Nano Zen 2600 (25 °C, Malvern,
Worcestershire, UK) as previously described (Wu et al., 2019). To de-
termine the entrapment efficiency (EE), drug-loaded LUVs were sepa-
rated from the unentrapped drug by ultracentrifugation (200,000g,
10 °C, 30min, Beckman model L8-70M with SW 60 Ti rotor, Beckman
Instruments, California, USA) (Wu et al., 2019). The drug concentra-
tions in both LUVs and supernatant (representing unentrapped drug
concentration) were quantified spectroscopically (Spectra Max 190
Microplate, Spectrophotometer Molecular devices, Sunnyvale, USA)
using wavelengths at 273 and 247 nm for caffeine and hydrocortisone,
respectively. Two samples for each batch of formulations were mea-
sured minimum three times. Experiments were repeated in minimum
duplicates (n≥2).
2.5. In vitro diffusion study
The in vitro diffusion studies of caffeine and hydrocortisone were
performed using standard Franz diffusion cells (0.64 cm2 diffusion area
jacketed flat ground joint, PermeGear diffusion cells and systems,
Hellertown, USA) following a previously described method (Wu et al.,
2019). The acceptor compartment was filled with 5mL PBS following
Table 1. Regenerated cellulose (Visking dialysis tubing MWCO
12–14 kDa, Medicell Membranes Ltd., London, UK), or alternatively,
Permeapad® (InnoME GmbH, Espelkamp, Germany) was used as dif-
fusion barrier and experiments were conducted at 35 °C (Julabo 200F
heating circulator, Julabo Inc., Allentown, USA). At time zero (start of
the experiment), 0.3mL of PBS (same composition as acceptor buffer)
was topped with 0.5 mL of LUV dispersion (2mM total drug con-
centration) in the donor compartment. As reference experiments, drug
solution (caffeine, 2mM) or suspension (hydrocortisone, 1mM, ther-
modynamic solubility) in PBS65 were also analysed. Aliquots of 0.5mL
were withdrawn from the acceptor compartment and replaced with
equal volumes of the respective PBS (with same tonicity) every 30min
over a period of 4 h.
2.6. Data analysis
2.6.1. Resistance to drug transport determination (R)
The resistance to drug transport through liposomal bilayer (RL,) was
calculated according to Wu et al. (2019). In brief, the initial part of
diffusional curves (up to 2.5 h) was used to calculate the drug flux (j)
through the diffusion barrier, which was supposed to be constant
during the experiment since the sink conditions were kept. The ap-
parent permeability (P) was determined by normalizing the flux over
the total initial concentration (cd) (see Eq. (3)):




The resistance to drug transport through liposomal bilayer (RL) (i.e.
the reciprocal function of permeability through the liposomal bilayer,
1/PL) was calculated from the total resistance to drug transport (RT,
measured in the liposomal dispersion experiments) and from the re-
sistance to drug transport through the barrier (RB, measured in drug
solution experiments) by Eq. (4):
=R R RL T B (4)
2.6.2. Non-linear regression analysis (Korsmeyer-Peppas model)
Drug transport constants (K) and transport exponents (n) of the
different liposomal formulations were determined by fitting of the in
vitro diffusion data to the Korsmeyer-Peppas equation (see Eq. (1))
using the add-in DDSolver program (China Pharmaceutical University,
Nanjing, China). Microsoft Office Excel (Microsoft Corporation, Red-
mond, USA) was used as built-in module of the DDSolver. The K and n
were determined in the range of Mt/M∞ 0–60% (Costa and Sousa Lobo,
2001).
2.7. Stability study
LUVs containing 0, 11 and 25% w/w cholesterol were prepared for
both model drugs (caffeine and hydrocortisone) in duplicates (n=2) as
described in Section 2.3. Each batch was divided into two aliquots and
stored in the fridge (at 6 °C) and at room temperature (at 22 °C) away
from light sources for 65 days in clear polypropylene tubes (VWR®
High-Performance centrifuge tubes, VWR International, Radnor, USA).
Samples were periodically withdrawn (72 h, 14, 35 and 65 days after
preparation) and analysed. The stability of liposomal dispersions was
evaluated in terms of tonicity, vesicle size distribution, ZP and EE
(analysis performed as described in Sections 2.2 and 2.4). Each sample
was measured minimum four times.
2.8. Statistical data evaluation
Student's t-test was used to determine the significance of difference




The general characteristics of liposomes used in the in vitro study are
presented in Tables 1 and 2. The LUV dispersions exhibited total initial
tonicity of around 400mOsm/kg (Table 1). The mean sizes of liposomes
were between 236 and 374 nm (Table 2). Incorporation of cholesterol
into the LUVs increased the mean sizes and polydispersity for caffeine-
LUVs (p≤0.010 and 0.001, respectively), and similarly for hydro-
cortisone-LUVs with 25% w/w cholesterol (PI, p=0.000). All LUVs
Table 1
Experimentally determined osmolality and pH for all LUV dispersions and PBS solutions used in the in vitro study. Results represent mean ± standard deviation
(n=2).
LUVs Cholesterol (% of lipid weight) Initial LUVs osmolality (mOsm/kg) Buffer type PBS osmolality (mOsm) PBS
pH
Caffeine 0 420 ± 11 PBShypo 119 ± 10 7.5 ± 0.1
PBSiso 418 ± 10 7.3 ± 0.0
PBShyper 718 ± 12 7.2 ± 0.0
11 392 ± 12 PBShypo 95 ± 16 7.6 ± 0.0
PBSiso 386 ± 5 7.3 ± 0.0
PBShyper 693 ± 23 7.2 ± 0.0
25 388 ± 4 PBShypo 88 ± 8 7.5 ± 0.0
PBSiso 393 ± 4 7.3 ± 0.0
PBShyper 692 ± 8 7.2 ± 0.0
Hydrocortisone 0a 383 ± 5 PBShypo 83 ± 5 7.6 ± 0.0
PBSiso 384 ± 5 7.3 ± 0.0
PBShyper 683 ± 5 7.2 ± 0.0
11 405 ± 5 PBShypo 105 ± 5 7.6 ± 0.0
PBSiso 405 ± 5 7.3 ± 0.0
PBShyper 705 ± 5 7.2 ± 0.0
25 383 ± 19 PBShypo 86 ± 16 7.6 ± 0.0
PBSiso 385 ± 16 7.3 ± 0.0
PBShyper 687 ± 15 7.2 ± 0.0
a n=3.
Table 2
Measured size (average diameter), polydispersity index (PI), ζ-potential (ZP) and entrapment efficiency (EE) for LUV dispersions used in the in vitro release study.
Results represent mean ± standard deviation (n= 2).
LUVs Cholesterol (% of lipid weight) Size (nm) PI ZP (mV) EE (%)
Caffeine 0 236 ± 36 0.25 ± 0.02 −3.7 ± 1.0 12 ± 1
11 289 ± 55⁎ 0.34 ± 0.04⁎ −3.0 ± 1.0 11 ± 2
25 374 ± 80⁎⁎ 0.45 ± 0.05⁎⁎ −3.5 ± 1.1 10 ± 1⁎⁎
Hydrocortisone 0a 246 ± 30 0.25 ± 0.01 −3.5 ± 1.0 68 ± 5
11 248 ± 38 0.24 ± 0.02 −4.1 ± 1.1 60 ± 3⁎⁎
25 261 ± 47 0.35 ± 0.03⁎⁎ −5.2 ± 1.1 51 ± 3⁎⁎
⁎ p≤0.050.
p≤0.001 when compared to the respective formulation without cholesterol.
a n=3.
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exhibited almost neutral surface charges. The EE was approximately
11% for caffeine-LUVs and considerably higher for hydrocortisone-
LUVs (51–68%). The EE decreased significantly with increased amount
of incorporated cholesterol especially for hydrocortisone-LUVs
(p≤0.001).
3.2. In vitro diffusion study
3.2.1. Drug diffusion studies
In Fig. 2, the diffusion profiles of caffeine and hydrocortisone in
aqueous solution as well as in liposomal dispersions (0% w/w choles-
terol) are reported for both regenerated cellulose and Permeapad®
barriers. As it can be seen, the drug diffusion profiles through the dif-
ferent barriers varied accordingly to the drug used; the formulation
(aqueous solution or liposomal dispersion) and the barrier (regenerated
cellulose or Permeapad®). Specifically, the amount of diffused drug was
significantly higher for caffeine than for hydrocortisone for both bar-
riers. For both drugs, the total amount of diffused drug after 2.5 h was
significantly higher (p < 0.000) from solution in comparison to LUV
dispersion when regenerated cellulose was employed as the barrier
(Fig. 2a, 49 ± 1 vs 35 ± 2% for caffeine and 40 ± 3 vs 16 ± 3% for
hydrocortisone, respectively). Similarly, the total amount of accumu-
lated hydrocortisone in the acceptor medium was significantly higher
for drug solutions in comparison to the liposomal formulations (cu-
mulative diffused after 2.5 h, 9 ± 2 vs 6%, p=0.004) when Per-
meapad® was employed as barrier (Fig. 2b right). Interestingly, when
Permeapad® was employed (Fig. 2b, lower-left), the amount of caffeine
accumulated in the acceptor medium from solution and liposomal dis-
persion was the same.
3.2.2. RL under the influence of changed external environments
In Fig. 3, the resistances to drug transport through liposomal bilayer
(RL) are reported for all the formulations prepared, for both drugs
(caffeine in Fig. 3a and hydrocortisone in Fig. 3b, respectively) and two
different types of barriers (regenerated cellulose and Permeapad®).





























































































Caffeine solution Caffeine-LUVs Hydrocortisone solution Hydrocortisone-LUVs
Fig. 2. In vitro diffusion study of caffeine (○) and hydrocortisone (∆) from solutions (filled symbols) and LUV dispersions (0% w/w cholesterol, empty symbols)
through regenerated cellulose (a) or, alternatively, Permeapad® (b) as barriers in isotonic conditions. Results represent the mean ± standard deviation (n=3,
*p≤0.050, **p≤0.010, ***p≤0.001).
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environment had a remarkable impact on RL. Specifically, RL was
lowest when caffeine-LUVs were exposed to hypotonic environments,
medium in isotonic and significantly higher level for hypertonic en-
vironment (Fig. 3a). For hydrocortisone-LUVs (Fig. 3b), the RL values
were considerably higher in comparison to the caffeine-LUVs in all
circumstances. Similarly to caffeine-LUVs, the RL was found to be lower
for hypotonic/isotonic environment and significantly (p < 0.050)
higher in hypertonic environment. The incorporation of cholesterol into
the liposomal membrane seemed not to significantly affect RL of hy-
drocortisone, whereas, for caffeine, a trend indicating reduction of RL
with growing concentration of cholesterol was observed (white bars).
The employment of a biomimetic barrier such as Permeapad® (grey
bars) resulted in a slight reduction in RL absolute values for caffeine in
comparison to regenerated cellulose even though the trend at different
external environmental tonicity was respected. The same was observed
for hydrocortisone, but in this case, a significant reduction of RL was
observed with increasing concentration of cholesterol (Fig. 3a–b).
3.2.3. Non-linear data fitting using Korsmeyer-Peppas model
The in vitro diffusion data obtained in this study were fitted ac-
cording to the Korsmeyer-Peppas equation, Eq. (1). For all data sets, the
correlation coefficient (R2) was rather high (min. 0.96 up to 1.00, data
are shown in Supplementary material, Figs. A.1–2) indicating a good
correlation within experimental data and Eq. (1). From the data fitting,
the transport constants (K, Fig. 4) and transport exponents (n, Fig. 5)
were determined. The K values were much higher for caffeine (ranged
between 8 and 25, Fig. 4a) in comparison to hydrocortisone (from 1 to
8, Fig. 4b). It is worth mentioning that K values were significantly
different for regenerated cellulose (white bars) and Permeapad® (grey
bars) and these differences were higher for hydrocortisone than for
caffeine.
As already observed for RL, a clear correlation between K and en-
vironmental ionic strength was found. Specifically, the higher ionic
strength in the external environment, the lower were the K value
(Fig. 4, 0% w/w cholesterol). This phenomenon was more evident when
using regenerated cellulose (white bars) as a barrier rather than Per-
meapad® (grey bars). In fact, no significant difference was determined
in K values between the hypotonic and isotonic environments em-
ploying Permeapad® as barrier for both drugs. Interestingly, the ex-
periments carried out on the regenerated cellulose barrier maintained a
similar trend for caffeine-LUVs, even though increasing amounts of
cholesterol were incorporated into LUV's lipid bilayer (Fig. 4a, 0–25%
w/w cholesterol). Differently, hydrocortisone seemed to somehow be
less affected to the environmental ionic strength by the presence of
cholesterol in the liposome's membrane (Fig. 4b, 0–25% w/w choles-
terol).
The n values determined for caffeine-LUVs using regenerated cel-
lulose as barrier at all tonicity conditions (Fig. 5a, white bars) ranged
between 0.74 and 0.92. The n in hypotonic environment was sig-
nificantly (p≤0.001) and consistently lowest in comparison to both
isotonic and hypertonic values (Fig. 5a). For the caffeine-LUV experi-
ments carried out with biomimetic Permeapad® barrier (Fig. 5a, grey
bars), n values were closer to 1, ranging between 0.83 and 0.97. For
hydrocortisone-LUVs (Fig. 5b), n values were generally higher than
caffeine-LUVs and in case of Permeapad®, they were even superior than
1. Moreover, an increasing trend in n values with increased cholesterol
amount was detected employing regenerated cellulose. This trend was
not evident for Permeapad® where the highest n values were detected at
11% w/w cholesterol.
3.3. Liposomal stability
The stability data obtained for the different liposomal dispersions
stored at two different temperatures (6 °C and 22 °C) are reported in
Table 3. As it can be seen, the tonicity of all the LUV dispersions was
relatively stable over the 65 days period. The mean sizes and PI of
caffeine-LUVs were relatively stable when stored up to 65 days at 6 °C.
The caffeine-LUVs formulations stored at room temperature (22 °C)
exhibited significant shifts in size distribution to smaller sizes
(p≤0.016) and narrower PI (p≤0.031) after approx. 14 days for the
formulations with 0 and 11% w/w cholesterol. For the hydrocortisone-
LUVs, the mean sizes and PI varied quite remarkably at both storage
temperatures.
All LUV dispersions exhibited rather neutral zeta potentials right
after formation, but became significantly more negative (p < 0.05)
after storage. For the caffeine-LUVs, the increase in ZP was more sig-
nificant for the samples stored at 22 °C, especially for the LUVs with no
cholesterol (change up to 40mV). For the hydrocortisone-LUVs, the
samples stored in the fridge (6 °C) exhibited significant variation in ZP
as well as those stored at room temperature (p≤0.050). However, in
this case, the ZP changes were rather small in magnitude (maximum
variation of 5mV).
The EE of caffeine-LUVs with various amount of cholesterol in-
corporated in the phospholipid bilayer (0, 11 and 25% w/w) showed a
mean EE of 13% and maximum variation of 6% during a period of
65 days of storage at 6 °C. Surprisingly, when the same formulations
were stored at 22 °C, increase of EE up to 40, 30 and 19% could be
found for caffeine-LUVs with 0, 11 and 25% w/w cholesterol, respec-
tively. Those results indicated that the liposomal integrity probably
changed during storage and for these reasons, as an additive informa-
tion, pictures of all the different LUV dispersions prepared for the sta-
bility study were taken at 65 days to better discriminate differences in
the sample appearance (see Supplementary material, Fig. B.1). As it can
be seen, the visual perception of caffeine-LUVs dispersions with 0% w/
w cholesterol stored at 22 °C had a more transparent/opaque colour
than those stored at 6 °C with a more white colour (Fig. B.1a, upper-
right compared to upper-left). On the contrary, the hydrocortisone-
LUVs (0–25% w/w cholesterol) showed more stable EE with a max-
imum variation of 4% (Table 3). These results emphasize the relevance
of investigating LUV dispersion's stability as changes in size, surface
charge and drug entrapment might have an impact on the drug release
kinetics from the liposomes.
4. Discussion
4.1. Liposome characterization
LUV dispersions used in this work were prepared aiming to be suited
for nasal delivery. For optimal transport through the nasal epithelium,
the vesicles should exhibit a size of 10–400 nm, neutral ZP and tonicity
around 300mOsm (Bourganis et al., 2018; Homer et al., 2000; Illum,
2007; Ohwaki et al., 1987). LUVs' tonicity, sizes, PI, ZP and EE were
found to be in the same order of magnitude as those employed in
previous studies (Wu et al., 2019).
As expected, the incorporation of the neutrally charged cholesterol
into the lipid bilayer (consisting of neutrally charged SPC) did not in-
duce any significant change in the surface charge of the liposomes.
In comparison to hydrocortisone-LUVs, the sizes and PI of caffeine-
LUVs, were more affected by the cholesterol incorporation in the
phospholipid bilayer, which might be related to the drugs localization
inside the LUVs (Briuglia et al., 2015; Leite et al., 2018).
Fig. 3. Resistance to drug transport through liposomal bilayers (RL) containing various amount of cholesterol (0, 11 and 25% w/w) for caffeine (a) or hydrocortisone
(b). Diffusion experiments were carried out employing regenerated cellulose (white bars) or, alternatively, Permeapad® (grey bars) barriers and exposing the LUV
dispersions to isotonic, hypotonic and hypertonic environments (tonicity difference of 0 and ± 300mOsm/kg within inner core of liposomes and external en-
vironment), respectively. Results represent the mean ± standard deviation (n=3, *p≤0.050, **p≤0.010, ***p≤0.001).
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The incorporation of cholesterol into liposomal membranes sig-
nificantly affected the EE of hydrocortisone, whereas the caffeine-LUVs
were not affected. This might be explained by the different affinity of
drugs for the liposomal bilayer (Di Cagno and Stein, 2019) and cho-
lesterol's affinity for the lipid bilayer. In fact, the negative effect of
cholesterol on EE for lipophilic compounds is well-documented (Ali
et al., 2010; Mohammed et al., 2004). From the obtained results, it was
evident that cholesterol prevented, to a certain degree, hydrocortisone
embedding into the liposomal bilayers by reducing the space available
for hydrocortisone (Table 2).
4.2. In vitro diffusion study
The current methods used to determine the release from liposomes
are the filtration, ultracentrifugation, solid phase extraction and dia-
lysis-based methods. The filtration and ultracentrifugation are two
methods that with the help of mechanical forces separate the nano-




































































































































0% cholesterol 11% cholesterol 25% cholesterol
0% cholesterol 11% cholesterol 25% cholesterol
a
b
Fig. 4. Transport constant (K) obtained from non-linear data fitting of diffusion experimental data for caffeine- (a) or hydrocortisone- (b) LUV dispersions with
various amount of cholesterol incorporated in the phospholipid bilayer (0, 11 and 25% w/w). Diffusion experiments were carried out employing regenerated
cellulose (white bars) or alternatively, Permeapad® (grey bars) as barriers. LUV formulations were exposed to isotonic, hypotonic, and hypertonic environments
(tonicity difference between inner core and external environment of liposomes of 0 and ± 300mOsm/kg), respectively. Results represent the mean ± standard
deviation (n=3, *p≤0.050, **p≤0.010, ***p≤0.001).
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suitable for easily deformable nanocarriers such as liposomes, as the
separation procedure might disrupt the nanocarrier leading to over-
rated release (Solomon et al., 2017). For this reason, solid phase ex-
traction is considered to be a more gentle method, and has been suc-
cessfully applied to separate free drug from liposomes (Xie et al., 2018).
However, some of the limitations with this method are that it is not
suitable for all types of release medium, and is dependent on the
medium composition (i.e. bile salts, ions, proteins), therefore the effi-
ciency of separation can be influenced (Nothnagel and Wacker, 2018).
Probably that is why the dialysis-based methods are more favoured, and
in this study, we used the classical Franz diffusion cell set up to monitor
the release from liposomes because of its convenience, cost-effective-
ness and simplicity.
4.2.1. Drug diffusion from drug solution and drug-loaded LUVs
The dialysis-based method used in this study allowed us to quantify
the amount of drug that diffused through a diffusion barrier. However,

































































































































0% cholesterol 11% cholesterol 25% cholesterol
0% cholesterol 11% cholesterol 25% cholesterol
a
b
Fig. 5. Transport exponent (n) obtained from non-linear data fitting of diffusion experimental results for caffeine- (a) or hydrocortisone- (b) LUV dispersions with
various amount of cholesterol incorporated in the phospholipid bilayer (0, 11 and 25% w/w). Diffusion experiments were carried out employing regenerated
cellulose (white bars) or, alternatively, Permeapad® (grey bars) as barriers. LUV formulations were exposed to isotonic, hypotonic, and hypertonic environments
(tonicity difference between inner core and external environment of liposomes of 0 and ± 300mOsm/kg), respectively. Results represent the mean ± standard
deviation (n=3, *p≤0.050, **p≤0.010, ***p≤0.001).
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carrier. For correct interpretation, it has been proposed to use reference
experiment of free drug solution (Wacker, 2017). For this reason, we
have presented here the drug diffusion profiles from solution and LUVs
through two different diffusion barriers.
The regenerated cellulose barrier is highly permeable to small and
neutrally charged molecules and the drug diffusion rate through the
barrier is highly controlled by the drug concentration gradient between
the both sides of the barrier (Bartels et al., 2005; Benavente, 1984;
Nothnagel and Wacker, 2018). On the other hand, the biomimetic
Permeapad® barrier consists of a lipid layer in between two support
sheets (Di Cagno and Bauer-Brandl, 2014). In contact with aqueous
solution, the lipid layer is assumed to create tightly packed vesicles
mimicking the structure of biological membranes (Di Cagno et al.,
2015). In other words, the Permeapad® barrier represents a biomimetic
barrier capable of discriminating drug permeability according to the
physicochemical property of drug molecules. Consequently, the drug
distribution coefficient at neutral pH (LogD7.4) plays a key role in the
net drug mass transport through the barrier (Brandl et al., 2007;
Nothnagel and Wacker, 2018).
As represented in Fig. 2, the total amount of diffused drug from
caffeine formulations was much lower (37–57% according to the for-
mulation tested) when studied with Permeapad® in comparison to re-
generated cellulose barriers (Fig. 2a–b). On the other hand, for hy-
drocortisone formulations, a reduction of 63–78% could be observed.
As expected, hydrocortisone was more retained by Permeapad® in
comparison to caffeine, due to its higher lipophilicity (logD7.4 of 1.6 for
hydrocortisone in comparison to 0.0 for caffeine) (Zhu et al., 2002).
As reported in previous studies (Di Cagno et al., 2015; Fadda et al.,
1998; Wu et al., 2017; Wu et al., 2019), the drug diffusion rate was
lower for liposomal dispersions in comparison to drug solutions when
analysed on regenerated cellulose barrier (Fig. 2). Surprisingly, this
difference was not evident when Permeapad® was employed. This in-
teresting finding indicates that, when biomimetic barrier was em-
ployed, the differences in drug transport properties within different
formulations were reduced if not annulled. This can be by reason of the
biomimetic barrier is the limiting step of the permeation in this case,
reducing the impact of the formulation on the total drug transport ki-
netic. However, for hydrocortisone, a small difference between diffu-
sion from drug solution or liposomal formulation was detectable, in-
dicating that this phenomena is highly drug dependent.
To evaluate better the liposomal bilayer's contribution to changed
drug diffusion profiles across the different barriers, we decided to re-
port the RL as shown in the next sections. We also incorporated various
amount of cholesterol into the liposomal bilayer (0–25% w/w) to study
the relationship between liposomal rigidity and drug release. Moreover,
we exposed the LUVs to different environmental tonicity to see if this
could affect the drug release.
4.2.2. Influence of cholesterol on RL
Liposomes containing hydrophilic molecules might experience
leakage due to cholesterol induced lipid bilayer reconstruction (Briuglia
et al., 2015; Schullery, 1977). The effect cholesterol has on the SPC
liposomes and the release properties from them can be translated from
the calculated RL values. The decreasing RL values indicated that more
drug was diffusing out of the nanocarrier. In agreement with the lit-
erature, the RL was found decreasing for both caffeine- (Fig. 3a) and
hydrocortisone-LUVs (Fig. 3b) when the amount of incorporated cho-
lesterol increased from 0 to 25% w/w.
On the other hand, it has also been argued that liposomes con-
taining cholesterol should exhibit higher liposomal bilayer rigidity and
the resistance to drug transport (RL) should increase as compared to
liposomes made of plain SPC (Leite et al., 2018; Milon et al., 1986).
Surprisingly, the findings from this study seem to deviate from the re-
ported literature. This fact can be explained by the variations of un-
entrapped drug concentration in the different formulations. As shown
in Table 2, the hydrocortisone entrapment was strongly affected by the
presence of cholesterol, whereas this was not found for the caffeine-
LUVs. Specifically, only minimal changes in the unentrapped drug
concentration for caffeine-LUVs with various amount of cholesterol
could be measured (ranged between 1758 and 1773 μM), whereas hy-
drocortisone-LUVs showed unentrapped drug concentrations of 798,
838 and 992 μM for 0, 11 and 25% w/w cholesterol, respectively. The
higher the unentrapped drug concentration, the higher the concentra-
tion gradient (Eq. (2)) and therefore the flux through the membrane. It
should be underlined that these data are in agreement with previous
reports of supersaturation induced by liposomal formulations (Di Cagno
and Luppi, 2013).
4.2.3. Influence of ionic strength on RL
Early works have shown that large unilamellar vesicles are sus-
ceptible to osmotic stress induced vesicle size changes (Mui et al., 1993;
Sun et al., 1986). Liposomes have the tendency to swell when exposed
to hypotonic environments. As a result of the swelling, the liposomal
membrane becomes thinner and this can contribute to increased release
from liposomes (i.e. reduced RL) (Ahumada et al., 2015; Alam et al.,
2016; Polozov et al., 2001). On the contrary, when liposomes are ex-
posed to hypertonic environments, liposomes shrink and the liposomal
membrane might become less permeable to drug permeation (i.e. higher
RL) (Ahumada et al., 2015; Fujiwara and Yanagisawa, 2014; Ohno
et al., 2009). Our results were in agreement with the literature
(Ahumada et al., 2015; Alam et al., 2016; Fujiwara and Yanagisawa,
2014; Ohno et al., 2009; Polozov et al., 2001). For almost all caffeine-
LUV formulations, the RL was significantly lower in hypotonic en-
vironment and highest for the hypertonic environment (Fig. 3a). Si-
milar trend was also observed for hydrocortisone to a lower extent
(Fig. 3b).
As it can be seen in Fig. 3a, the RL values were negative for the
caffeine-LUVs when experiments were conducted using Permeapad®
barriers. This result indicates that, in some cases, linear regression
applied for data treatment and RL calculation, even though feasible,
might lead to incomplete- or miss-interpretation of the data. This might
be due to the experimental set up conditions where the drug release is
highly influenced by the equilibrium across the diffusion barrier.
One upcoming apparatus for drug release study from liposomes is
the flow-through USP 4 (Tang et al., 2019; Yuan et al., 2017). This
apparatus provides continuous flow of the release medium into a cell
containing the drug formulation. The release medium with instant re-
leased drug is then pumped through a separation device (e.g. dialysis-
based device) to remove liposomal drug, and the collected sample can
be measured in situ at predetermined time points. The advantages with
this method include its continuous renewal of the release medium, and
the easily varied medium composition according to the solubility of the
drug. Moreover, the apparatus can easily adjust variables such as
temperature, flow rate, and detection wavelength. Sample measure-
ments can be automatic, and relatively little manual work is required.
However, due to the fact that relatively few companies develop the
flow-through cells, and the complexity of the apparatus, this method is
still not mainstream (Solomon et al., 2017).
The main purpose of this study was not to improve the experimental
set up conditions, but to better interpret the obtained diffusion data
collected from available equipment in our laboratory. It has to be
mentioned that even though the flow-through USP 4 drug release assay
might be a superior method, and has shown some promising results for
studying release from liposomes (Tang et al., 2019; Yuan et al., 2017),
this method is still limited by the barrier properties that separates the
liposomal drug from released drug. Therefore, more processing of the
diffusion data is still required for correct interpretation of the release
mechanism from liposomes (Jain and Jain, 2016; Solomon et al., 2017;
Wacker, 2017).
Two of the most common mathematical methods used to study non-
linear diffusion profiles are the Higuchi and Korsmeyer-Peppas model.
In this study, we investigated the diffusion data employing the
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Korsmeyer-Peppas model.
4.2.4. Data fitting to the Korsmeyer-Peppas model
Since the aim of this study was to investigate the contributing al-
terations in liposomal bilayer properties relevant for drug release, the
Korsmeyer-Peppas model was chosen due to its ability to provide the
descriptive information on both release kinetics and mechanism of drug
release. It should be underlined that the data we have been fitting to the
model refer to the diffusion through low retention/high retention bar-
riers, however, the data also reflect (as described in Fig. 1) the release
kinetics from the nanocarriers.
The parameter K indicated the constant drug transport that can be
seen intuitively as directly proportional to the drug release kinetics
from LUVs. In fact, higher K indicated faster drug release. On a con-
trary, lower value of K indicated a low transport kinetic and therefore
poor drug release from nanocarriers. Interestingly, caffeine-LUVs gen-
erally expressed higher K values in comparison to hydrocortisone-LUVs
(Fig. 4a and b). This was expected, since caffeine is known for its high
permeability through phospholipid barriers (Di Cagno et al., 2015;
Flaten et al., 2006). It should be underlined that K and RL were in rather
good agreement; the higher the RL, the lower value of K, and vice versa.
As seen before for RL, K also seemed to be highly influenced by changes
in the ionic strengths of external environments. Specifically, the higher
the increase in the external ionic strength (consequently shrinkage of
liposomes) the K became lower, indicating a clear reduction of drug
release from liposomes.
The K changed more drastically in response to the environment
when the regenerated cellulose barriers were employed in comparison
to the Permeapad® barriers. This implies that, when biomimetic bar-
riers were employed (i.e. higher retention barrier), the drug formulation
plays a minor role in the net final drug transported through the barrier.
This was also an interesting finding, highlighting the fact that dialysis
barriers were extremely efficient to measure formulation kinetics but
not necessarily predictive for in vitro-in vivo correlations.
The advantage with the non-linear fitting approach was that a larger
part of the experimental data was efficiently fitted (Mt/M∞ up to 60%)
and seemed to better represent the drug diffusion kinetics from lipo-
somes. Moreover, using this data treatment approach, there was no
need to measure reference sample (i.e. drug solution). The application
of Korsmeyer-Peppas model resulted in the time-efficient and precise
method for interpreting diffusion data from nanocarriers.
Under the influence of osmotic stress, the drug release kinetics of
both caffeine (Fig. 4a) and hydrocortisone (Fig. 4b) from liposomes
exhibited less variations in K when cholesterol was incorporated in the
bilayers (0 vs 25% w/w). The more stable K values in different en-
vironmental ionic strengths indicated that the liposomal sensitivity to
osmotic influences decreased. Possible explanation could be that cho-
lesterol embedment into the liposomal bilayer decreases its flexibility
(Leite et al., 2018).
The advantage with the Korsmeyer-Peppas model was the me-
chanistic considerations this model permitted, describing the drug re-
lease mechanism from liposomes by providing the transport exponent,
n. In order to have a Fickian diffusion process, when no boundaries are
present, n should be equal to 0.5, whereas values of n between 0.5 and 1
indicates non-Fickian diffusion and are indications of boundary region
affecting the passive drug diffusion (Costa and Sousa Lobo, 2001). For
the regenerated cellulose experiments (Fig. 5), n values for caffeine
were always lower than 1. The lowest value of n measured for the
diffusion of caffeine was in hypotonic environment (0.75–0.78) when
the lipid bilayers should be the most stretched and therefore with the
lowest resistance (Fig. 3) (Ahumada et al., 2015; Alam et al., 2016;
Polozov et al., 2001). Interestingly, when liposomes were exposed to
isotonic and hypertonic environments, the n value increased re-
markably (between 0.83 and 0.92). This variation in n indicated that
the diffusion of caffeine was moving even further from a Fickian be-
haviour. This can be very well explained by the increasing resistance of
caffeine transport through liposomal bilayers induced by vesicles'
shrinkage (Ahumada et al., 2015; Fujiwara and Yanagisawa, 2014;
Ohno et al., 2009). Considering the experiments with regenerated cel-
lulose barrier, in the case of hydrocortisone, n values were higher than
for caffeine ranging between 0.86 and 0.98. This finding suggests that
hydrocortisone was from the start diffusing in a more controlled
manner from the liposomal bilayer. The release profile of hydro-
cortisone seemed to be less affected by the changes in ionic strengths of
liposomal surrounding environment (as observed in previous studies
(Wu et al., 2017, 2019)).
For the Permeapad® experiments, the n were found relatively more
stable and were less affected by changes in the external environment of
LUVs. As mentioned previously, it was plausible that the higher re-
tention of Permeapad® in comparison to regenerated cellulose overrules
the liposomal effect (K≪ KI).
4.3. Formulation stability
All LUV formulations prepared in this study retained a stable toni-
city upon storage at both 6 and 22 °C (Table 3). Stable tonicity is an
important parameter considering the overall stability of liposomal
suspensions (Grit and Crommelin, 1993).
The more stable LUV dispersions in terms of size, PI and EE were the
ones stored at 6 rather than at 22 °C, as expected. Moreover, low tem-
peratures (4–6 °C) are the recommendable storage conditions for lipo-
somes (Grit and Crommelin, 1993).
Instability of LUV dispersions in terms of drug loading can be de-
scribed as the leakage of originally-associated liposomal content during
storage. As expected, the hydrocortisone-LUVs exhibited stable EE up to
65 days at both 6 and 22 °C independently of the amount of in-
corporated cholesterol. Surprisingly, the EE of caffeine-LUVs stored at
22 °C seemed to increase over time. Similar increase in drug loading
upon storage has been reported for other small hydrophilic compound
such as rivastigmine (MW of 250 g/mol (Pubchem, 2019b)). Caffeine
has MW of 194 g/mol (Pubchem, 2019a). In the study carried out by
Arumugam et al., an increase in EE of rivastigmine in liposomes was
measured after 3months of storage in comparison to freshly prepared
drug-loaded liposomes (Arumugam et al., 2008). This might be an in-
dication that the liposomal bilayer structure is permitting drug to pass
through the liposomal membrane considering that we did not remove
the unentrapped drug from the formulation. Analysing the samples
visually, the caffeine-LUV dispersions without cholesterol had a more
transparent/opaque colour in comparison to the formulations with
cholesterol (11–25% w/w). The increase in the EE for those formula-
tions was probably due to drug migration to equilibrium in the samples
as if the liposomal bilayers were no longer present. However, it could be
observed that the changes in caffeine entrapment were not evident
when cholesterol was in the lipid bilayer; it is well known that cho-
lesterol stabilizes phospholipid bilayers (Briuglia et al., 2015; Grit and
Crommelin, 1993).
Taking into account all the variables measured, LUVs with 11% w/
w cholesterol seemed to be the most stable formulation and exhibited
suitable storage profiles in terms of size distribution, ZP and EE for the
development of drug-loaded LUVs intended for nose-to-brain targeted
drug delivery.
We are currently testing several drugs with different lipophilicity as
well as charge to confirm the applicability of proposed approach.
5. Conclusions
Drug release from LUVs was significantly affected by the ionic
strengths of the external environment confirmed by both linear (zero
order) and non-linear (Korsmeyer-Peppas) regression models.
Korsmeyer-Peppas model was proven to be suitable to analyse all drug
transport data obtained in this study, providing important information
on the release mechanism from the carrier in addition to being time
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efficient (less controls needed) unlike the zero order approximation.
The drug release from LUVs could be tailored by the incorporation of
cholesterol, and LUVs with 11% w/w cholesterol seemed to be the
optimal liposomal composition in terms of stability and responsiveness
to osmotic stress. In spite of the fact that regenerated cellulose is con-
sidered to be a standard, simpler and cheaper barrier used for the
transport study, the Permeapad® appeared a more reliable when it
comes to in vitro-in vivo correlation due to closer similarities to biolo-
gical membranes. The results obtained in this work are rather relevant
as the data can be utilized for the development of liposomal formula-
tions intended for nose-to-brain targeted drug delivery.
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Content: 
1. Fitting the in vitro diffusion data to the Korsmeyer-Peppas model for caffeine-
LUVs (Fig.A.1) and hydrocortisone-LUVs (Fig.A.2). 
2. Picture of drug-loaded LUVs after 65 days of storage at 6 and 22°C (Fig.B.1). 
 
 
Fig.A.1: Fitting of caffeine diffusion experimental results to the Korsmeyer-Peppas 
model. Diffusion experiments were carried out employing regenerated cellulose (a) or 
alternatively, Permeapad® (b) as the barriers. The drugs were formulated in LUV 
dispersions with various amount of cholesterol incorporated in the phospholipid 
bilayers (0, 11 and 25% w/w) and the LUV dispersions were exposed to isotonic, 
hypotonic and hypertonic environments (tonicity difference of 0 and ±300 mOsm/kg 
within inner core of liposomes and external environment). Results represent the 
mean ± standard deviation of three parallel experiments (n=3, *p≤0.050, **p≤0.010, 
***p≤0.001). 
 
Fig.A.2: Fitting of hydrocortisone diffusion experiment results to the Korsmeyer-
Peppas model. Diffusion experiments were carried out employing regenerated 
cellulose (a) or alternatively, Permeapad® (b) as barriers. The drugs were formulated 
in LUV dispersions with various amount of cholesterol incorporated in the 
phospholipid bilayers (0, 11 and 25% w/w) and the LUV dispersions were exposed to 
isotonic, hypotonic and hypertonic environments (tonicity difference of 0 and ±300 
mOsm/kg within inner core of liposomes and external environment). Results 
represent the mean ± standard deviation of three parallel experiments (n=3, 
*p≤0.050, **p≤0.010, ***p≤0.001).  
 
 
Fig.B.1: Photographs of LUV-dispersions with caffeine (a) or hydrocortisone (b) and 
various amount of cholesterol incorporated in the phospholipid bilayers (0, 11 and 
25% w/w) after 65 days storage at 6 and 22°C. Each tube represents one replicate 
out of total two replicates (n=2). 
 
  
 
